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Abstract
Prion diseases, also known as Transmissible Spongiform Encephalopathies (TSEs), are 
fatal conditions which affect humans and animals. The hallmark of Transmissible 
Spongiform Encephalopathies is the accumulation in the brain of PrPSc, which is an 
abnormal isoform of the cellular protein PrPc. It has been proposed that PrPSc is able to
r  p
impose its own conformation on PrP , but the molecular mechanism by which PrP is 
converted into PrPSc is unclear.
PrPc and PrPSc share the same primary sequence but they are different in their 
biochemical properties. PrP is rich in alpha helices, detergent soluble and Protease K 
sensitive; on the other hand, PrPSc is mainly composed of beta sheets, detergent 
insoluble and Protease K resistant.
To better understand PrPSc generation, a genetic screen to identify proteins that 
preferentially interact with a misfolded version of PrP has been employed. This novel 
protein-protein interaction system takes place in the yeast cytoplasm where PrP has 
been reported to adopt a beta sheet-rich conformation characterised by increased 
Protease K resistance.
Initial analysis revealed that one candidate molecule, PrP Interacting Protein 7 
(PIP7), encoded a transmembrane protein present on the cell surface, suggesting a 
potential function as a novel PrP receptor. The interaction between PIP7 and PrP has 
been confirmed in vitro by GST pull down experiments and in vivo by co- 
immunoprecipitation studies. A panel of monoclonal antibodies directed against the C- 
terminus of PIP7, which contains the PrP binding region, has been generated.
FACS analysis using these antibodies confirmed the presence of PIP7 on the cell 
surface of N2a cells, commonly used to study PrPSc propagation, and PIP7 
immunohistochemistry has revealed an intense staining in all brain regions including the 
cortex, hippocampus and cerebellum. Overexpression of PrP in N2a cells resulted in an 
accumulation of PIP7 surface levels. Furthermore, PIP7 levels appear to be reduced in 
the brains of PrP knockout mice. The direct correlation between the levels of PIP7 and 
PrP suggests a potential role for PIP7 as a regulator in prion biology.
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Chapter 1: Overview o f Transmissible Sponsiform 
Encephalopathies
Transmissible spongiform encephalopathies (TSEs) are progressive neurodegenerative 
disorders affecting both humans and a variety of animals. They include Creutzfeldt- 
Jakob disease (CJD), Gerstmann-Straussler-Scheinker disease (GSS), Fatal Familial 
Insomnia (FFI), and Kuru in humans, Scrapie in sheep, Bovine Spongiform 
Encephalopathy (BSE) in cattle, Chronic Wasting Disease (CWD) in deer and elk and 
Transmissible Encephalopathies in mink (Figure 1.1). The brains of affected individuals 
are characterised by neuronal loss, astrocytosis, spongiform changes and with or 
without characteristic amyloid plaques and fibrils consisting of abnormal PrP molecules 
(Bell and Ironside, 1993; Masters and Richardson, 1978) (Figure 1.2).
A common feature of all TSEs or prion diseases is the aberrant metabolism of the host 
encoded prion protein (PrP) which can exist in at least two conformations, distinguished 
by their physicochemical properties. The cellular form, PrP , is a membrane-bound 
protein, the function of which still remains unclear. Its structure comprises a C-terminal 
globular domain, enriched in a  helical secondary structure. On the contrary, PrPSc, the 
disease associated conformation is rich in p structure and displays detergent insolubility 
and partial resistance to proteolysis treatment (Pan et al., 1993a). Finally, it has been 
suggested but not proven unequivocally that PrPSc is the real infectious agent (Prusiner, 
1982).
The aim of this chapter is to provide a broad introduction to human and animal TSEs 
and a general overview of the biology of the prion protein, with special emphasis on 
what is known about the nature of the infectious agent. More specific aspects of prion 
disease, although interesting, will not be covered here since they have been reviewed 
exhaustively elsewhere (Aguzzi and Heikenwalder, 2005; Collinge, 2001; Prusiner, 
1998; Weissmann, 2004).
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Figure 1.1 Prion diseases affecting humans and animals.
Prion diseases can affect humans and a great variety of animals. In humans, there are at least 
three possible origins; Sporadic and Inherited cases involve somatic and germ line point mutations 
in the PRNP gene, encoding for the prion protein PrP. Infectious transmission includes contamination 
through surgical procedures (iCJD), ritualistic cannibalism (Kuru) and more recently infection 
from bovine prions (vCJD). In animals, prion diseases include Scrapie in sheep and goat, Bovine 
Spongiform Encephalopathy in cattle, Chronic Wasting Disease in deer and elk, encephalopathy 
in mink, cats and several exotic ungulates. Abbreviations: Creutzfeldt-Jakob disease (CJD), 
Gerstmann-Straussler-Scheinker disease (GSS), Fatal Familial Insomnia (FFI), Bovine Spongiform 
Encephalopathy (BSE), Chronic Wasting Disease (CWD), Feline Spongiform Encephalopathy 
(FSE).
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Histopathological changes in the brain of affected patients include: A) fine vacuolation also 
referred to as spongiosis of the grey matter (H&E staining); B) astrocytic and microglial hyperplasia 
and hypertrophy (GFAP staining); C) Prion protein deposition either in large amyloid plaques 
or non-amyloid deposits; D) brain homogenate from infected patients presents the pathological 
isoform of the prion protein, which shows partial resistance to Protease K treatment. Modified 
from Glatzel and Aguzzi, 2001.
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1.1 Human TSEs
Human Prion diseases are the best studied and are unique since they may be classified 
on their etiological basis which may be sporadic, inherited or acquired by infection.
1.1.1 Sporadic prion diseases
Human prion diseases were originally described in the early 1920s by Creutzfeld and 
Jakob whose names remained linked to the common definition of sporadic prion disease 
(Creutzfeldt, 1920; Jakob, 1921).
Sporadic CJD (sCJD) is the most frequent case of TSE in humans, accounting for 
almost 85% of total, and with a uniform incidence of 1/106 per year. Sporadic cases 
were diagnosed when no specific infectious or genetic origin could be proven. The 
cause of sporadic CJD is still unknown: the current hypothesis is the spontaneous 
generation of abnormal PrP due to random spontaneous somatic mutations. 
Homozygosity in position 129, where either methionine (M) or valine (V) may be 
present, has been identified as a predisposing determinant for sCJD susceptibility 
(Palmer et al., 1991). The disease is characterised by an onset in middle age with a peak 
between 60-65 years and a very fast progression to death occurring generally within 6 
months (Collinge, 2001).
1.1.2 Infectious prion diseases 
Kuru
Kuru, initially believed to be originated by a “slow virus”, spread among individuals of 
the Fore linguistic group living in the highlands of Papua New Guinea (Gajdusek and 
Zigas, 1957). However, it was later revealed that endocannibalism led to horizontal 
transmission of the disease: during ritualistic feasts, women and children consumed the 
brains and internal organs of deceased relatives. The disappearance of the cannibalistic 
rituals resulted in a drastic decline in Kuru incidence, supporting the proposed 
mechanism of transmission. The possible origin is believed to be a single case of 
sporadic CJD and oral transmission was responsible for the prolonged incubation time, 
approximately 10-15 years with rare cases of up to 40 years. Disease onset and 
progression were longer compared to sCJD and ataxia was reported in most of the cases.
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Analysis of the PRNP  129 (M/V) polymorphism in 80 patients and 95 unaffected 
controls demonstrated that Kuru preferentially affected individuals with the M/M 
genotype (Lee et al., 2001a).
Iatrogenic transmission
Almost 30 years ago the first case of iatrogenic transmission of CJD was documented: a 
patient receiving a cornea transplant developed CJD and later was found that also the 
donor died of the same pathology (Duffy et al., 1974). Altogether, in the past years, 
hundreds of cases of iatrogenic transmission have been reported. More than half of the 
total cases of iatrogenic CJD are linked to treatment with human pituitary growth 
hormone, extracted from cadavers, to treat dwarfism or gonadotrophins to treat 
infertility in women (Koch et al., 1985; Powell Jackson et al., 1985). A few cases of 
disease transmission caused by contamination of neurosurgical instruments originally 
were reported by Jones and Nevin in the early 1950s. Weissmann and colleagues have 
further shown the intrinsic ability of infectious prions to bind steel, the principal 
component of surgical instruments, and have developed an effective decontamination 
procedure (Flechsig et al., 2001; Jackson et al., 2005; Zobeley et al., 1999).
New Variant CJD
Following the BSE crisis in the UK in the late 1980s, a CJD Surveillance Unit was 
introduced to estimate the possibility of transmission from cows to humans. In 1996, ten 
patients were originally reported with a pathological phenotype different from all 
previously CJD reported cases (Will et al., 1996). The disease which became known as 
variant CJD (vCJD) presented an early onset of symptoms, with an average of 26 years 
compared to 66 years characteristic of sporadic CJD. These new cases also exhibited 
prolonged disease duration (13-14 months compared to 5 months for spontaneous CJD 
(sCJD)). In vCJD, PrP accumulation was also reported to occur in peripheral tissues 
such as the tonsils, spleen and lymph nodes, which had never been reported for sCJD 
(Hill et al., 1997b). Post mortem examination revealed the presence of “florid” amyloid 
plaques, positive for the prion protein, surrounded by a halo of spongiform change 
(Ironside et al., 1996). Apart from the epidemiological link, there is an abundance of 
other supporting biochemical and histopathological evidence associating vCJD with
16
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BSE. Firstly, macaque inoculated with BSE show neuropathological features analogous 
to vCJD cases (Lasmezas et al., 1996). Furthermore both BSE and vCJD share a 
common glycosylation fingerprint, distinct from all other cases of prion disease 
(Collinge et al., 1996). Finally BSE and vCJD have the same incubation time and 
produce a similar pattern of lesions, when introduced into transgenic mice (Bruce et al., 
1997). To date, 107 cases of vCJD have been confirmed in the UK by post mortem 
autopsy and no accurate estimation of future cases can be made. It is however 
noteworthy that all vCJD cases described so far present M/M homozygosity at the 
polymorphic codon 129.
Recently a patient who developed vCJD after receiving red blood cells from a donor 
who subsequently died from variant CJD has raised public concern about the safety of 
blood and blood derivatives (Ironside and Head, 2004). Blood transmission has been 
studied in sheep where BSE infectivity by blood transfer was successfully achieved 
(Houston et al., 2000). Infectivity has also been successfully transmitted to rodents but 
not to primates, using blood from CJD and Kuru patients. Studies in animal models 
suggest that most prion infectivity in blood may be cell-associated, with lower levels in 
the plasma, and there is evidence suggesting that any infectivity present may be reduced 
during the process of plasma fractionation (Will, 2003). However, the possibility that 
plasma or blood products can transmit the disease in human cannot be completely 
excluded or confirmed at present.
1.1.3 Inherited prion disease
Only 10-15% of human prion diseases are genetically inherited as autosomal dominant 
traits (Hsiao et al., 1989). All cases of familial CJD (fCJD) have been unequivocally 
linked to mutations in the PRNP  gene, as all cases of GSS and FFI. One noteworthy 
mutation is the D178N substitution which shows the ability to give rise to different 
neuropathological phenotypes according to which polymorphic residue is present in 
position 129: the presence of a methionine results in FFI presenting as a progressive 
sleep disorder and affecting more than 30 different families worldwide (Goldfarb et al., 
1992). Conversely, when the D178N mutation was found in combination with a valine 
in position 129, patients present a severe dementia and the pathological features are
17
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Figure 1.3 Pathogenic PRNP mutations and polymorphisms.
The diagram shows a schematic representation of the human prion protein, above which are 
listed the mutations (missense substitutions and insertions) linked to familial CJD, GSS and FFI. 
Below are shown the many polymorphisms, including the Ml29V which has been linked to 
disease susceptibility and different neuropathological phenotypes. Adapted from Collinge J., 
2001.
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typical of the cases of familial CJD (Gambetti et al., 1995). More than 20 different 
PRNP mutations have been described to date: they mainly occur within the C-terminal 
half of the PrP molecule and they involve missense substitutions with the only 
exception of a nonsense mutation (Pocchiari, 1994) (Figure 1.3).
Human prion diseases do not appear to be homogeneous and can show variable 
phenotypes; despite this apparent difference, all the human prion diseases have been 
successfully transmitted to primates: Kuru was the first one in 1966 CJD followed in 
1968 and finally GSS in 1981 (Gajdusek et al., 1966; Gibbs et al., 1968; Masters et al., 
1981).
1.2 Animal TSEs
1.2.1 Scrapie
Scrapie was originally reported more than 200 years ago and is endemic in many 
countries (Brown and Bradley, 1998). It is a fatal neurodegenerative condition affecting 
sheep and goats. Different routes of infection have been suggested for the spreading of 
the disease and ingestion of infected material seems to be the most likely possibility; 
however, introduction through skin lacerations or maternal transmission cannot be 
excluded (Elsen et al., 1999; Pattison et al., 1972).
1.2.2 Chronic Wasting Disease and Mink Transmissible Encephalopathies
Chronic Wasting Disease (CWD) and Transmissible Mink Encephalopathies (TME) 
affecting wild cervid and mink respectively were reported in the late 1960s in Colorado 
and 1947 in Minnesota (Marsh and Hadlow, 1992; Williams and Young, 1980). Some 
polymorphisms in the cervid PRNP  gene have been described for CWD but not for 
TME and their relationship with susceptibility is still under investigation. Similarly to 
Scrapie, the route of infectivity for CWD and TME remain unclear but seem to involve 
lateral transmission. It has been suggested that TME was generated by ingestion of 
material contaminated by Scrapie or by exposure to an as-yet uncharacterised prion 
disease in cattle (Marsh et al., 1991).
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1.2.3 Bovine Spongiform Encephalopathy (BSE)
BSE, also known as Mad Cow disease, was recognised in the United Kingdom in 1986, 
with a peak of around 1200 cases/month in 1993, and was promptly associated with 
other TSE’s, such as Scrapie due to the presence of the typical brain lesions (Anderson 
et al., 1996; Wells et al., 1987). It is well accepted that BSE reached epidemic 
proportions due to the wide use of dietary protein supplements, namely meat and bone 
meal (MBM), containing the scrapie agent. Previously, treatment with lipid solvents 
were believed to inactivate the infective agent until inactivation procedures were 
changed in the late 1970s in order to minimise expenses (Ernst and Race, 1993; 
Prusiner, 1997). The dramatic decline in the number of reported cases reflected the 
decision to ban the practice of feeding animal remains to cattle in 1988. BSE cases have 
been described in other European countries such Switzerland, France and Germany, 
albeit with a total incidence 100 fold lower than in the UK, where it has had a 
substantial impact on the livestock industry (Detwiler and Rubenstein, 2000). Strain 
studies in mice aiming to characterise the BSE agent revealed the existence of a single 
strain of the transmissible agent in contrast with the multiple strains identified for 
scrapie in sheep (Bruce et al., 1994).
1.3 The Spread of prions
1.3.1 Peripheral invasion
Despite the wealth of experimental studies involving intracranial inoculation, natural 
TSE infections are most commonly acquired by peripheral exposure to the infectious 
agent: infection through the food chain was initially responsible for the spread of BSE 
among cattle resulting the emergence of vCJD in humans (Bruce et al., 1997; Hill et al., 
1997a; Wilesmith et al., 1991). Therefore it is crucial to understand how infectivity, 
once acquired peripherally reaches the CNS. At early stages following peripheral 
inoculation, laboratory animals accumulate infectivity in lymphoid tissues, long before 
possible detection in the central nervous system (Farquhar et al., 1994; Kimberlin and 
Walker, 1979). However, when PrPSc is introduced into Prnp'A mice via intraperitoneal 
route no disease is transmitted to the brain, suggesting the requirement for at least one 
intermediate compartment expressing PrP (Blattler et al., 1997). Lymphoid tissue 
involvement is not always a prerequisite but may reflect strain specificity like in the
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case of BSE and sCJD, where PrPSc is mainly accumulating in the CNS (Hill et al., 
1999b; Somerville et al., 1997). On the other hand, sheep affected by scrapie and vCJD 
patients presented infectivity in lymphoid tissues, with PrPSc detected in both follicular 
dendritic cells (FDC) and tingible body macrophages in the germinal centres (GCs), 
specialised regions responsible for B cells affinity maturation (Hilton et al., 1998; 
Vankeulen et al., 1996). A number of different cell populations are involved in the 
spread of TSE infectivity, as I will discuss below.
B and T lymphocytes
Lymphocytes of the T-cell lineage have been shown to be dispensable for scrapie 
pathogenesis as early demonstrated by the unaltered incubation time in mice subjected 
to thymectomy and later confirmed by inoculation of transgenic mice deficient in the T 
cell compartment (Klein et al., 1997; McFarlin et al., 1971). In contrast, B lymphocyte 
impairment had a profound effect on neuroinvasion, even if their expression of the prion 
protein was not an absolute requirement (Klein et al., 1998). However, sub-lethal y- 
irradiation, known to kill all active dividing cells like B and T lymphocytes but also 
monocytes, did not affect scrapie pathogenesis as also B cell restricted PrP expression 
did not restore spleen replication in a PrP knockout background (Fraser and Farquhar, 
1987; Montrasio et al., 2001). This apparent contradiction could be explained by the key 
role played by B lymphocytes in the secretion of cytokines, like TNF and lymphotoxin 
a  and p, required for the maturation and correct maintenance of many other cell types 
like follicular dendritic cells and the general micro architecture of secondary lymphoid 
organs (Cyster et al., 1999; Kosco-Vilbois et al., 1997).
Follicular Dendritic Cells and Complement
Follicular dendritic cells (FDC) were positively identified as PrP expressing cells in 
tissues from spleen, lymph nodes, and Peyer’s patches in both infected and uninfected 
mice (McBride et al., 1992). Moreover, in infected mice FDCs were found as 
preferential sites for PrPSc accumulation (Kitamoto et al., 1991). Their resistance to 
irradiation and their strict dependency from mature B cells made them an ideal 
candidate for a critical role in the neuroinvasion process. Independent experiments, 
based on genetically modified immunodeficient mice, came to the same conclusion: 
mice lacking mature FDCs did not present spleen infectivity (Brown et al., 1999b; Koni
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et al., 1997; Mabbott et al., 2000; Matsumoto et al., 1996; Montrasio et al., 2000). There 
are however some inconsistencies in these experiments such as the dependency on the 
particular strain used: RML, in contrast with ME7, seemed to accumulate in the spleen 
even in the absence of PrP expression on FDCs as long as other cells, like lymphocytes, 
were PrP positive (Blattler et al., 1997). It was hypothesised that FDCs could uptake 
PrPSc after peripheral inoculation in the same way they capture and retain foreign 
antigens in a complex with complement components. In support of this hypothesis, mice 
lacking specific components of the complement cascade were partially protected from 
the scrapie agent, following intraperitoneal exposure (Klein et al., 2001; Mabbott et al., 
2001).
Macrophages
Tingible body macrophages are present inside the germinal centres and contain 
intracellular depositions of PrPSc in infected animals (Jeffrey et al., 2000). A positive 
role as a scavenger of infectivity has been proposed for macrophages based on both in 
vitro and in vivo data (Beringue et al., 2000; Carp and Callahan, 1982). However, it 
remains unclear whether macrophages actively clear scrapie infectivity or whether PrPSc 
uptake occurs by passive sequestration.
Dendritic cells
Dendritic cells (DCs) are known to patrol the organism in order to collect antigens 
before delivering them to the lymphoid centres (Banchereau et al., 2000). Different lines 
of evidence suggest a potential role for dendritic cells for the transport of infectious 
prions to the germinal centres: DCs have been shown to be chemotactically attracted by 
the cytotoxic PrP 106-126 fragment and, more relevantly, a subpopulation of DCs is 
able to transport PrPSc from the intestine to mesenteric lymph nodes (Huang et al., 2002; 
Kaneider et al., 2003).
M cells
Prion infectivity can be orally introduced as in the case of BSE and vCJD (Will et al., 
1996). Before reaching the Peyers patches, prions have to escape the gut lumen. M cells 
have been studied in their ability to uptake both foreign antigens and pathogens, 
translocate across the gut epithelial layer and present them to components of the 
immune system such as dendritic cells and lymphocytes (Neutra et al., 1996). Recently,
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in vitro experiments have demonstrated the possibility that M cells act as a mucosal 
portal for prion entry upon dietary exposure (Heppner et al., 2001).
1.3.2 The journey from Spleen to Brain
As suggested above, prions replicate in peripheral organs before reaching the CNS, in a 
way dependent on the presence of at least one intermediate PrP expressing tissue 
(Blattler et al., 1997; Race et al., 2000). Original experiments have shown that, 
following intraperitoneal injection, replication occurred specifically in the 
corresponding segment of the spinal cord, connected through the splanchnic nerves of 
the sympathetic nervous system (Baldauf et al., 1997). Moreover lymphoid organs are 
mainly innervated by the sympathetic network (Felten et al., 1988). Recent 
investigations proved the hypothesis that the sympathetic route serves as a link between 
the lymphoreticular compartment and the CNS: damaging the sympathetic nervous 
system (SNS), with chemical or immunological approaches, resulted in reduced prion 
titres and in some cases prevention of the disease. In the same study, a complementary 
approach was also taken to show that transgenic mice in which lymphoid organs were 
hyper-innervated by sympathetic nerves were characterised by reduced incubation time 
and higher titres of infectivity were found in the spleen (Glatzel et al., 2001). The 
accumulated evidence implies a possible scenario in which infectivity spreads 
peripherally in the lymphoreticular system, in a way dependent directly by FDC and 
with the indirect participation of B lymphocytes and complement components, before 
reaching the CNS via peripheral SNS innervations (Aguzzi et al., 2001). However many 
questions remain unanswered, for example, whether FDC are responsible for the direct 
transfer of infectivity to the SNS terminals or if intermediate cell types are involved, as 
suggested by the fact that the germinal centres within the lymphoid tissue appear to be 
poorly innervated.
Once invasion has taken place in the PNS, the infectious agent still has to travel to the 
CNS. Both axonal and non-axonal transport systems have been proposed: for PrPc a 
mechanism of fast axonal transport has been reported but for PrPSc all available data is 
indirect, estimating a speed of 1-2 mm/day and not compatible with a fast axonal 
transport (Borchelt et al., 1994; Kimberlin et al., 1983). The finding of PrPSc presence in 
the region surrounding the axons of peripheral fibres supports the idea of an alternative,
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non-axonal, transport mechanism (Groschup et al., 1999; Hainfellner and Budka, 1999). 
In the latter case, a domino-like mechanism, requiring expression of PrP, could be 
envisaged (Glatzel and Aguzzi, 2000). Finally, it is also possible that the two 
mechanisms could somehow not be mutually exclusive.
Prion replication was historically restricted to CNS and lymphoid tissues (Legname et 
al., 2004). A recent report had raised the concern about PrPSc presence in non-lymphoid 
organs, which were able to accumulate PrPSc in the presence of chronic inflammation 
(Heikenwalder et al., 2005). This apparent new tropism of prion replication could be 
explained on the basis that inflammed organs like the kidney, liver and pancreas present 
with infiltration of B and T cells together with FDC and tingible body macrophages.
1.4 The nature of the infectious agent
The initial observation that the scrapie agent was resistant to inactivation with 
conventional procedures which were known to destroy nucleic acids and inactivate 
viruses offered the first indication that it might differ from any other known pathogen 
(Alper et al., 1967; Gordon, 1946; Pattison, 1965b). An accumulation of evidence 
suggested that the main constituent of the infectious agent was proteinaceous in nature. 
For many years, the true nature of the agent responsible for this group of diseases 
remained an enigma for the scientific community. The breakthrough was offered by the 
discovery of the prion protein: researchers were able to identify a single protein, called 
PrP or the prion protein, by enrichment for infectivity in the brain of a scrapie infected 
Syrian Hamster (Bolton et al., 1982). The prion protein was initially characterised by its 
Protease K resistance and was designated PrP27'30 based on its apparent molecular 
weight. Later studies proved that PrP27'30 was derived by proteolytic cleavage from a 
larger protein of 33-35 KDa, named PrPSc (Oesch et al., 1985). PrPSc had the ability to 
co-purify with infectivity and all treatments that destroyed PrPSc resulted in prion 
inactivation. Determination of the N-terminal sequence of PrP ' led to the 
establishment that the prion protein was encoded by a host gene, named Prnp in mice 
and PRNP  in humans (Basler et al., 1986). Under physiological conditions, the gene 
product is a protease sensitive protein known as PrP , the function of which remains 
unclear.
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1.4.1 The protein only hypothesis
Based on the evidence that prion infectivity always co-purifies with a protein 
component, and more specifically, with PrPSc, the Nobel laureate Stanley Prusiner 
proposed the modem definition of prions: “Small proteinaceous infectious particles that 
resist inactivation by procedures which modify nucleic acids” (Gabizon et al., 1988; 
McKinley et al., 1983; Prusiner, 1982; Prusiner, 1989). According to Prusiner’s idea, 
PrPSc is the infectious agent able to propagate itself by causing the conversion of 
endogenous PrP . On one hand, the protein only hypothesis successfully managed to 
accommodate phenomena such as prion strains and species barrier, without having to 
evoke nucleic acids. On the other hand, many attempts to disprove Prusiner’s 
hypothesis have previously failed as all attempts to isolate a prion specific nucleic acid 
were unsuccessful to date.
1.4.1.1 Mechanisms of prion replication
Two models of the conformational conversion of PrPc into PrPSc have been so far 
proposed: A) the template-directed refolding; B) the seeding model (Figure 1.4).
Template-directed refolding
The template-directed refolding model makes the assumption of the existence of a high 
energy barrier between PrPc and PrPSc conformations (Prusiner, 1991) (Figure 1.4A). 
PrPSc is predicted to be more stable but remains kinetically inaccessible. On the other 
hand, a small population of PrPc could exist in an alternative conformation denoted 
PrP*, able to bind a still uncharacterised cellular factor called Protein X, whose 
existence has to date been based on genetic evidence (Cohen et al., 1994; Telling et al., 
1995). PrP* describes a metastable intermediate and its existence could only be proved 
once it has been isolated.
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Figure 1.4 Models for the conversion of P rl*  to PrP**.
A) Template directed refolding model: PrPc and PrPSc are assumed not to be in direct equilibrium 
due to the presence of a high energy barrier preventing conversion. However PrPc can exist in an 
alternative conformation called PrP* which in association with a still uncharacteriscd molecular 
chaperone, Protein X, is able to bind PrPSc and form the replication competent complex. PrPSc 
could arise by infection or, most likely in familial or sporadic cases, by the presence of point 
mutations which could destabilise PrP or stabilise PrP*. B) The seeding model postulates the 
existence of equilibrium between PrPc and PrPSc. Such equilibrium is in favor of PrPc, however 
PrP50 can be stabilised only when it forms a crystal-like aggregate, also called “seed”. The formation 
of the initial seed is the rate-limiting step and once formed, monomeric PrP is rapidly incorporated. 
When the seed reaches a critical size, its fragmentation generates new seeds resulting in the overall 
cascade of amplification.
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The complex PrPVProtein X could recruit to some extent PrPSc and form the so-called 
replication competent assembly. The heterodimer composed of PrP*/PrPSc would 
undergo conversion to a homodimer PrPSc/PrPSc with sub-sequential amplification. 
PrPSc could arise by infection or, most likely in familial or sporadic cases, by the
C* *presence of point mutations which could destabilise PrP or stabilize PrP , resulting in a 
lower energy barrier between the physiological and pathological isoforms and 
facilitating a process that otherwise would be extremely rare.
Evidences of the existence of Protein X arise from transmission studies of sCJD to 
transgenic mice (Telling et al., 1994; Telling et al., 1995). Mice expressing human PrP 
(TgHuPrP) in the presence of the endogenous mouse PrP were resistant to inoculation 
whereas complete susceptibility was observed when the human transgene was expressed 
in the P rnp '1' background. Conversely, mice expressing a mouse-human chimeric 
construct (TgMHu2M) were susceptible to human prions and the ablation of the 
endogenous mouse gene had only a modest effect in reducing incubation time. The data 
suggested the idea of competition between the endogenous mouse and the exogenous 
human prion protein for a host factor able to bind to the mPrP with higher affinity 
compared to the hPrP. Later studies mapped the putative interaction site for Protein X: 
residues 167-171 and 214-218, which form a discontinuous epitope. Point mutations in 
these specific positions have been suggested to change the relative affinity for Protein X 
and to prevent its participation in prion propagation as supported by the observation of 
protective polymorphic residues in sheep (Hunter et al., 1993; Kaneko et al., 1997b).
The seeding model
According to the seeding or nucleation model the limiting step in the conversion 
mechanism would be the formation of an initial seed formed by PrPSc molecules (Jarrett 
and Lansbury, 1993)(Figure 1.4B). PrPc and PrPSc would be in constant thermodynamic 
equilibrium, determined by the mass action rule. Such equilibrium favours PrPc and 
only a small amount of PrPSc would be present at any given time, due to its intrinsic 
instability. Only in the rare event of the formation of a highly ordered structure or 
“seed”, PrPSc would get stabilised. The seed would be able to grow by the addition of 
new PrPSc molecules until reaching a critical size. Upon breakage, new seeding nuclei 
are formed and more PrPSc molecules could be incorporated. The generation of new 
seeds would lead to further amplification in the system and a much faster kinetic of 
production of PrPSc molecules. The limiting step of the whole process would be the
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initial generation of the seed, which is a function of the local PrPSc concentration and 
that could spontaneously arise in case of familial prion disease or be exogenously 
introduced.
Although there is a great deal of evidence in favour of both models, to date, neither has 
been confirmed or disproved.
1.4.1.2 PrP strains
One of the most challenging aspects of the protein only hypothesis remains the 
explanation of the existence of different prion strains, as was originally identified in 
sheep. Prion strains are different in their biological properties: originally, strains were 
classified not only by incubation time but also by the pattern of neuronal vacuolation 
and PrPSc deposition when introduced into inbred mice (Bruce et al., 1992; Dickinson et 
al., 1968; Fraser and Dickinson, 1973). The observation that the same inbred line was 
able to propagate different strains with different properties excluded that strain 
specificity was determined simply by the PrP primary structure. To be defined as a 
strain the observed biochemical properties had to be transmissible to an experimental 
animal both of the same and different species. Two hamster adapted scrapie strains, 
derived from mink and called “hyper” (HY) and “drowsy” (DY) suggested a possible 
explanation without invoking the requirement of a nucleic acid (Pattison and Millson, 
1961). HY and DY produced distinct syndromes in the inoculated recipients and, 
following limited proteolysis, had different migration patterns on polyacrylamide gels 
(Bessen and Marsh, 1994). The explanation to the differential protease sensitivity was 
based on the original assumption of the existence of more than one PrPSc conformation 
(Prusiner, 1991). In order to distinguish between the different conformers and to 
facilitate their classification, limited proteolysis with Protease K had been extensively 
employed. Because different subtypes show different cleavage sites between amino 
acids 79 and 103, Protease K digestion produces resistant cores exhibiting slightly 
different gel mobility (Parchi et al., 2000). More recently, strains have been 
distinguished not only by molecular weight after Protease K digestion but also 
regarding the relative ratio of the different glycoforms (Collinge et al., 1996).
In summary, the protein only hypothesis postulates that different strains are the direct 
consequence of different pathological PrP conformations, as also supported by 
differential resistance to denaturating agents (Safar et al., 1998).
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1.4.1.3 The species barrier
As above mentioned, PrP strains are characterised both by biochemical and pathological 
features. When laboratory animals are inoculated with infected material of the same 
species, all animals develop disease within a very narrow period of time. The definition 
of a species barrier was based on the original observation that, when animals were 
inoculated with prions from different specie, they did not develop disease with the same 
efficiency and presented much longer and heterogeneous incubation times (Pattison, 
1965a). However, if the first passage occurred, sub-sequential passages resulted in a 
reduction in the incubation time, a process referred to as “adaptation” (Kimberlin and 
Walker, 1977). The concept of a species barrier has been studied with the help of 
transgenic animals and cell-free conversion systems and the unequivocal conclusion 
was that the PrP primary sequence in both donor and acceptor has to be the same in 
order to obtain successful and reproducible conversion (Caughey, 2003). PrP 
conversion to PrPSc has been schematised as a two-step event: the binding between the 
two different isoforms seems to precede the actual change in conformation, as outlined 
in in vitro studies, where heterologous PrPSc was able to bind efficiently the endogenous 
PrPc even if there was no successful production of new PrPSc molecules (Horiuchi et al., 
2000). On the same line of evidence, heterozygosity at codon 129 in human has been 
suggested to elicit a protective role against sCJD which occurs more often in 
homozygous individuals (Priola, 1999). The species barrier can be overcome by the 
introduction of a transgene encoding the donor sequence into the recipient mouse 
(Prusiner et al., 1990). Moreover, transgenic mice overexpressing exclusively the 
human form were susceptible to CJD and have been extensively used as a model to 
study transmission of BSE to human (Collinge et al., 1995).
1.4.1.4 Attempts to prove the protein only hypothesis: generation of infectivity in 
vitro
It is well accepted that PrPSc is derived from the normal host protein PrPc and the two 
isoforms, despite sharing the same amino acid sequence, are extremely different in 
terms of their secondary structure. They also differ in their biochemical properties - 
PrPSc is relatively detergent insoluble and displays increased resistance to Protease K
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digestion compared to PrPc. According to the protein only hypothesis, PrPSc is believed 
to be able to self impose its own pathological conformation in an autocatalytic manner 
using the normal host isoform PrPc as a substrate (Griffith, 1967; Prusiner, 1982). 
Although the generation of PrP deficient mice has demonstrated the absolute 
requirement for PrPc in prion pathogenesis, definitive proof is still missing (Biieler et 
al., 1993). In order to be proven, the disease must be reproduced in a recipient animal by 
a molecule totally generated in vitro and in the absence of possible nucleic acid 
contamination which might still leave room for alternative interpretation.
Unlike in the mammalian system, yeast prions closely illustrate the prion hypothesis: 
the yeast proteins HET-s and Sup35 were successfully converted in vitro to their prion 
state, characterised by an altered and self-propagating conformation, and used to infect 
other cells (Maddelein et al., 2002; Sparrer et al., 2000; Tanaka et al., 2004).
I will here review some of the many attempts taken to generate infectivity in vitro.
More than a decade ago, the first attempt to generate PK resistant PrP, namely PrPRes, 
mixing equimolar amounts of PrPc and PrPSc was unsuccessful (Raeber et al., 1992). 
Later, Kocisko and colleagues succeeded in the task of converting radio labelled PrP to 
a PK resistant form by mixing highly enriched protein fractions obtained by 
immunoprecipitation from infected brain homogenate. This attempt had the 
disadvantage of using a large molar excess of PrPSc over PrPc, preventing not only the 
detection of infectivity associated with the newly synthesised material but questioning 
the compatibility with the in vivo process where PrP is definitely the most abundant 
specie (Kocisko et al., 1994). In vitro studies has shown that PrPRes formation can be 
efficiently stimulated by chaotropes/detergents, chaperons, sulphated glycans and 
elevated temperatures (DebBurman et al., 1997; Wong et al., 2001). It is worth 
mentioning that an in situ conversion system, based on brain slices from infected mice, 
has been developed, allowing the study of conversion in a setting compatible with the 
tissue cytoarchitecture (Bessen et al., 1997).
In agreement with the seeding model, Saborio and colleagues have developed a new 
technique, called protein-misfolding cyclic amplification (PMCA), which allows very 
efficient amplification of the an initial PrPSc inoculum (Saborio et al., 2001). The 
technique is based on incubation cycles alternated with sonication steps which produce 
PrPSc oligomeric seeds able to catalyse the further conversion of PrPc molecules, in a
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way conceptually analogous to a DNA polymerase chain reaction. PMCA proved able 
to amplify indefinitely the original inoculum and the in vitro produced PrPRes had 
biochemical properties similar to the ones observed in vivo, such as resistance to 
denaturation and proteolysis, tendency to form aggregates and, more importantly, in 
vivo infectivity (Castilla et al., 2005). However, the approach could not exclude the 
contribution of other molecules, for example, RNA which had been originally proposed 
to be involved in the generation of strain diversity and more recently had been 
demonstrated to stimulate prion protein conversion in vitro (Deleault et al., 2003; 
Weissmann, 1991).
Later, different groups focussed their energy towards the far more challenging task of 
generating infectivity de novo, without the assistance of an original PrPSc inoculum. 
Different groups successfully converted recombinant PrP, produced in bacteria, into a 
P-rich isoform that showed partial Protease K resistance. Moreover, these rearranged 
molecules were detergent insoluble and resistant to denaturation induced by chemical or 
physical agents. Some of them also showed the ability to polymerise into structures that 
resembled the one extracted from the brains of animals affected by prion disease 
(Liberski et al., 1991). Original experiments aimed to generate PrPRes were performed in 
the presence of aggressive denaturing agents such as Urea and Guanidine hydrochloride 
(Hornemann and Glockshuber, 1998; Swietnicki et al., 1997). A further level of 
complexity was introduced by the observation that recombinant PrP could 
spontaneously unfold at low pH and in reducing condition to give rise to a still soluble 
conformation dominated by the presence of a p sheet structure, called PrPp (Jackson et 
al., 1999). However, using a very elegant setting, Hill and colleagues have shown that 
de novo generated PrPp was still not infectious (Hill et al., 1999a).This could be 
eventually explained by the possible requirement of still uncharacterised cellular 
element such as above mentioned Protein X (Telling et al., 1995).
Very recently, a fragment of the prion protein (amino acids 89-230) was successfully 
folded in amyloid fibrils and, when injected into transgenic animals overexpressing the 
same fragment, produced a disease with features common to TSE (Legname et al., 
2004). As a proof of its infectivity, the disease was transmitted to recipient mice in a 
second passage. Despite being the closest attempt to confirm all the requirements of the 
protein only hypothesis, there is still the doubt that the disease might have risen
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spontaneously in the transgenic mice used for the study and that inoculation of 
“synthetic prions” might have simply accelerated a spontaneous event. Based on the 
different histopathological manifestation of the disease, Legname and collegues 
considered their result to be the generation of a novel prion strain.
1.4.2 Alternative hypotheses
Despite being the most accepted explanation, the protein only hypothesis was not the 
only one proposed and had to face high scepticism from the scientific community. 
TSE’s had been suggested to arise by an unconventional virus or a virino infection 
(Dickinson and Outram, 1988; Gajdusek, 1977; Kimberlin, 1982). PrP localisation on 
the cell surface suggested its putative role as viral receptor. In PrP knockout mice, the 
virus could not enter the cell, resulting in resistance to scrapie inoculation (Rohwer, 
1991). Co-purification of infectivity with PrPSc had been proposed to be a result of 
putative sequence homology between a unidentified viral protein and PrPSc itself. The 
resistance of purified infectious preparations to procedures known to hydrolyse nucleic 
acids argued that either the prion genome was very small or did not even exist whereas a 
conservative explanation predicted that the putative genome was highly protected 
(Alper et al., 1967). Original experiments proved that an average of one oligonucleotide, 
shorter than 80 bases, could be found per ID50 unit (Kellings et al., 1992). More recent 
data, using return refocusing electrophoresis, excluded also the viroid hypothesis. The 
conclusion of the authors was that the possibility of a prion specific polynucleotide was 
highly remote (Safar et al., 2005). Among the many suggested hypotheses, it is worth 
mentioning: a replicating polysaccharide with membranes and infection by a 
Spiroplasma-like agent (Bastian, 1979; Gibbons and Hunter, 1967).
The Unified theory
Charles Weissmann tried to mediate the conflicting hypotheses by proposing an 
“unified theory”: a PrP conformer, designated PrP*, would be part of the infectious 
agent in association with a small host encoded RNA molecule, the co-prion; PrP* and 
the co-prion would replicate independently and the possibility of incorporation of 
alternative RNA would explain the different phenotypes between prion strains 
(Weissmann, 1991). A report in which in vitro PrPSc amplification was stimulated by
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addition of a RNA fraction from mammalian tissues has recently added new strength to 
the unified theory (Deleault et al., 2003).
1.5 Biology of the prion protein
1.5.1 PrP Structure
The structures of recombinant PrP, obtained from mouse, hamster and human, have 
been studied by nuclear magnetic resonance (NMR) and they present the same overall 
conformation (Hosszu et al., 1999; James et al., 1997; Riek et al., 1996). Mature PrP 
can be divided into two different regions: an unstructured N-terminal domain and a 
highly structured C-terminus, both of approximately 100 residues each. The N-terminus 
contains five tandem repeats of a consensus sequence of eight amino acids 
(PHGGGWGQ), the expansion of which was originally linked to familial prion disease 
(Owen et al., 1992). The octapeptide region has been shown to bind copper ions with 
high affinity (Kd 10'14 M), suggesting a physiological role of the prion protein in copper 
homeostasis (Homshaw et al., 1995). More recently a second copper binding site has 
been characterised between residues 96 and 111 (Kd 4 10‘14 M) (Jackson et al., 2001). 
The C-terminus contains three a  helices and a very short antiparallel p sheet, with a 
single disulphide bound linking helices 2 and 3, displaying a globular fold like structure 
(Riek et al., 1996). Rearrangement of the overall secondary structure is necessary to 
produce PrPSc, which has higher p sheet content (Pan et al., 1993b). It is noteworthy that 
most of the PrP sequence is not necessary for prion propagation: the N-terminal deletion 
up to residue 80 is still replication competent and transgenic animals harbouring a 
construct lacking amino acids 23-88 and 141-176 (known also as PrP106) are still 
susceptible to disease (Fischer et al., 1996; Supattapone et al., 1999). Nevertheless, the 
presence of the N-terminal domain seems to facilitate efficient prion propagation, as 
shown for the transgenic A23-88, which developed the disease albeit with an incubation 
period three times longer than their wild-type counterparts (Supattapone et al., 2001).
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1.5.2 Cellular trafficking of PrP
1.5.2.1 PrPc Biosynthesis
PrP is a sialoglycoprotein, attached to the cell surface via a glycosylphosphatidylinositol 
(GPI) anchor and its biogenesis is similar to that of other membrane and secreted 
proteins (Stahl et al., 1987). PrP is synthesised as a polypeptide chain of 254 residues. 
The first 23 amino acids provide a signal peptide required for the correct targeting to the 
rough endoplasmic reticulum (ER); removal of the signal results in failure to reach the 
plasma membrane and in cytoplasmic accumulation of the prion protein (Lee et al., 
2001b). Once inside the ER, PrP is subject to different post-translational modifications: 
two potential N-linked glycosylation sites (Asn-X-Thr, positions 180 and 196 of mouse 
PrP) can be modified by addition of mannose-rich oligosaccharides, sensitive to 
digestion by endoglycosidase H. The ER lumen also provides the correct environment 
for the formation of a single disulphide bond between cysteines 178 and 213 (Turk et 
al., 1988). Finally the last 24 residues at the C-terminus are cleaved before the 
attachment of the GPI moiety to serine 230. In order to reach the cell surface, the prion 
protein translocates to the Golgi compartment where the oligosaccharides chains 
undergo complex modifications such as glycan sialylation (Figure 1.5).
1.5.2.2 PrP internalisation
Early experiments showed a constant cycling of the prion molecule between the plasma 
membrane and the endocytic compartment from which most of PrPc returns to the cell 
surface (Shyng et al., 1993). Surface iodination labelling and immunofluorescence 
microscopy showed a typical transit time of 1 hour. During each passage a small 
fraction (1-5%) undergoes a proteolytic cleavage near residue 110. After the cleavage, 
both fragments return to the cell surface but the N-terminal fragment is secreted in the 
extra cellular space (Harris et al., 1993). PrP trafficking appears to be a complex cellular 
event and the mechanism of PrP internalisation is still a matter of debate, since 
caveolae, rafts and clathrin coated pits have all been shown to be involved.
Pioneering experiments using chicken PrP proved that the N-terminus was important for 
correct internalisation by coated pits as deletion mutants within this domain 
accumulated at the plasma membrane (Shyng et al., 1995b). Indeed, the same sequence
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Figure 1.5 Three-dimensional model of human PrPc.
PrP is composed of an N-terminal unstructured region and, as illustrated, a C-terminal globular 
domain with an overall a-helical structure (red). During its transit along the secretory pathway, 
the Prion protein acquires specific features such as two N-linked sugar chains (blue), a disulphide 
bond (yellow) and a GPI anchor (orange) responsible for its correct localisation at the cell surface 
Adapted from Collinge J., 2001.
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when cloned in front of Thy 1, another GPI anchored protein, was sufficient to change 
its membrane environment and confer the ability of entering coated pits (Sunyach et al., 
2003). Experiments with hypertonic buffer and a dominant negative mutant of dynamin 
I (K44A) provided compelling evidence for the key role played by clathrin coated pits 
in PrP endocytic uptake (Shyng et al., 1994). However, it has to be mentioned that 
dynamin can also be found at the neck of caveolae and the previous experiment cannot 
exclude impairment of internalisation via caveolae (Henley et al., 1998). The generation 
of GFP tagged PrP allowed a further insight into the internalisation mechanism (Lee et 
al., 2001b). GFP-PrP localises with the endosomal marker transferrin, the uptake of 
which involves coated pits (Magalhaes et al., 2002). PrP behaviour is rather unusual 
compared to most GPI-anchored proteins which are internalised via a clathrin-dynamin 
independent pathway. Moreover, the lack of a cytoplasmic domain in PrP suggests the 
existence of a PrP transmembrane receptor, with a clathrin coated pit signal in its 
cytoplasmic domain (Harris et al., 1996).
On the other hand PrP also possesses the ability to co-purify with caveolar markers such 
as ganglioside GM1 and antibody crosslinking of GPI proteins is known to trigger 
endocytosis by a caveolae dependent pathway (Mayor and Riezman, 2004; Vey et al., 
1996). Furthermore PrP copper-stimulated endocytosis was selectively blocked by 
filipin, a compound known to bind membrane sterols and alter caveolar 
structure/function (Marella et al., 2002).
A possible explanation to the apparent contradiction is that it cannot be excluded that 
copper-induced and unstimulated/constitutive endocytosis occur by alternative 
pathways including both caveolae and clathrin coated pits. Understanding the 
trafficking of the prion protein remains an ambitious goal since the cellular site of 
interaction/conversion between PrP and PrP has been proposed to take place on the 
cell surface or in an internal compartment (Taraboulos et al., 1992).
1.5.2.3 PrP and Rafts
Once on the cell surface, PrP molecules are found within rafts: highly ordered 
microenvironments, enriched in cholesterol and sphingolipids, and characterised by 
their insolubility in non-ionic detergents (Naslavsky et al., 1997). Rafts are highly
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specialised domains that can selectively include or exclude proteins to variable extents 
and are believed to form preferential foci for signal transduction events (Simons and 
Toomre, 2000). PrP association with rafts is an event that occurs early in the secretory 
pathway and seems to have a role in stabilising its correct folding, as shown by 
cholesterol depletion experiments (Samataro et al., 2004). Rafts may be sites for 
conversion of PrPc to PrPSc since exchange of the GPI anchor with the CD4 
transmembrane domain not only removes PrP from rafts but also prevents PrPSc 
formation (Kaneko et al., 1997a; Taraboulos et al., 1995). The presence of PrP in lipid 
rafts is not contradictory with its association with coated pits: only a small population of 
total PrP undergoes endocytosis at a given time and possibly leaves the raft 
microenvironments before entering the coated pits, as seen in primary neurons and 
neuroblastoma cells (Sunyach et al., 2003).
1.5.2.4 Organelles involved in PrP trafficking
Intracellular trafficking requires transport between different subcellular compartments. 
Pioneering observations suggest that the trafficking of caveolae internalised proteins 
divert from the classic route involving the endosomal/lysosomal network (Anderson, 
1998). Insight into the mechanism of vesicle transport has been mainly achieved by the 
study of the Rab proteins (Zerial and McBride, 2001).
Cellular and ultra-structural analysis reveals the presence of PrPc in the Golgi and in 
endosomal intracytoplasmic organelles, with no cytoplasmic or synaptic vesicle labeling 
(Laine et al., 2001). GFP-PrP transits through the Rab5-positive early endosome 
compartment whereas GFP-GPI does not (Magalhaes et al., 2002). However, PrPc has 
been reported in caveosomes - endosomes containing caveolin - in non neuronal cell 
lines (Peters et al., 2003). Knowledge of the routeing of PrPc could be extremely useful 
in understanding which subcellular compartments are involved in the generation of 
PrPSc, since changes in trafficking can delay scrapie onset in vivo (Gilch et al., 2001). In 
parallel, PrPSc generation was increased in an in vitro cell model by transfection of a 
dominant-negative Rab4 and a constitutive active Rab6a mutant. The former regulates 
membrane recycling from early endosomes to the plasma membrane whereas the latter 
stimulates the retrograde trans-Golgi transport. Instead, a mutated version of Rab9 
which is normally responsible for cargo sorting from late endosomes to the Golgi 
apparatus did not alter PrPSc formation (Beranger et al., 2002). Based on their data, the
37
Chapterl
authors hypothesised the involvement of retrograde transport of PrPSc to the ER, where 
it could seed the conversion of still immature PrPc molecules.
As a final remark, there is a wealth of evidence suggesting that PrPc may use different 
mechanisms of internalisation, involving both clathrin dependent and independent 
routes. Conversely, PrP internal trafficking seems less heterogeneous and canonical 
endosomal organelles play an important role, at least in neuronal cells.
1.5.3 PrP alternative topologies and localisation
1.5.3.1 Transmembrane PrP
In addition to the translocated isoform, denoted SecPrP, different transmembrane 
topologies of the prion protein were originally described using cell free systems in 
combination with microsomal membrane preparations (Hay et al., 1987). Two 
transmembrane PrP conformations have been reported so far and they differ in term of 
whether the C-terminus (CtmPrP) or the N-terminus (NtmPrP) of the protein is directed 
towards the ER lumen. The production of these isoforms is dependent on the putative 
transmembrane region (amino acids 113-135) and the upstream hydrophilic sequence 
(104-112), termed STE for Stop Transfer Effector. Usually, CtmPrP and NtmPrP are only 
produced in small amounts (less than 10% of the total) during the transit through the 
endoplasmatic reticulum but the introduction of point mutations was able to alter the 
relative ratio of the different topologies. Transgenic mice harbouring a CtmPrP favouring 
mutation (20-30% of the total) developed spontaneous neurodegeneration, including
p i
ataxia and this was in line with studies reporting increased levels of PrP in some 
cases of inherited prion disease (GSS mutations P105L and A117V) (Hegde et al., 
1998). However, both transgenic mice and human cases did not show spontaneous 
accumulation of PrPSc. Quite surprisingly, when challenged with exogenous PrPSc, 
CtmPrP mice not only accumulated PrPSc but a direct proportional accumulation of 
CtmPrP was observed at the expense of SecPrP (Hegde et al., 1999). The observation led 
the authors to speculate about a possible active role of CtmPrP in prion disease 
pathogenesis. The mechanism by which transmembrane PrP could induce neurotoxicity 
is still uncharacterised and under investigation.
Most recently a PrP construct carrying the mutations L9R-3AV (3AV is the designed 
name of the triple mutation Al 12V/A114V/A117V) produced exclusively CtmPrP when
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transfected into cell lines. The mutant protein failed to reach the cell surface and was 
retained in the endoplasmic reticulum (Stewart et al., 2005). However, neurons derived 
from transgenic mice harbouring the above mutations, accumulated CtmPrP in the Golgi 
apparatus and expressed an equal amount of SecPrP (Stewart and Harris, 2005). Tg 
(L9R-3AV) mice developed a severe neuropathology presenting neurodegeneration in 
different brain areas, including the cerebellum and hippocampus. Strikingly, disease 
onset was prolonged in the Prnp'A background compared to the wild type, suggesting 
that CtmPrP caused neurodegeneration via a mechanism dependent on the presence of 
wild type PrP.
NtmPrP differs more from the other topologies due to the absence of the GPI moiety and 
the lack of glycosylation. At the present moment, NtmPrP has not been associated with 
any TSE pathology and there is no conclusive evidence for its existence in vivo.
1.5.3.2 Cytoplasmic PrP
Plasma membrane proteins could spontaneously undergo misfolding during their transit 
to the endoplasmic reticulum and a mechanism known as retrograde transport usually 
ensures that misfolded, and potentially toxic, species are degraded in the cytoplasm by 
the proteasome complex (Kopito, 1997). Accumulation of even a small amount of 
cytosolic PrP (cytPrP), induced by treatment with proteasome inhibitors, was shown to 
be toxic in cell lines (Ma and Lindquist, 2001). In parallel, transgenic animals 
overexpressing a cytoplasmic version of PrP, due to the removal of the N-terminal 
signal peptide, developed ataxia and cerebellar neurodegeneration in a gene dosage 
dependent manner (Ma et al., 2002). CytPrP generated insoluble aggregates and proved 
to be partially Protease K resistant, two hallmarks typical of PrPSc-like conformations 
(Ma and Lindquist, 2002). Conversely another group has speculated that 
retrotranslocation could be an artefact due to an excessive increase in PrP messenger 
rather than a genuine reduction of the proteasome machinery (Drisaldi et al., 2003).
In striking contrast, there are at least two lines of evidence arguing against cytPrP 
toxicity. Firstly, PrP was found to be expressed in the cytosol of a small population of 
neurons in the hippocampus, thalamus and somatosensory neurocortex and none of the 
examined cells appeared either apoptotic or necrotic (Mironov et al., 2003); secondly, 
cytPrP is able to counteract Bax-mediated apoptosis in human primary neurons and
39
Chapterl
neuroblastoma cells (Roucou et al., 2005; Roucou et al., 2003). Hopefully, further 
studies will clarify the true role of cytosolic PrP in pathogenesis.
1.6 PrP Function
Despite its pivotal role in prion disease, after more than ten years since the generation of 
PrP knockout mice, the function of the prion protein still remains an enigma (Biieler et 
al., 1992). It was expected that the ablation of the Prnp gene could generate useful 
information regarding the function of PrP. Instead, no obvious phenotype was observed, 
posing the dilemma of how a protein highly expressed in the brain, where its expression 
is finely regulated during development, and in many other cell types could be 
dispensable for the organism. Only later analysis revealed minor alterations in electro 
physiological and circadian rhythm although these observations could not be completely 
reproduced by independent analysis (Collinge et al., 1994; Herms et al., 1995; Tobler et 
al., 1996).
Some of the putative functions attributed to PrP in the past years are outlined below 
giving emphasis to its suggested role in copper metabolism, signal transduction and pro- 
and-anti apoptotic functions.
1.6.1 Copper metabolism
The continuous endocytic recycling followed by PrP argues in favour of a role in active 
uptake of an extracellular ligand. PrP’s role in copper uptake and metabolism was 
initially suggested by its high binding affinity and by the later observation that 
following exposure to copper (100-500 pM) more than half of the PrP surface pool was 
internalised by endocytosis (Brown et al., 1997; Pauly and Harris, 1998). The 
mechanism by which copper stimulates endocytosis is not clear although a recent report 
has suggested a process involving protein misfolding (Kiachopoulos et al., 2004). PrP 
binds not only copper but also other metal ions such as zinc, manganese and nickel 
(Brown et al., 2000; Pan et al., 1992).
Synaptosomal fractions from PrP knockout mice presented a 50% decrease in copper 
concentration, favouring the possibility of copper re-uptake by PrP in the presynapses 
(Kretzschmar et al., 2000). Impaired copper uptake could result in reduced activity of
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cytosolic super oxide dismutase (SOD1), which requires copper and zinc as coenzymes 
to elicit its catalytic activity, and PrnpA mice were more sensitive to oxidative stress as 
monitored by increased oxidation of proteins and lipids (Herms et al., 1999). Moreover, 
recombinant PrP, either from mouse or chicken, was found to harbour SOD1 activity in 
vitro (Brown et al., 1999a). All the above evidence seemed to point in favour of an 
active role of PrP in copper homeostasis. However, other investigators failed to detect 
any difference in the amount of subcellular copper or in dismutase activity between 
Prnp+/+ and PrnpA mice (Hutter et al., 2003; Waggoner et al., 2000). Therefore, the role 
of the prion protein in these pathways remains controversial.
1.6.2 Cell survival and apoptosis
A divergent set of evidence has been generated regarding the role of the prion protein in 
cell survival and cell death. PrP was found to interact directly with the anti-apoptotic 
protein Bcl-2 and was able to confer partial resistance to apoptosis induced by 
anisomycin treatment (Chiarini et al., 2002; Kurschner et al., 1995); in line with this, 
primary neurons derived from Prnp'A mice have been shown to be more prone to 
neuronal death (Kuwahara et al., 1999). Furthermore, PrP interaction with the cell 
surface protein STI1 has been shown to activate a protective pathway, related to cAMP 
and PKA signalling (Zanata et al., 2002).
In clear contradiction to the above data suggesting a neuroprotective role, the work of 
other groups has pointed towards an active involvement of PrP in cell death. PrP 
overexpression was reported to increase cell death triggered by staurosporin treatment 
and caspase 3 activity whereas primary cultured neurons from PrP knockout mice were 
partially protected (Paitel et al., 2002; Paitel et al., 2004). In a different approach, the 
prion protein fragment, spanning amino acids 106-126, exhibited the ability to induce 
apoptosis in rat hippocampal neurons possibly through binding to the low affinity 
neurotrophin receptor p75 in neuroblastoma cells (Della-Bianca et al., 2001; Forloni et 
al., 1993). The same peptide led to JNK-Jun pathway activation and consequent cell 
death in primary cortical neurons (Carimalo et al., 2005).
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1.6.3 Signal transduction
Insights suggesting a possible PrP function in signal transduction came from 
crosslinking experiments using a-PrP antibodies. In a first report the tyrosine kinase 
Fyn was activated in a PrP dependent manner (Mouillet-Richard et al., 2000). The 
response was restricted to cells differentiated in vitro in the serotonergic or 
noradrenergic lineages and subsequent studies suggested a role for PrP in the 
homeostasis of serotonergic neurons (Mouillet-Richard et al., 2005). Since PrP and Fyn 
lie on opposite faces of the plasma membrane, the transmembrane molecule NCAM, 
previously purified in association with PrP, could mediate the signal transduction 
resulting in neuritogenesis (Santuccione et al., 2005; Schmitt-Ulms et al., 2001). 
Conversely, PrP specific monoclonals rapidly triggered apoptosis in hippocampal and 
cerebellar neurons in vivo (Solforosi et al., 2004).
PrP participation in signal transduction pathways was also suggested by its ability to 
interact with the adaptor protein Grb2, involved, for example, in the activation of MAP 
kinases (Spielhaupter and Schatzl, 2001). Finally, PrP has been suggested to participate 
in lymphocyte activation: this study showed that PrP expression was increased 
following cell activation and antibodies against PrP suppressed mitogen-induced 
activation (Cashman et al., 1990).
1.6.4 PrP interacting proteins
The possibility that proteins interacting with PrP may elucidate the physiological 
function of PrPc or play a role in prion diseases, has led to a quest for prion interacting 
proteins. Some of the interacting partners may be involved in the conformational 
transition responsible for the generation of PrPSc and, therefore, could be potential 
targets for therapeutic approaches. Many proteins have been isolated in the past for their 
ability to interact with PrP. Figure 1.6 shows some of the PrP partners which have had 
their binding sites identified.
Stanley Prusiner originally suggested the existence of a molecular chaperone, known as 
Protein X, involved in the transconformation process (Telling et al., 1995). Quite 
interestingly, the heat shock protein 60 (Hsp60) was originally isolated from a HeLa 
cDNA library as a novel PrP interactor and its bacterial homologue, GroEL, was able to
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induce aggregation of recombinant PrP in vitro (Edenhofer et al., 1996; Stockel and 
Hartl, 2001). Wild type PrP and the mutant Q217R bound the ER chaperone Bip, which 
might play a role in the quality control of newly synthesised molecules (Jin et al., 2000). 
PrP may not only interact with chaperones but itself possesses chaperoning activity 
similar to the nucleocapsid protein from HIV-1 and the ability to bind nucleic acids 
(Gabus et al., 2001). This could be of relevance, since host encoded RNA molecules 
have recently been shown to be required for in vitro conversion between PrPc and PrPSc 
(Deleault et al., 2003).
Amongst the most recently identified interactors, tubulin has been proposed to be 
responsible for the correct transport of PrP along the microtubular track whereas 
interaction with NRAGE, a cytoplasmic protein believed to facilitate apoptosis, has 
been suggested to modulate neuronal viability (Bragason and Palsdottir, 2005; 
Nieznanski et al., 2005). It is noteworthy that both tubulin and NRAGE, like many other 
isolated partners, do not share the same subcellular compartment with PrP resulting in a 
difficult interpretation of where the interaction may occur.
1.6.5 PrP: receptor or ligand?
Despite its constant recycling in the endocytic pathway, the main cellular localisation of 
PrP remains the plasma membrane, arguing in favour of its possible function as a 
receptor or ligand, as later supported by experimental evidence (Gauczynski et al., 
2001; Zanata et al., 2002).
PrP acts as cellular receptor for laminin and mediates neuritogenesis both in PC 12 cells 
and in primary neurons (Graner et al., 2000a; Graner et al., 2000b). The 37 KDa laminin 
receptor precursor (LRP) was initially identified as a PrP interactor by a yeast two- 
hybrid screen and its levels were increased in scrapie infected animals compared to 
uninfected controls (Rieger et al., 1997). Subsequently, a function of the LRP/LR 
complex was proposed in mediating internalisation of exogenous recombinant PrP 
(Gauczynski et al., 2001). Glycosamynoglycans (GAGs) show the ability to interact 
with PrP and the binding affinity is enhanced by the presence of copper ions (Pan et al., 
2002). Recently, Heparan Sulphate has also been proposed as a receptor for the uptake 
of prion rods (Horonchik et al., 2005). In summary, novel approaches need to be 
undertaken to provide further insight into the role of PrP which, being so
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Figure 1.6 Prion interacting molecules.
PrP precursor molecules are processed by cleavage of the N- and C- terminal signal peptides to 
produce a protein, which contains a positively charged region (yellow), five octarepeats (gray), 
a highly conserved hydrophobic domain (blue) and three alpha helices (red). Numbers in italics 
indicate the start and the end of each structural domain. The binding site of each Prion interacting 
partner is reported in brackets, apart for Synapsin I and Grb-2, which have not been mapped in 
detail. All numbers refer to human PrP sequence; Pintl and Casein kinase interacting domains 
are mapped against mouse (°) and bovine (*) PrP respectively.
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evolutionary conserved, must have a clear physiological function apart conferring 
susceptibility to prion disease.
1.7 PrP-related syndromes
1.7.1 Discovery of Dpi, the PrP homologue
In order to clarify the normal function of the prion protein, two lines of mice devoid of 
PrP (ZrchI and Edbg) were independently generated and have been reported to develop 
normally (Biieler et al., 1992; Manson et al., 1994). Quite surprisingly, a third PrP null 
line, known as Ngsk, showed a completely different phenotype: mice developed 
massive Purkinje cell degeneration in the cerebellum with consequential ataxia from 6 
months after birth (Sakaguchi et al., 1996). Bona fide proof that the phenotype was due 
to the absence of the product of the Prnp gene was the rescue by crossing with a line 
overexpressing wild type PrP (Nishida et al., 1999). Nevertheless, the explanation why 
different knockout lines exhibited different phenotypes was still elusive: clearly it was 
not due to the absence of PrP because the ZrchI and Edbg lines, despite lacking the 
prion protein, remained healthy.
The solution was provided when Westaway and colleagues identified the Prnd gene, 
during the sequencing of the DNA region around the Prnp gene (Moore et al., 1999). 
The Prnd  gene lies 16 kb downstream of Prnp and contains an open reading frame 
predicted to encode a protein related to PrP. Two major transcripts (2.7 and 1.7 Kb) 
have been reported and the product of the gene was named Dpi or Doppel for 
Downstream prion protein-hke gene. The ataxic phenotype was later ascribed to the 
ectopic expression of Dpi in the Nagasaki line. In wild type mice, Dpi transcripts were 
undetectable in brain but deletion of the splice acceptor site present in front of Prnp 
exon 3, which was ablated in the strategy used to generate the Ngk line but not in the 
Zrch or Edbg lines, resulted in an intergenic spicing event between the Prnp and Prnd 
genes: the result of which was a chimeric transcript, produced under the control of the 
Prnp promoter and containing the first two non-coding Prnp exons linked to the Dpl- 
encoding Prnd exon. This was later confirmed by the generation of other knockout lines 
(Zrchll and RcmO) using targeting strategies analogous to the one employed for the 
generation of the Ngsk line and showing a similar ataxic phenotype. Moreover, 
introduction of cosmid DNA expressing Dpi was able to further accelerate the ataxic
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syndrome in Zrchll mice as a direct consequence of the higher levels of Dpi present in 
the CNS. On the other hand, a single PrP allele could abrogate Dpi toxicity and extend 
the lifespan of the mice (Rossi et al., 2001).
More recently a third gene, called Prnt has been reported downstream of P rnd , 
confirming the existence of three PrP related open reading frames within 50 Kb 
(Makrinou et al., 2002).
1.7.1.1 Dpi: Structure and Function
Prnp and Prnd do not share homology at the DNA level, suggesting an ancient gene 
duplication event of an ancestor prion gene. Dpi, like PrP, was characterised as an N- 
glycosylated protein, anchored to the cell surface by a GPI moiety (Figure 1.7A) 
(Silverman et al., 2000). Similarity between PrP and Dpi is confined to the C-terminal 
domain: Dpi lacks the octarepeats and the hydrophobic region present at the N-terminus 
of PrP. Nevertheless Dpi and PrP share the ability to bind copper and despite being only 
25% identical regarding the amino acids composition, the C-terminus of PrP and Dpi 
are largely superimposable (Qin et al., 2003)(Figure 1.7B).
Mice in which the Prnd gene has been interrupted by insertion of a neomycin cassette 
display normal development but mutant males are infertile due to abnormal 
gametogenesis, demonstrating an unexpected physiological function of Dpi (Behrens et 
al., 2002). Dpi was found to be dispensable for prion disease progression as investigated 
using a neuronal grafts paradigm (Behrens et al., 2001). Furthermore, protein folding 
intermediates induced by urea treatment, which exist for PrP, cannot be detected for Dpi 
arguing against the possibility that Dpi can get converted to a pathological conformer 
(Nicholson et al., 2002).
1.7.1.2 Structural-functional analysis of Dpi toxicity
PrP seems to possess the ability to antagonise Dpl-mediated toxicity since Dpi can 
trigger cell death only in the absence of PrP. Many models have been proposed to 
account for this observation: among which, the idea that PrP and Dpi are able to 
compete for an as-yet unknown common ligand involved in a signal transduction 
pathway, as suggested by the binding of PrP and Dpi Fab’s to cerebellar granule cells 
(Legname et al., 2002). Recently, Westaway and colleagues have elegantly shown
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Figure 1.7 Structural comparison of PrP and Dpi.
A) Prion proteins share common features such the presence of three alpha helices (shown in 
red), g lycosylation (CHO) and attachm ent to the plasm a membrane via a 
glycosylphosphatidylinositol anchor (GPI). At the N-terminus a conserved cluster of basic 
residues is present (++); conversely, Dpi and the PrP deletion mutant AF do not present the 
octarepcat region (grey boxes), the stop transfer effector region (STE) and the hydrophobic core 
(<D), required for the generation of the transmembrane isoforms.
B) NMR structure of human PrP and mouse Dpi. Alpha helices are shown in red and beta strands 
are represented in cyan. Although the overall 3D structures are quite conserved, Dpi presents 
an interruption in the second alpha helix (B/B’) and a shorter loop spacing between alpha helices 
B and C. Modified from Westaway and Carlson, 2002.
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which determinants within Dpi and PrP are important to elicit neurotoxic and 
neuroprotective activity respectively (Drisaldi et al., 2004): residues 101-125 in Dpi 
were necessary to mediate cell death in cerebellar granule cells derived from Prnp'f' 
mice, meanwhile the positively charged sequence 23-KKRPKP-28 and the octarepeat 
region of PrP were necessary to rescue Dpl-mediated toxicity. Additionally, the 
observation that four missense fCJD point mutations change the PrP residues in the Dpi 
counterparts (V I801, E196K, E200K, E21 IQ) had led the researchers to speculate about 
a possible Dpl-like mechanism of toxicity in some inherited prion disease (Mastrangelo 
et al., 2002).
1.7.1.3 The Shmerling Syndrome
In an attempt to define which regions within PrP are necessary to support prion 
propagation, Shmerling and colleagues introduced different deletions extending from 
the N-terminus towards the C-terminus in a PrP knockout background. Mutant 
constructs termed AE and AF, lacking amino acids 32-121 and 32-134 respectively, 
caused an ataxic phenotype associated with massive reduction in the number of granule 
cells in the cerebellum, within three months of birth. Massive astrogliosis and 
spongiosis were also observed and the toxic phenotype was completely abrogated by the 
re-introduction of a single copy of wild type PrP (Shmerling et al., 1998).
The analogy between the Shmerling and Dpi Syndromes was, after the discovery of the 
latter, quite evident since Dpi not only structurally resembles the PrP-AF mutant (Figure 
3.7A) but the two disorders also share common symptoms including ataxia and 
cerebellar cells loss. Furthermore, the toxic effect of Dpi and PrP deletions could be 
rescued by a single copy of full length PrP. The only apparent discrepancy was due to 
the vectors used to generate the transgenic lines: the “Half Genomic PrP” vector, used 
to drive the expression of the AE and AF mutations, was active in granule cells but 
inactive in Purkinje cells, meanwhile Dpi expression was under control of the complete 
PrP promoter, known to be transcriptional active mainly in Purkinje cell and much less 
in granule cells (Fischer et al., 1996). When targeted specifically to Purkinje cells, the 
PrP-AF mutant was able to phenocopy Dpi overexpression and, once more, toxicity was 
abrogated by the presence of a single copy of wild type PrP (Flechsig et al., 2003).
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Finally, ubiquitous expression of Dpi resulted not only in loss of Purkinje but also 
granule cells (Moore et al., 2001).
1.7.1.4 A possible common toxicity pathway
All the evidence pointed in the direction that both PrP-AF and Dpi might cause cell 
death through the same pathway, either interfering with a survival signal or activating a 
cell death cascade. A classic dominant negative effect, such as interference of truncated 
PrP or Dpi in a pathway requiring PrP, cannot be invoked since the pathology develops 
in the knockout background only. Weissmann and coworkers suggested a possible 
model: PrP would normally bind an as-yet uncharacterised ligand Lprp via its C-terminal 
globular domain and elicit a survival signal via its N-terminal flexible tail (Shmerling et 
al., 1998). The lack of an obvious phenotype in PrP knockout mice would be due to the 
interaction between Lprp and ji, a hypothetical protein with functional properties similar 
to PrP and able to trigger the same signal cascade. Truncated PrP, and possibly also 
Dpi, could still bind Lprp but not activate the downstream pathway, behaving like a 
dominant inhibitor of Jt. However, the existence of Lprp and j i remains speculative since 
no potential candidate exhibiting such behaviour have been suggested so far.
1.8 The aim of the experimental work
As reviewed above, after many years the physiological function of PrP still remain 
elusive. The aim of the present work was the identification of novel PrP interacting 
molecules which would be extremely useful to characterise the molecular pathways in 
which PrP is involved. On the other hand, the system I have used allowed to screen for 
candidates which preferentially bind misfolded PrP; such proteins not only could clarify 
the mechanism responsible for PrPSc generation but could provide novel therapeutic 
targets in the cure of prion disease.
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Chapter 2: Materials and Methods
2.1 Tissue Culture
2.1.1 Cell lines and media 
Mouse Neuroblastoma N2a
Uninfected N2a cells were obtained from the ATCC and cultured according to their 
recommended guidelines. Chronically infected N2a were kindly provided by Dr. P. 
Kloehn from the MRC Prion Unit, London. Cells were cultured in OPTIMEM 
supplemented with 10% FCS - heat inactivated for 30 minutes at 56°C - and 
penicillin/streptomycin.
Human 293T
Human 293 cells were obtained from the ATCC and cultured according to the suppliers’ 
protocol. Cells were grown in Dulbecco Modified Eagle Medium containing 10% heat 
inactivated FCS, penicillin/streptomycin and L-glutamine.
Human HCT116
HCTs cells were provided by the CRUK Cell Production Unit. Cells were grown in 
Dulbecco Modified Eagle Medium, supplemented with 10% heat inactivated FCS, 
penicillin/streptomycin and L-glutamine.
Stock solution of penicillin (10000 u/ml), streptomycin (10 mg/ml) and L-glutamine 
(200 mM) were diluted 1:100 and were purchased from GibcoBRL.
2.1.2 Cell maintenance and passaging
All cell lines were grown in a 5% CO2 incubator at 37°C and were routinely passaged at 
1:5 or 1:10, twice a week. 293T and HCTS116 cells were trypsinised with 10X Trypsin 
(GibcoBRL) diluted to IX in PBS. Media was removed and cells washed once in PBS 
before being trypsinised for 5 min at 37°C and resuspended in 10 ml of pre-warmed 
media.
N2a passaging did not require trypsin but were gently detached by pipetting.
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2.1.3 Cell freezing
Confluent cells were gently detached from plates by mild trypsinisation and centrifuged 
for 5 minutes at 900 rpm. The resulting pellet was then resuspended in 1 ml of freezing 
buffer (90% FCS, 10% DMSO) at a concentration of 2 106 cells/ml and stored at -70°C. 
The following day, aliquots were transferred to a liquid nitrogen tank for long term 
storage.
2.1.4 Cell thawing
Frozen vials were quickly transferred from the liquid nitrogen storage to a 37°C water 
bath. Once completely thawed, the 1 ml aliquot was diluted in 10 ml complete media 
and spun down for 5 minutes at 900 rpm. The supernatant was then discarded and the 
pellet resuspended in 10 ml of complete media and transferred to a 10 cm dish to allow 
recovery.
2.1.5 Standard Lipofectamine 2000 Transfection
Cells were transfected using the Lipofectaminie 2000 reagent (Invitrogen) according to 
the manufacturers’ protocol. Briefly, cells were plated in 10 cm dishes at 70% 
confluence the day before transfection. 20 pg plasmid DNA and 40 p,l Lipofectamine 
2000 were diluted into two separate tubes, each containing 1.5 ml serum-free 
OPTIMEM. The contents of the tubes were mixed together and subsequently incubated 
at room temperature for 20-30 minutes. In the meantime, cells were washed once with 
OPTIMEM and incubated in the presence of the complex (3 ml final) for 4-5 hrs at 
37°C. The complex was aspirated and after one wash with OPTIMEM, complete media 
was added. Cells were analysed 48 hours post transfection by Western blot or FACS 
assay.
2.1.6 siRNA transfection
A pool composed by four siRNAs against the human PIP7 gene was purchased from 
Dharmacon (catalog # M-013452-00); a non targeting control pool was used to assess 
specificity (catalog # D-001206-13). Pools were dissolved in RNAase-free water to a
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final concentration of 20 pM and stored at -20°C. Human 293T cells were transfected 
with Lipofectamine 2000 according to manufacturers’ conditions. Briefly, cells were 
plated the day before transfection in order to obtain plate at 70% confluence. 60 pi of 
Lipofectamine 2000 and 20 pi of siRNA stock pool were dissolved in separate tubes, 
each one containing 500 pi of serum-free OPTIMEM. After 5 minutes, the contents of 
the two tubes were gently mixed by pipetting and allowed resting for 30 minutes in 
order to form the transfection complex. In the meantime, cells were washed once with 
serum-free OPTIMEM and 3 ml of serum-free OPTIMEM was added; the complex (1 
ml) was added to the plate in order to reach a final siRNA concentration of 100 nM. 5 
hours later, the complex was removed, cells were washed once and 10 ml of complete 
media were added. SiRNA efficiency was judged at two different time points: 36 and 60 
hours after transfection. The following day, cells were resuspended and splitted into 
three aliquots: the first one for FACS analysis, the second for Western blot analysis. 
The last aliquot was re-plated. The next day, further aliquots were taken and the 
experiment was terminated.
2.1.7 Cell Treatments
2.1.7.1 Pentosan Sulphate and Suramin
Human 293T cells were transfected as described above; 24 hrs later, the media was 
changed and the following compounds were dissolved in complete media: Suramin 
(Sigma) 200 pg/ml, Pentosan Sulphate (Fibrase, TEOFARMA) 100 pg/ml. Cells were 
returned to the incubator for additional 24 hrs before being fixed and processed 
according to the standard FACS protocol.
2.1.7.2 PIPLC
In order to specifically release all GPI anchored proteins, confluent N2a cells were 
washed once with PBS. PIPLC (GLYKO) was diluted in serum-free OPTIMEM to a 
final concentration of 250 mU/ml and added to the culture. Cells were incubated for 2 
hours at 37°C, the media was then removed and cells were washed twice with PBS, 
before fixation in 4% PFA.
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2.2 Yeast Physiology
2.2.1 Yeast strain phenotype
S. cerevisiae CDC25-2 cells were ura3, lys2, leu2, trpl, his200, ade2-101, cdc25-2 
temperature sensitive. Cells were grown in YPD media at 25°C. Cells were routinely 
checked for the presence of revertants able to grow at the restrictive temperature of 
36°C.
2.2.2 Standard yeast transformation
100 ml of yeast culture in mid-log-phase (OD6oo= 0.4) were spun at 3000 rpm for 5 
minutes, washed once in 1 ml water, once in 1 ml of TEL buffer. Cells were 
resuspended in 1 ml of TEL (50 pi of cell suspension was found suitable for one 
transformation). DNA to be transformed was prepared in a separate tube (2 pg of vector 
in a final volume of 8 pi) and mixed with 2 pi of 10 mg /ml salmon sperm DNA, used 
as carrier, boiled for 5 minutes at 95°C and placed on ice for 5 minute. 50 pi of cell 
suspension were added to the DNA and gently mixed. 300 pi of TELP buffer were 
added, samples were vortexed strongly for about 10 seconds then incubated at 25°C for 
4 hours. After incubation, heat shock was performed for 15 minutes at 42°C, the tube 
was spun at room temperature for 2 minutes at 6000 rpm, the supernatant was aspirated 
and the pellet was resuspended in 1 ml 1 M Sorbitol. 100 pi were plated, and remaining 
cells were spun down again and resuspended in 100 pi 1 M Sorbitol and plated. Plasmid 
DNA containing the suitable auxotrophy marker (LEU2 or URA3) allowed selecting 
transformant in defined synthetic media on the base of nutritional requirements. Plates 
were incubated at 25°C and colonies were visible after 2-3 days.
2.2.3 Yeast extracts
50 ml of S. cerevisiae culture was grown in the appropriate selection media until 
OD6oo=0.5 (5 x 108 cells), and centrifuged in Falcon tubes at 3000 rpm for 5 minutes. 
The pellet was resuspended in 3 ml of buffer A and incubated for 10 minutes at room 
temperature. After spinning down at 2000 rpm for 2 minutes, the supernatant was 
aspirated, the pellet resuspended in 2 ml of buffer B and transferred to a 2 ml eppendorf 
tube. 4 pi of 20 mg/ml Zymolase T-100 solution was added and the sample was
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incubated for 10 min at 37°C in a water bath. All the following steps were performed in 
cold room. Tubes were spun for 1 minute at 4000 rpm; the pellet was washed once in 1 
ml of ice cold buffer C, spun 1 min at 4000 rpm and an equal volume of buffer EB was 
added to the pellet (5 x 108 cells yield 80-100 pi pellet). Triton X-100 was then added to 
a final concentration of 0.25% and cells were lysed on ice for 3 min with occasional 
vortexing. This resulted in the production of a whole cell extract. In order to separate 
soluble and insoluble fractions, an additional centrifugation step was performed (10  
minutes at 13000 rpm): the supernatant was the soluble fraction and the pellet was the 
detergent insoluble fraction. The pellet was resuspended in 100 pi of EB buffer.
2.2.4 Library subcloning for rRRS
The original RRS full brain mouse library was a generous gift from Dr Ami Aronheim. 
In order to perform the screen using the rRRS approach, the whole library was 
subcloned into the pYESRas(61)AF plasmid using the restriction enzymes EcoRI and 
Xhol.
2.2.5 cDNA library transformation
The above described standard yeast transfection protocol was modified as follows: 1.6 
litres of CDC-2 yeast, previously transformed with the plasmid encodying Myr-PrP23- 
230 as bait, were grown until OD6oo= 0.4. Cells were washed once in water and once in 
TEL. A total amount of 160 pg of library DNA was mixed with 120 pi of 10 mg /ml 
salmon sperm DNA. Yeast were finally plated on 44 plates (YNB/Glucose, - Leu, -Lira) 
and incubated at 25°C. As negative controls, cells transfected only with the bait or 
empty pYESRas vector were plated at 36°C. These controls allowed the detection of the 
presence of revertant or possible contamination during the transfection procedure.
2.2.6 Library screen
Colonies (1 x 105) appeared 4-5 days after library transformation. Plates were replica 
plated on two different YNB/Galactose plates, either with or without methionine. Both 
sets of plates were incubated at 36°C for an additional 5-7 days. Thereafter, colonies 
that exhibited efficient growth only on the plate lacking methionine, as compared to the
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twin plate containing methionine, were picked to a YNB/Glucose plate lacking ura and 
leu, using a grid. Candidates were allowed to grow for 2-3 days at 25°C before 
undergoing an additional replica plating step and being tested a second time for 
methionine dependent growth. Only colonies which passed both tests were processed 
for DNA extraction.
2.2.7 Plasmid DNA extraction
Candidate clones were picked and grown overnight in 5 ml YNB media lacking ura. 
The following day, yeast cells were centrifuged and the pellet washed once in water 
before resuspension in 100 pi of STET Buffer; 0.2 g of 0.45 mm glass beads (Sigma) 
were then added and the samples were vortexed vigorously for 10-15 minutes; 
following the addition of another 100 pi of STET Buffer, samples were boiled at 95°C 
for 10 min and let cooled on ice. An aliquot of 100 pi was transfered to a new tube, 
mixed with 50 pi of 7.5 M Ammonium Acetate, incubated for 1 hour at -20°C and 
centrifuged at full speed. 100 pi of supernatant were placed in a new tube and DNA was 
precipitated with 200 pi of ice cold 100% Ethanol. After 10 min of refrigerated 
centrifugation, pellet was washed once with 70% Ethanol and finally resuspended in 20 
pi of water. 1 pi was used to transform chemically competent bacteria. Transformation 
reactions were plated on Ampicillin plates and allow growing overnight. Single colonies 
were picked and expanded by miniprep. DNA was compared to bait by EcoRI-XhoI 
restriction digestion.
2.2.8 Candidate identification
Inserts were excised by enzymatic digestion (EcoRI-XhoI) and subcloned into the 
pGEX vector. Standard sequencing reactions were performed using the following 
primers:
Forward 5’ ggg ctg gca age cac gtt tgg tg 3’
Reverse 5 ’ ccg gga get gca tgt gtc aga gg 3 ’
The resulting sequences were submitted to the BLAST server.
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2.2.9 Solutions and Media
YPD MEDIA 
Yeast extracts 1.1% w/v 
Bacto Peptone 2.2%
D-Glucose 2%
Bacto Agar >20g/500ml
YNB/GALACTOSE MEDIA 
Yeast Nitrogen Base 0.32%
Ammonium Sulfate 2.5 g 
Galactose 15 g 
D-Raffinose 10 g 
Glycerol 10 g 
Bacto Agar >20g/500ml
YNB/GLUCOSE MEDIA 
Yeast Nitrogen Base 0.85g 
Ammonium Sulfate 2.5 g 
Glucose 10 g 
Bacto Agar >20g/500ml
All amino acid solutions were obtained from Sigma. 5 mg/ml stock solutions were 
prepared - with the exception of methionine which was 20 mg/ml in order to obtain 
efficient repression of bait expression -  and stored at 4°C. All stock solutions were 
diluted 1:100 before use.
YEAST BUFFER A:
100 mM PIPES/KOH pH9.3 
10 mM DTT 
0.1% Na-Azide
YEAST BUFFER B
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50 mM Kpi pH 7.4 
0.6 M Sorbitol 
10 mM DTT
YEAST BUFFER C 
50 mM HEPES/KOH pH 7.5 
100 mM KC1
2.5 mM MgCl 
0.4 M Sorbitol
EB BUFFER
50 mM HEPES/KOH pH 7.5 
100 mM KC1
2.5 mM MgC12 
1 mM DTT
Protease inhibitor cocktail
TEL BUFFER
10 mM TRIS/HC1 pH 7.5
0.1 mM EDTA
100 mM Lithiun Acetate
TELP BUFFER 
10% 10X TEL 
10% H20
80% of 50% PEG solution
STET BUFFER 
8% Sucrose 
50 mM TRIS pH 8.0 
50 mM EDTA 
5% TRITON X-100
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2.3 Molecular Biology
2.3.1 PrP constructs
Bait generation for the Ras Recruitment System
The murine PrP open reading frame, encompassing residues 23 to 230, was amplified 
by PCR using as a template the previously described Half genomic PrP plasmid (Fischer 
et al., 1996) and cloned into pYES2 plasmid containing an active form of Ras (amino 
acids 2-185) lacking its C-terminal CAAX box by BamHI-Notl restriction digestion. 
Following the above cloning step, the Ras-PrP fusion was subsequently subcloned into 
pMet25 by Hindlll-Notl digestion. Since the original pMet vector contained only a 
Hindlll site in the multiple cloning sites but not a Notl site, a pMet25-M-Chp plasmid 
was used as backbone, since it provided a unique Notl site at the 3’ end of the Chp. 
Forward: 5’a ccc ggatcc atg aaa aag egg cca aag cct gga ggg tgg aac acc 3’
Reverse: 5’aat aat gcggccgc tea ggatct tct ccc gtc gta ata ggc ctg gg 3’
All primers used in this work were manufactured by Sigma-Genosys.
Bait generation for the reverse Ras Recruitment System
PrP23-230 was amplified by PCR using the following primers:
Forward: 5’a ccc aagctt atg aaa aag egg cca aag cct gga ggg tgg aac acc 3’
Reverse: 5’aat aat gcggccgc tea ggatct tct ccc gtc gta ata ggc ctg gg 3’
For the myristoylated version, an alternative forward primer containing the vSrc signal 
was used: 5’a ccc aagctt atg ggg age age aag age aag ccc aag gac ccc age cag ege aaa 
aag egg cca aag cct gga ggg tgg 3’
Following enzymatic digestion by Hindlll-Notl, the fragments were inserted into the 
pYEplacl81 plasmid, previously modified with a Met3 promoter, chosen for its higher 
regulation stringency compared to the Met25.
GFP-PrP fusion constructs
Fusions between the green fluorescence protein (GFP) and PrP wild type, AE, AF and 
ASP were a generous gift from Dr Vilma R. Martins and have been previously fully 
characterised (Lee et al., 2001b).
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Full length PrP
Full length PrP was provided by Prof A. Negro and Dr C. Sorgato (Massimino et al., 
2004).
Endocytosis impaired PrP mutant
The 3F4 mouse PrP construct and the NGAG mutant were kindly provided by Professor 
Roger Morris (Sunyach et al., 2003).
2.3.2 PIP7 constructs 
Full length PIP7
The pBK hnRNP M4 construct was kindly provided by Dr. O. Bajenova and Professor 
P. Thomas and has been previously described (Bajenova et al., 2003; Bajenova et al., 
2001).
PIP7 fusion constructs
The PIP7 fragment was excised from the library vector by EcoRI-XhoI enzymatic 
digestion and subcloned in pGEX. To generate constructs expressing exclusively the 
Tandem Repeat region or the RRM3 domain fused either to GFP or GST, polymerase 
chain reaction was performed using pGEX-PIP7 as template in combination with the 
following primers:
Tandem Repeats:
Forward: taa taa aga att cag gag cgc atg ggc gca ggc tta gg 
Reverse: taa teg gaa ttc tta ggc ctt cct ggc tac tcc agg tgc 
RRM3:
Forward: taa taa aga att cag ggt gga gcc gga ggt get age 
Reverse: taa teg gaa ttc tta age att tct ate aat teg aac ate
Amplification products were cloned in the EcoRI site of pEGFP-C3 vector (Clontech) 
or pGEX (Amersham-Biosciences) to generate GFP and GST fusions respectively.
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2.3.3 Miscellaneous constructs:
The GFP-GPI plasmid was kindly provided by Dr. Chiara Zurzolo.
2.3.4 Cloning
2.3.4.1 DNA restriction digestion
One unit of restriction enzyme digests 1 pg DNA in one hour at 37 °C. Restriction 
digests contained 2 pg DNA, 2 pi 1 OX recommended buffer and 5 units of restriction 
endonuclease (NEB). Water was added to 20 pi. After 2 hours at 37 °C the reactions 
were stopped with 5 pi loading buffer and loaded onto an agarose gel.
2.3.4.2 Gel electrophoresis for separation of DNA fragments
Agarose gel electrophoresis was carried out in horizontal gel chambers. Depending on 
the size of the DNA fragments agarose concentrations between 0.8% and 2 % were 
used. The agarose was dissolved in IX TAE Buffer (w/v) in a microwave and 
ethidiumbromide was added to a final concentration of 10 pl/g agarose. The gel was 
poured into a gel chamber and left to polymerise. DNA fragments were loaded in the 
wells and separated at voltages between 60 and 125V depending on gel size and 
percentage. Bands were visualized by a UV transilluminator.
2.3.4.3 Purification of DNA fragments with a GFX PCR DNA and Gel Band 
Purification Kit
The band of interest was cut out from the gel with a sterile scalpel, transferred to an 
eppendorf tube and 500 pi of Capture buffer were added and the tube was incubated at 
60°C until the agarose was completely dissolved. For purification of PCR products, 
instead, 300 pi of Capture buffer were added. All following steps are the same for PCR 
products and purifcation from agarose gels. The sample was then transferred to a GFX 
column and incubated for one minute at room temperature. Afterwards it was 
centrifuged for 30 seconds at 13000 rpm in a microcentrifuge. The flow-through was 
discarded and the column washed with 500 pi of wash buffer and centrifuged again at 
14000 rpm for 30 seconds. Finally the GFX column was transferred to an eppendorf
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tube and the DNA was eluted by spinning 50 pi water through the column at 13000 rpm 
for 1 min.
2.3.4.4 Dephosphorylation of Vector DNA
To avoid possible religation of vector DNA the the 5’-ends of the purified digested 
vectors were dephosphorylated with 1 pi alkaline phosphatase , 2 pi of NEB 3 buffer in 
a final volume of 20 pi for 1 hour at 37 degrees. Dephosphorylated DNA was 
subsequently purified on a DNA purification column.
2.3.4.5 Ligation of DNA fragments
Ligations were carried out overnight at 16°C. For each reaction 1 pi of T4 ligase, 2 pi 
T4-ligase buffer and vector and insert DNA in a ratio of 3:1 were used in the final 
volume of 20 pi.
2.3.4.6. Preparation of chemically competent E. coli
Bacteria were allowed to grow overnight in 5 ml of LB media at 37°C with vigorous 
shaking. The following day 2 ml were used to inoculate 500 ml of LB media and the 
bacterial culture was allowed to reach OD6oo=0.5. The culture was then divided into two 
sterile centrifuge beakers and incubated on ice for 30 minutes, before spinning 12 
minutes at 2500 rpm. Supernatant was discarded and each pellet was resuspended in 20 
ml RF-1 buffer and transfered to a 50 ml Falcon tube. After 15 minutes on ice, cells 
were spun for 12 minutes at 2500 rpm, the supernatant discarded and each pellet 
resuspended in 3.5 ml of RE-2 Buffer. Aliquots were immediately stored at -80°C. All 
operations were performed in sterile conditions and using sterile equipment.
2.3.4.7 Transformation of E. coli
An aliquot of 100 pi competent XL-1 Blue cells was thawed on ice and mixed with 0.5 
pg DNA. The mixture was incubated on ice for 30 minutes, heated to 42°C for 1 minute 
and transferred back on ice for further 5-10 minutes. 500 pi of LB were added and the 
transformation mixture was incubated for 1 hour at 37°C. 150- 200 pi were spread on a
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plate containing the appropriate antibiotic (Ampicillin or Kanamycin lOOpg/ml) and 
incubated overnight at 37 °C.
2.3.4.8 Isolation of Plasmid DNA with Qiaprep Spin Miniprep Kit
5 ml of an overnight bacterial culture were centrifuged for 5 min at 3500 rpm and the 
supernatant discarded. The pellet was resuspended in 250 pi of buffer PI and 250 pi of 
buffer P2 (lysis buffer) and incubated for 5 min at room temperature to allow lysis. The 
reaction was stopped with 350 pi of neutralization buffer N3 and the solution was spun 
for 10 min at 13000 rpm in a microcentrifuge. The supernatant was applied to the 
column for binding of the DNA, centrifuged for 1 min at 13000rpm and washed with 
250 pi buffer PE and recentrifuged. After discarding the flow through the columns were 
centrifuged again to remove the last remaining wash buffer. The column was then 
placed into an eppendorf tube and 50 pi of H2O were added. For the elution of the DNA 
the columns were centrifuged at 13000 rpm for 1 min again and the eluted DNA was 
stored at -20°C.
2.3.4.9 Isolation of Plasmid DNA in a preparative scale with Qiagen Maxiprep Kit
Bacteria containing the plasmid of interest were cultured overnight in 200 ml and 
harvested by centrifugation for 15 min at 3500 rpm. The pellet was resuspended in 10 
ml buffer PI and 10 ml buffer P2 were added for alkaline bacterial lysis and the sample 
was incubated for 10 min at room temperature. After lysis the reaction was neutralized 
with 10 ml of chilled buffer P3, incubated on ice for 20 min and centrifuged for 30 min 
at 4000 rpm. The supernatant was applied to columns which had been equilibrated with 
10 ml buffer QBT. The DNA bound to the column was washed twice with 30 ml buffer 
QC and finally eluted by applying 15 ml elution buffer QF. The DNA was precipitated 
with 10.5 ml isopropanol and the tube centrifuged for 30 min at 15000 g. The DNA 
pellet was dried and diluted in a suitable volume of H2O to achieve a final concentration 
of 1 pg/pl.
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2.3.4.10 DNA isolation from mouse tail biopsy
500 pi of Tail Buffer were added to a 5 mm tail biopsy and incubated overnight at 55°C. 
The sample was placed on Eppendorf Mixer for 5 minutes. Following addition of 250 pi 
of 5M NaCl, samples were mixed for further 5 minutes and spun for 10 minutes full 
speed on a bench centrifuge. 500 pi of supernatant were transferred to a new tube and 
mixed with an equal volume of isopropanol. In order to precipitate the DNA, tubes were 
centrifuged for 10 minutes at full speed and the pellet, once washed with 70% Ethanol, 
was resuspended in 200 pi H2O. 1 -2 pi were used for each genotyping reaction.
2.3.4.11 Genotyping mouse genomic DNA by PCR
LacZ primers were used for genotyping the XE413 and NPX275 mice.
Forward CGT CAC ACT ACG TCT GAA CG 
Reverse CGA CCA GAT GAT CAC ACT CG 
The product was a band of 500 bp.
2.3.4.12 DNA sequencing
For a typical sequencing reaction: 8 pi of BDT v3.1 (BigDye terminator kit from 
Applied Biosystems UK, shipped stock was diluted 1:16), 3.2 pmoles of primer, 200 ng 
DNA, water up to a final volume of 20 pi.
The reaction was placed in a thermal cycler and the following program was performed: 
STEP1 go to 96°C (2.5°/sec)
STEP2 denaturation 96°C for 1.00 minute 
STEP3 denaturation 96°C for 10 seconds 
STEP4 go to annealing temp (1.0°/sec)
STEP5 annealing (temperature varied according to the primer melting temperature) 
STEP6 go to extension temp 60°C (1.0°/sec)
STEP7 annealing 60°C for 4.00 minutes 
STEP8 Cycling go to STEP3 X 24 
STEP9 cooling 4°C forever
Reactions were purified using DyeEx Spin Columns (QIAGEN). DNA sequencing was 
performed on an Applied Biosystems 3730 DNA Analyser, a capillary sequencing 
platform.
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2.3.4.13 Solutions
DNA Loading buffer:
50 mM Bromophenolblue 
1 mM EDTA (pH 8.0)
50 % (w/v) Glycerol
5OX TAE buffer:
242 g Tris
57.1 ml glacial Acetic acid
100 ml 0.5M EDTA
H2O up to 1 litre (final pH 7.8)
LB-Medium: 
lOgNaCl 
10 g tryptone 
5 g yeast extract
pH adjusted to pH 7.4 with NaOH 
H2O to 1 litre
LB-Agar:
LB Medium as above described 
20 g Agar before autoclaving
RF-1 Buffer:
12 g Rubidium-chloride 
9 g Manganese-chloride x 2H2O 
2.94 g Potassium-Acetate
1.5 g Calcium-chloride x 2H2O 
150 g Glycerol
pH adjusted to 5.8 with Acetic Acid. 
H2O up to 1 litre
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RF-2 Buffer:
2.09 g MOPS
I.2 g Rubidium Chloride
II.0  g Calcium-chloride x 2H20 
150 g Glycerol
pH adjusted to 6.8 with Sodium-Hydroxide 
H2O to 1 litre
RF-1 and RF-2 solutions were passed through a 0.22 \i filter and stored at 4°C.
2.4 Production of mouse monoclonal antibodies
All procedures described below have been performed by the CRUK Antibody Unit.
2.4.1 Immunisation Schedule
Recombinant GST-PIP7 fusion protein was produced as described in section 2.X. In 
order to generate PIP7 specific antibodies, GST was removed by digestion with 
Thrombin protease according to the manufacturer instruction. 20 p,g of antigen were 
injected as immunogen per animal. Each injection volume did not exceed 0.1 ml at each 
of the 2 sites/mouse. All injections were made subcutaneously. A total of 4 Cd-1 
females (HARLAN) were immunised according the following schedule:
DAY OPERATION
0 Pre-bleed and Primary immunisation in Complete Freunds
21 First boost in Incomplete Freunds
31 First test bleed
49 Second boost in Incomplete Freunds
59 Second test bleed
65
Chapter 2
11
87
Third boost in Incomplete Freunds
Final Bleed
All test bleeds were analyzed by Western Blot and ELISA confirming the mounting 
immune response and positive mice were identified.
2.4.2 Splenocytes isolation
The spleen was aseptically removed and placed into a 10 cm tissue culture dish 
containing 10 ml of pre-warmed DMEM medium with no serum. Any possible 
contamination by connective tissue was trimmed off and discarded. Using sterile 
scissors, several small holes were cut in the spleen. Using a 1.0 ml syringe and a 19 
gauge needle, media was aspirated and flushed inside the spleen until most of the cells 
were released into the dish. Any cell clumps were disrupted by pipetting. Cells were 
then transferred to a sterile centrifuge tube. The culture dish was washed once with an 
additional 10 ml of pre-warmed medium lacking serum which was passed once through 
a 0.2 micron filter and combined with the first 10 ml. Cell clumps were allowed to 
attach and the supernatant, containing the splenocytes, was transfered to a fresh tube.
2.4.3 Splenocytes fusion
Splenocytes were washed twice in serum-free DMEM and spun at 400 g. 20 ml of 
mouse myeloma cells were washed once and combined with the splenocytes solution. 
After a further centrifugation step at 800 g for 5 minutes, the medium was removed and 
the pellet was resuspended in 0.5 ml of 50% PEG solution in medium. PEG was slowly 
added to the pellet while cells were resuspended by gentle stirring with a pipette. Cells 
were allowed to rest for a minute. A 10 ml pipette was filled with pre-warmed media 
lacking serum and 1 ml was added to the cell suspension during the subsequent minute 
with continuous stirring. After the addition of the remaining 9 ml, cells were centrifuged 
at 400 g for 5 minutes. After discarding the supernatant, cells were resuspended into 10 
ml of medium supplemented with 20% FCS and IX Azaserine Hypoxantine (final
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working concentration 5.7 pM Azaserine, 100 pM Hypoxanthine). The cell suspension 
was mixed with 100 ml of the same medium: 100 pi cells were aliquoted in 10 wells of 
a 96 well plate and placed in a 37°C incubator. Clones were visible after 4-5 day.
2.4.4 ELISA
Antigen specific ELISA
The following procedure was used to screen test bleeds and hybridoma clones.
Plates were coated with the antigen used for immunisation (C-terminal portion of PIP7) 
at a final concentration of 3 pg/ml in PBS and left overnight at 4°C. The next day, 
ELISA plates were washed once with PBS-T and rinsed 5 times with sterile water. To 
avoid non specific binding, plates were incubated overnight at 4°C with 20% w/v non 
fat dry milk in PBS. The following day, the blocking solution was removed and wells 
were washed once with sterile water. For test bleeds, 10 pi was added to the first well 
and serial dilutions were made. For hybridoma fusion, 90 pi of cell supernatants were 
used. The plates were incubated overnight at 4°C or, alternatively, for 2 hours at room 
temperature. Supernatant/bleed was removed and the following washes were performed: 
IX PBS-T, 5X water. Anti-mouse secondary antibody, HRP conjugated, was diluted 
1:2000 in PBS-T and incubated on the plates for 1 hour at room temperature. 3 washing 
steps in PBS-T were finally performed. For the detection, the OPD peroxidase substrate 
(Sigma) was used according to the manufacturer’s guidelines. Briefly, one urea tablet 
was mixed with 20 ml of water and once fully dissolved an OPD hydrogen peroxide 
tablet was added. 75 pi of the resulting solution was added to each well. Reactions were 
stopped by adding 50 pi of 2 M HC1. Plates were read using a microplate reader set to 
490 nm.
Subclassing ELISA
Positive clones were transferred from a 96 to a 24 well plate containing DMEM/20% 
FCS and IL6. After one week, the supernatant was tested in order to determine the 
antibody subclass. Affinity purified anti subclass antibodies were kept as stock solutions 
at 1 mg/ml and diluted to 5 pg/ml in PBS prior to use. Aliquots of 50 pi of the diluted 
anti subclass antibody were added to each well overnight at 4°C. The next day, plates
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were washed 3 times with PBS and blocked with 200 pi 2% non fat dry milk in PBS for 
2 hours. A final wash with PBS-T was performed at the end of the blocking step. 50 pi 
of test sample were taken from hybridoma culture and added in duplicate into each well 
containing the different antibody subclasses and incubated for 2 hours at room 
temperature. Three washes with PBS-T were performed before the addition of 50 pi of 
1:1000 dilution of goat anti-mouse Fab-peroxidase conjugated in PBS-T. Plates were 
incubated for 2 hours at room temperature and washed three times in PBS-T. Substrate 
for detection was prepared as described for the standard ELISA protocol. Photographs 
of the plate were taken using a Polaroid camera. The procedure was repeated at least 
once in order to have unambiguous result.
2.4.5 Antibody purification
2.4.5.1 Purification of Mouse IgGl antibody
2 litres of filtered supernatant were buffered with 1 litre of 3M Ammonium Sulphate pH 
9.0; the final pH was adjusted to 9.0 with 10 M NaOH before loading onto a 25 ml 
Protein A column (5ml/minute). Bound antibodies were eluted with 0.1M Citrate pH 
4.0; after elution, the solution was immediately neutralized using 10 M NaOH and 
antibodies were desalted in PBS.
2.4.5.2 Purification of Mouse IgG3 antibody
1 litre of filtered supernatant was buffered with 100 ml of 1M TRIS pH 8.0; the final pH 
was carefully adjusted to 8.0 with 10M NaOH before loading on a 25 ml Protein A 
column (5ml/minute). Bound antibodies were eluted with Gentle Elution Buffer 
(PIERCE); antibodies were first desalted in 0.1M TRIS and subsequently in PBS.
2.4.5.3 Desalting Purified Antibody
A G25 (Amersham) column was equilibrated with 4 volumes of PBS before applying 
the purified Ab solution. The column was loaded with antibody solution (20% column 
volume) and elution was obtained by the addition of 1 volume of PBS.
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2.4.5.4 Antibody storage
All antibodies were sterile filtered and stored at 4°C. For long term storage, aliquots 
were frozen at -80°C.
2.5 Protein Biochemistry
2.5.1 Protein preparations 
Cell lysate
Growth media was removed and cells were washed once in PBS. Cells were lysed 
directly on the plate by addiction of Lysis Buffer (500pl/10 cm dish). Total lysate was 
transferred to an eppendorf tube and left on ice for 10 minutes. Lysate was spun at 1000 
g for 5 minutes in a refrigerated bench centrifuge, in order to eliminate the cell debris. 
Protein concentrations were determined by Bradford assay.
Total brain homogenate
Mouse brains, from mice older than 2 months of age, were mechanically homogenized 
in PBS in order to obtain a 10% w/v preparation. The solution was then subjected to a 
centrifugation step of 5 minutes at 1000 g in a refrigerated centrifuge. Protein 
concentrations were determined by Bradford assay.
Brain membrane enrichment protocol
Total mouse brain was homogenized in Buffer A with a teflon/glass potter (20 strokes) 
to reach a final concentration of 40 mg/ml. The homogenized tissue was centrifuged at 
1000 g for 5 min. The supernatant was collected, transferred to a new tube and 
centrifuged at full speed for 15 min. The pellet containing a crude membrane fraction 
was resuspended in Buffer A. Bradford assay was performed to estimate the protein 
concentration.
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2.5.2 Bradford assay
Protein concentrations were determined using the Bio-Rad Protein Assay, based on 
absorbance shift in Coomassie Brilliant Blue G-250 (CBBG) when bound to arginine 
and aromatic residues. The anionic (bound form) has a maximum absorbance at 595 nm 
whereas the cationic form (unbound form) has an absorbance maximum at 470 nm. The 
5X stock solution was diluted in H2O and 1 ml was aliquoted in polystyrene cuvettes of 
1 cm path lenght. 2 pi of protein lysate was dissolved in each cuvette. Concentrations 
were obtained by linear interpolation with a calibration curve of known concentrations, 
prepared using bovine albumin as a standard.
2.5.3 Production of recombinat GST fusion proteins
pGEX plasmids containing the PIP7 cDNAs were trasformed in E. coli; a single colony 
was picked and inoculated in 100 ml of LB/Ampicillin and allowed to grow overnight at 
37°C. The next day, the culture was diluted 1:10 in fresh LB/Ampicillin and allowed to 
grow until OD6oo=0.5. At this step, one aliquot of uninduced bacteria was taken for later 
analysis. In order to stimulate recombinat protein production, IPTG was added to a final 
concentration of 0.4 mM. Bacteria were allowed to grow for an additional 4 hours with 
vigorous shaking at 30°C. The culture was spun down at 5000 rpm for 10 minutes at 
4°C.
All the following steps were performed in cold room: the bacterial pellet was 
resuspended in 10 ml of NETN buffer. Lysozyme was added at the final concentration 
of 100 pg/ml and bacteria were incubated on ice for 30 minutes with occasional mixing. 
The solution was then sonicated with 10-20 pulses (power 50%, duty 50%) and spun at 
10000 g for 10 minutes at 4°C. The supernatant contained the total bacterial lysate.
2.5.4 Purification or recombinant proteins
In order to purify recombinant fusion proteins from the whole bacterial lysate, the 
supernatant was incubated with glutatione sepharose beads (Amersham Biosciences) for 
1 hour at 4°C (1 pi of dry beads binds 5-10 pg of GST). Beads were washed 3 times 
with NETN buffer and bound proteins were eluted by adding a freshly prepared solution 
of glutathione (20 mM in 100 mM TRIS pH8, 120 mM NaCl). Several small elutions 
were found to be more efficient than a single elution step. Beads were rotated for 10
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minutes at 4°C per elution. Supernatant pools were dialyzed in PBS for 24 hours in 
order to remove excess glutatione. For long term storage, glycerol was added to 10% 
final volume and samples were stored at -20°C.
2.5.5 GTS pull down assaye
50 pg of purified GST-fusion protein were coupled to 30 pi of glutathione sepharose 
beads and rocked at 4°C for 2-3 hours. Beads were washed three times in NETN buffer 
and incubated overnight at 4°C with 1.2 mg of 10% (w/v) mouse brain homogenate 
diluted in IP buffer of the specified pH. The following day, beads were washed three 
times in IP buffer, resuspended in sample buffer and processed by Western blot.
2.5.6 Protease K digestion
A stock solution of 40 mg/ml Protease K (Sigma) was made and stored in 100 pi 
aliquots at -20°C. Digestion reactions were performed at the final specified 
concentration of 50 pg/ml for brain homogenate and 30 pg/ml for mammalian cell 
lysate, 5 pg/ml for yeast lysate. When Protease K digestion was performed after a GST 
pull down experiment, 100 pi of Prnpf' brain homogenate (1.5 mg/ml) was added in 
order to avoid overdigestion. If not otherwise specified, digestion reactions were 
performed at 37°C for 1 hour in a thermomixer. Digestions were terminated by addition 
of PMSF (2mM final) and incubation on ice (30 minutes), before addition of the SDS 
sample buffer.
2.5.7 Immunoprecipitation
1 mg of total brain homogenate or N2a cell lysate was diluted in a final volume of 1 ml 
with IP Buffer. 10 pg of antibody were added and the tube was placed with gentle 
rocking at 4°C for 4 hours or overnight. At the end of the incubation step, 20 pi of sheep 
anti-mouse magnetic beads (DYNAL) were added per reaction and further incubated for
2 hours at 4°C. Beads were finally washed three times in IP Buffer (1 ml/wash) before 
addition of 30 pi of sample buffer. Samples were boiled for 10 minutes at 95°C and 
processed according the standard Western Blot protocol.
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2.5.8 SDS-PAGE
SDS-PAGE was performed on 1.5 mm Biorad mini gels or 1.5 mm Biorad vertical gels. 
Table 2.1 shows the composition of the resolving gel for either 2 small gels (left 
column) or 1 big gel (right column). The percentage of the resolving gels is given in the 
head of the table. According to the molecular weight of the protein of interest, 8% to 
15% polyacrylamide gels were used. The resolving gel was overlaid with isopropanol to 
ensure a smooth gel interface. Before adding the stacking gel, the isopropanol was 
removed and the gel surface rinsed with water. Table 2.2 shows the compositon of the 
stacking gel. TEMED and APS cause were added immediately prior before pouring the 
gel.
Table 2.1 Composition of resolving gel for SDS-PAGE and required volume of 
TEMED and APS. The volume of TEMED and APS is independent of the gel- 
percentage and therefore given only once for each size of gel.
Percentage 8% 10% 12% 15%
Buffer 1 (ml) 3.75 7.5 3.75 7.5 3.75 7.5 3.75 7.5
AcrylBis 3 6 3.75 7.5 4.5 9 5.6 11.2
H20 8.25 16.5 7.5 15 6.75 13.5 6.7 11.4
TEMED 25pi (sma 1) 50pl (large)
APS 75pi (small) 150pl (large)
After pouring the stacking gel the comb was inserted immediately and the gel was left 
for polymerisation. The comb was removed from the polymerised gel and the slots were 
rinsed with water. To obtain an even loading of samples, the required amount of sample 
was added to 4X sample buffer and filled up to the final volume with lysis buffer. The 
solution was boiled at 95°C for 5 min and then loaded onto the gel. As a standard for the 
molecular weight a prestained marker (New England Biolabs) was used. Gel 
electrophoresis was performed in a gel tank filled with IX Running Buffer and under 
the constant amperage of 45 mA for 2-3 hrs. Total proteins were transferred to a 
nitrocellulose membrane (Schleicher and Schuell) using semi-dry apparatus (SemiPhor, 
HOEFER) for 1 hour applying a current of 0.8 mA/cm2 of membrane.
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Table 2.2 Composition of stacking-gel for SDS-PAGE
Small Big
Buffer2 (ml) 2 4
AcrylBis 0.6 1.2
h 2o 5.4 10.8
TEMED 25pl 50pl
APS 75pl 150pl
2.5.9 Western blot
After transfer from the gel to the membrane the transfer efficiency was confirmed by 
staining all proteins with Ponceau red (Sigma). The membrane was incubated 5 min in 
the Ponceau solution. The excess of Ponceau was rinsed away with water and the 
membrane was blocked in blocking buffer on a shaker for 1 hour at room temperature or 
at 4°C overnight to avoid unspecific binding of the antibodies. The membrane was 
subsequently incubated with the primary antibody against the protein of interest for 1 
hour at room temperature. All primary antibodies (1 mg/ml) were diluted 1:1000 in 
blocking buffer. Following the incubation with the primary antibody the membrane was 
washed 3 times for 10 min each at room temperature in washing buffer to remove 
unbound antibody. The secondary antibody was chosen depending on the nature of the 
primary antibody. For mouse monoclonal primary antibodies the secondary one was a 
peroxidase conjugated anti-mouse IgG, for rabbit polyclonal antibodies the secondary 
antibody was a peroxidase-conjugated anti-rabbit-IgG. Both secondary antibodies 
(Sigma) were used in dilution of 1:3000 in blocking buffer and the membranes were 
incubated for 30 min at room temperature. Blots were washed 3 times in washing buffer 
as described above and proteins were visualized using an ECL kit (Amersham- 
Pharmacia) according to manufacturers’ instruction: the two solutions of the kit were 
mixed in 1:1 ratio and the membrane was incubated for 1 min in the solution. Different 
exposures were taken using Kodak MBX autoradiography films and an automatic 
fixer/developer (IGP Com paq).
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2.5.10 Buffers and Solutions
Lysis Buffer:
150 mM NaCl 
25 mM Tris pH8 
0.5% TRITON X-100 
0.5% DOC 
Protease inhibitors
IP Buffer:
150 mM NaCl 
0.5% NP-40
Either 50 mM Tris / MOPS / Na-Acetate 
pH adjusted as required by the experiment. 
Protease inhibitors
NETN buffer:
100 mM Nacl 
20 mM Tris pH8 
1 mM EDTA 
0.5% NP-40 
Protease inhibitors
Buffer A:
0.32 M Sucrose 
0.1 mM PMSF 
1 mM MgC12 
10 mM Hepes 
1 mM NaHC03 
Protease inhibitors
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PROTEIN GEL SAMPLE BUFFER (4X):
4 ml SDS 10%
1.6 ml Tris pH 6.8 
2 ml glycerol
1.9 ml H20
0.5 ml B-mercaptoethanol 
Bromophenol blue
BUFFER 1 
544.95 g Tris 
pH adjusted to 8.8 
H2O up to 3 litres
Solution was autoclaved and stored at 4°C.
SDS was added to a final concentration of 0.4% before use.
BUFFER 2 
181.65 g Tris 
pH adjusted to 6.8 
H2O up to 3 litres
Solution was autoclaved and stored at 4°C.
SDS is added to a final concentration of 0.4% before use.
10X SDS-PAGE RUNNING BUFFER
240 g Tris
1120 g Glycine
200 ml SDS 20% solution
H2O up to 8 litres
10X TRANSFER BUFFER:
29 g Glycine 
58 g Tris-base
3.7 g SDS 
H2O up to 1 litre
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IX TRANSFER BUFFER:
100 ml 10X transfer buffer 
200 ml Methanol 
700 ml H20
PBST 
400ml PBS 
400ml Tween20
WB BLOCKING BUFFER:
5% w/v non fat dry milk in PBST
2.6 Microscopy and Cell imaging techniques
2.6.1 FACS 
Cell Fixation
Cells were washed once with ice cold PBS and resuspended by gentle pipetting in PBS. 
Cells were centrifuged at 900 rpm for 3 minutes at room temperature, supernatant was 
discarded and the pellet gently resuspended in 4% PFA/PBS and left on ice for 15 
minutes for fixation. Cells were washed once in PBS and resuspended in 2 ml of FACS 
Buffer (2%FCS in endotoxin free PBS).
Antibody Staining
An aliquot of 0.5x106 cells was transferred into FACS tubes (FALCON) for staining. 
When internal staining was performed, the FIX and PERM Kit was used (CALTAG 
Laboratories) following manufacturer’s guidelines. Otherwise cells were incubated with 
100 pi of primary antibody solution in FACS buffer (ICSM18 and different PIP7 
antibodies were used at a final concentration of 10 pg/ml whereas undiluted hybridoma 
supernatant was used for TfR staining) on ice for 30 minutes. Cells were washed once 
in FACS buffer, spun at 900 rpm for 2 minutes and resuspended in 100 pi of labelled 
secondary antibody (10 pg/ml). Following an incubation step of 30 minutes on ice, the 
pellet was washed once and resuspended in 300 pi of FACS buffer.
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Data acquisition and analysis
All samples were analysed with a FACS Calibur device. Forward and side scatter were 
adjusted in order to avoid collection of cell debris or cell clumps. Unless stated 
otherwise, 25000 events were collected for each sample. Statistical analysis was 
performed using the FLOJO software.
2.6.2 FRET 
Antibody labelling
A prepacked aliquot of Cy3 monofunctional dye (Amersham Bioscience) was firstly 
dissolved in 20 pi of DMF. Four hundred and fifty pi of sterile filtered aPIP7 4G4 
antibody (1 mg/ml) were mixed with 50 pi Bicine (1 M, pH 8.0) in a small glass 
container covered in aluminium foil to protect from light exposure. The container was 
placed on a magnetic stirrer and the Cy3 solution was carefully added dropwise. The 
coupling reaction took approximately 1 hour at room temperature. To separate the 
labelled antibody from the free unincorporated dye, the reaction was run through on a 
10 ml disposable chromatography column (BIORAD) according to the manufacturer’s 
protocol. Briefly: the column was washed three times with PBS; the coupling reaction 
containing the Cy3-Ab was loaded on the column, followed by 3 ml of PBS. A fraction 
of 1.5 ml was collected in an eppendorf tube. Spectroscopic analysis was performed in 
order to determine the Dye/Antibody ratio. Labelled antibody was sterile filtered and 
kept at 4°C for a maximum of 2 weeks.
Immunofluorescence for FRET
The complete procedure was performed at room temperature. Mouse N2a cells were 
plated on glass coverslips and transfected with mouse GFP-PrP or with GFP as a 
negative control. 48 hours post transfection, cells were washed twice with PBS and 
fixed for 10 minutes with 4% PFA/PBS. After two additional washes in PBS, cells were 
permeabilised with a 0.2% TritonX 100/PBS solution for 5 minutes. A fresh solution of 
lmg/ml of Na-Borohydrate/PBS was then added and left for 5 minutes in order to 
quench any remaining PFA and any cellular autofluorescence. Two PBS washes were
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performed before a blocking step of 5 minutes with a 1% BSA/PBS solution. Cells were 
incubated for 1 hour with the previously labelled a-PIP7-Cy3 antibody at the final 
concentration of 10 pg/ml. After 2 washes in PBS, coverslips were mounted using 
MOWIOL/DABCO and allowed to dry overnight at 37°C. Slides were stored at 4°C in 
the dark.
Fluorescence Resonance Energy Transfer (FRET) by Fluorescent Lifetime 
Imaging Microscopy (FLIM) in Frequency Domain
A detailed description of the FRET monitored by FLIM can be found elsewhere 
(Larijani et al., 2003). Lifetime detection was monitored in the frequency (phase) 
domain. Phase methods provide an average lifetime where sinusoidally modulated light 
is used to excite the sample. The measurement of the phase shift and the relative 
modulation depth of the emitted fluorescence compared to the excitation lead to the two 
lifetime values Tau-phase (tp) and Tau-modulation (xm). The average fluorescence 
lifetime, < t >, is defined by the average (Tm+ r p)/2.1 monitor the decrease in lifetime of 
donor (EGFP) in the presence of the acceptor (Cy3 dye). All images were taken using a 
Zeiss Plan-APOCHROMAT 100x/1.4 numerical aperture, phase 3 oil objective, with 
images recorded at a modulation frequency of 80.218 MHz. GFP-PrP was excited using 
the 488 nm line of an Argon/Krypton laser and the resultant fluorescence separated 
using a dichroic beamsplitter (Q505 LP; Chroma Technology Corp.). FRET acquisition 
and analysis was performed by Dr Veronique Calleja, Cell Biophysics Laboratory, 
CRUK.
2.6.3 Immunofluorescence 
PIP7 immunofluorescent staining
Cells were washed twice with PBS and fixed with 4% PFA for 10 minutes at room 
temperature. For nuclear PIP7 staining, cells were permeabilised with 0.5%Triton/PBS 
for 5 minutes whereas for surface labelling cells were left untreated. Cells were blocked 
with 10% FCS/PBS (supplemented with 0.1% Triton for nuclear labellings) for 30 
minutes at room temperature prior to antibody incubation. All PIP7 antibodies were 
diluted to 10 pg/ml in the appropriate blocking solution for 1 hour at room temperature,
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washed 3 x 5  minutes with block and incubated with Cy3 conjugated goat anti mouse 
IgG (H&L) for 30 minutes at room temperature in the dark. Cells were finally washed 3 
x 5 minutes with PBS prior to nuclear staining with Dapi and mounting in Mowiol. 
Cells were visualised on a Zeiss Axioplan 2 upright microscope using AxioVision 4.1 
imaging software. This experiment was performed in collaboration with Dr Nnennaya 
Kanu.
Confocal analysis of PrP-PIP7
Confocal analysis was performed by Dr Axel Behrens using a Zeiss Axioplan Upright 2 
and Zeiss Axiovert 200 Inverted microscopes.
2.6.4 Immunohistochemistry
The described procedures were performed by the CRUK Histopathology Unit
2.6.4.1 Immunohistochemical staining on paraffin sections
Brain samples were fixed overnight in 10% NBF (100 ml 37% formaldehyde, 4 g 
NaF^PC^, 6.5 g Na2HPC>4 in 1L H2O) transferred into 70% Ethanol and embedded in 
paraffin block. Four microns sections were cut from each block and placed on glass 
charged slides. Slides were subjected to a standard de-waxing protocol as follows: 2 x 
10 minutes in Xylene, 2 minutes sequentially in 100%, 95%, 90%, 80%, 70%, 50%, 
25% ethanol and 5 minutes in PBS. After antigen retrieval (12 minutes in a microwave 
in 0.1M Sodium Citrate pH6), slides were blocked for 30 minutes. For PIP7 staining, 
the 4C2 antibody (1 mg/ml) was used at the final dilution 1:250 in combination with a 
mouse on mouse kit (DAKO ARK).
2.6.4.2 LacZ staining to monitor p-galactosidase activity
Brain samples from adult mice were fixed in LacZ fix solution (0.2% glutaraldehyde, 
5mM EGTA, 2mM MgCb in PBS) for 20 minutes. Following 3 washes of 5 minutes 
each in wash solution (2mM MgCh, 0.02% NP-40 in PBS), slides were incubated at 
37°C in staining buffer (1 mg/ml X-Gal, 2.12 mg/ml Potassium Ferrocyanide, 1.64 
mg/ml Potassium Ferrycianide dissolved in wash solution). Stainings were stopped by 
repetitive washes in PBS and samples were stored at 4°C.
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2.7 Scrapie analysis
2.7.1 Scrapie Cell Assay
Five thousands chronically infected ceils (iPKl clone, a generous gift from Dr. Peter 
Klohn, MRC Prion Unit, London) were plated on a 96 wells plate in the presence of the 
different a-PIP7 monoclonal antibodies; a-PrP specific antibody ICSM18 and an 
isotype control were also included, in order to assess treatment specificity. After 4 days, 
cells were passaged at 1:8 dilutions and allowed to grow for 3 additional day, in the 
continuous presence of the antibodies. In order to establish the number of PrPSc positive 
cells, an aliquot of 1000 cells was supplemented with 24000 non infected cells and 
plated in each of 7 wells (containing 200 pi PBS) of an ELISPOT plate (Multi Screen 
Immobilon-P 96-well Filtration Plates, sterile, Millipore, previously activated with 70% 
ethanol) and washed twice with PBS by suction. After 1 hour at 50°C, 50 pi of PK (0.5 
pg/ml) were added to each well, and incubated for 90 min at 37°C. The samples were 
washed with PBS, exposed to 2 mM PMSF for 10 min, and washed again with PBS. 
After incubation with 160 pi of 3 M guanidinium thiocyanate, 10 mM Tris HCl (pH 8.0) 
for 10 min, the filters were washed four times with PBS and incubated with 160 pi of 
Superblock for 45 min. 50 pi ICSM18 (0.6 pg/ml, inTBST/1% non fat milk) was added; 
after 1 hour the supernatant was removed, and the wells were washed 7 times with 
TBST. 50 pi of alkaline phosphatase-conjugated anti-IgGl (Southern Biotechnology 
Associates; 1:4,500 in TBST/1% milk powder) was added for 1 hour. Wells were 
washed 8 times with TBST, and 50 pi of alkaline phosphatase conjugate substrate 
(prepared as recommended by Bio-Rad) was added for 8 min and followed by 2 washes 
with water. Plates were stored in the dark at -20°C. PrPSc-positive cells were counted 
using the Zeiss KS ELISPOT system (Stemi 2000-C stereo microscope equipped with a 
Hitachi HV-C20A color camera and a KL 1500 LCD scanner and WELLSCAN 
software from Imaging Associates, Bicester, U.K.). The settings were optimized to give 
a maximal ratio of counts for PrPSc-positive samples relative to negative control 
samples, while keeping the sample counts as high as possible. The described procedure 
was performed by Dr. P. Klohn at the Institute of Neurology, London.
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2.7.2 Neuronal Graft
Neuronal ectoderm was obtained from E l3.5 embryos (derived from XE413 x NPX275 
crosses). The detailed procedure has been described elsewhere (Behrens et al., 2001). 
Stereotactic injection of neuroectoderm was performed by Dr. Sebastian Brandner with 
the help of Heike Naumann at the MRC Prion Unit, London.
2.8 Reagents
2.8.1 Antibodies
Clone name Antigen Origin/Supplier
Primary Abs
actin actin Sigma
PIP7 4C2 hnRNP M4 CRUK Monoclonal Service
PIP7 4G4 hnRNP M4 CRUK Monoclonal Service
PIP7 4G5 hnRNP M4 CRUK Monoclonal Service
PIP7 5H1 hnRNP M4 CRUK Monoclonal Service
PIP7 1B8 hnRNP M4 CRUK Monoclonal Service
0X26 Transferrin Receptor CRUK Monoclonal Service
HPC1 Syntaxinl Molecular Neuro PathoBiology 
Lab CRUK
ICSM18 PrP MRC Prion Unit
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6H4 PrP Prionics
Secondary Ab
HRP goat anti 
Mouse
- Sigma
APC Rat anti 
Mouse IgGi
- BD Pharmigen
R-PE Goat anti 
Mouse IgG3
- SouthemBiotec
Alexa 488 Goat 
anti Mouse IgG
- Molecular Probes
Cy3 Goat anti 
Mouse IgG
- Jackson Laboratories
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Chapter 3: Identification o f proteins interacting 
with mis folded PrP
3.1 INTRODUCTION
There is a wealth of evidence that the critical event in the occurrence of transmissible 
spongiform encephalopathies is the generation of PrPSc, described as the 
neuropathological isoform of the normally host encoded protein PrP . Its original 
isolation in association with infectivity, the cloning of the cognate cDNA and the 
finding that it is encoded by a host gene are just few of the milestones in modem prion 
biology (Basler et al., 1986; Bolton et al., 1982; Chesebro et al., 1985).
The transition appears to be mainly conformational since no differences in primary 
amino acids sequence or post-translational modification have been found. The two 
isoforms differ in both secondary structure and biochemical properties (Figure 3.1 A). 
PrP is mainly composed of a  helical structures, in contrast with the rich p content of 
the abnormal isoform (Caughey et al., 1991). PrPSc is insoluble in non-denaturing 
detergents and has the property to form highly ordered amyloid aggregates like fibrils 
and plaques. Moreover it is partially resistant to protease digestion whereas PrPc is 
completely sensitive (McKinley et al., 1983). Protease K digestion has been extensively 
used in laboratory research to discriminate between the two species and, more 
importantly, it has proved one of the most valuable tools in the diagnosis of prion 
disease, such as BSE in cattle.
Different in vitro conditions have been established in order to confer to recombinant PrP 
some of the PrPSc-like properties, namely increased P sheet content, tendency to form 
aggregates and partial PK resistance (Jackson et al., 1999; Lee and Eisenberg, 2003). 
The transition from a predominantly a  helical secondary structure to a p rich one is 
believed to be the first step in the conversion reaction and may proceed through one or 
more folding intermediates, called PrPp (Swietnicki et al., 1997).
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Figure 3.1 Alternative PrP conformations.
A) Secondary structure and biochemical features of different PrP isoforms. PrPc denotes the 
cellular isoform of the prion protein characterised as being mainly composed of alpha helices, 
detergent soluble and sensitive to Protease K digestion. PrP is the abnormal, pathogenic isoform 
and is enriched in beta sheets, mainly detergent insoluble and resistant to limiting proteolysis. 
Many attempts to generate infectivity in vitro have successfully produced different PrP 
conformations, here summarised as PrPp, exhibiting an increased content in p structures, increased 
insolubility and tendency to form aggregates. PrP* has been originally used to describe a 
metastable conformation of PrP when bound to Protein X (Cohen et al, 1994).
B) According to my working hypothesis, misfolding of PrPc is required in order to produce the 
structural rearrangement resulting in the generation of PrPSc. Such a process could require both 
spontaneous and enzymatic steps and the identification of binding proteins specific for intermediate 
conformations could be very valuable for therapeutic approaches.
Chapter 3
The in vivo existence of PrPp is mainly speculative but PrPp could partially overlap with 
PrP*, a metastable intermediate supposed to arise during the conversion from PrPc to 
PrPSc (Cohen et al., 1994).
According to my current working hypothesis, the series of events resulting in the final 
appearance of PrPSc could in principle involve either spontaneous biophysical or 
enzymatic steps (Figure 3.IB).
In support of this idea, despite presenting many of the properties typical of PrPSc, none 
of the |3 isoforms produced in vitro has been shown so far to be infectious suggesting 
that some o f the PrPSc properties could arise spontaneously in vitro by 
physico-chemical manipulation but possibly one or more unidentified auxiliary 
molecules are required to confer infectivity (Hill et al., 1999a). This hypothesis is 
supported by recent results obtained with the protein misfolding cyclic amplification 
(PMCA): successful in vitro amplification of infectivity has been achieved but only 
when complete brain homogenate is used (Castilla et al., 2005).
Recently, Linquist and colleagues have shown that PrP, when expressed in a 
heterologous system like the yeast cytoplasm, becomes detergent insoluble and partially 
PK resistant. The same group have also shown that whenever glycosylation and 
oxidation of the sulphydryl bond were prevented, PrP adopted PrPSc-like properties in 
mammalian neuroblastoma cells (Ma and Lindquist, 1999). The yeast cytoplasm is far 
more acidic than the cytoplasm of mammalian cells and it is known to provide a more 
reducing environment. Modification of the pH and the redox potential were key steps in 
the generation of in vitro PrPp and the physico-chemical properties of the yeast 
cytoplasm seemed to recapitulate the same conditions as in a test tube. This could 
partially explain the newly acquired biochemical properties of the prion molecule: 
actually in S. cerevisiae, prions can occur spontaneously, albeit at low rates, perhaps 
providing an optimal physiological environment to study PrP conversion.
The focus of the experiments described in this chapter was to attempt to establish a 
novel screening strategy with the aim of isolating novel PrP interacting molecules. 
Conventional two-hybrid systems, although extremely versatile and powerful, are
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known to have some intrinsic limitations and has been already successfully and 
extensively employed for searching for prion interacting molecules: Bcl-2 (Kurschner et 
al., 1995), Hsp60 (Edenhofer et al., 1996), the 37KDa laminin receptor precursor 
(Rieger et al., 1997), synapsin lb, Grb2 and Pintl (Spielhaupter and Schatzl, 2001). 
With the only exception of the laminin receptor precursor, which had been studied in 
great detail, physiological relevance for the remaining interactions is yet to be 
demonstrated. One of the main criticisms of this kind of approach is that the cytoplasm 
is not the natural environment for the prion protein and many of the isolated interactors 
were exclusively cytoplasmic, such as Grb2. Moreover, no data was obtained regarding 
the conformation adopted by PrP in these screens.
Increasing evidence suggests that in vivo PrP has to undergo a partial misfolding and 
this provides the rational of my experimental design. My approach was to exploit the 
newly acquired properties of the prion protein, when expressed in the cytoplasm of S. 
cerevisiae, to screen a cDNA library in order to find candidate proteins that 
preferentially interact with misfolded PrP, either PrPp or PrP*.
Proteomic approaches have shown that proteins act in complexes in order to fulfil their 
physiological functions (Gavin and Superti-Furga, 2003). The identification of new PrP 
interacting molecules would be extremely helpful for the clarification of the 
involvement of PrP in specific cellular pathways and could lead to the elucidation of its 
biological function. From this point of view, it is very difficult to conceive that the 
structural conversion resulting in the production of PrPSc is an event occurring 
independently from the cellular context. If host encoded proteins were involved in PrPSc 
generation, their identification could be beneficial to the development of new 
therapeutic approaches to a disease that so far has no effective treatment.
3.2 RESULTS
3.2.1 The Ras Recruitment System (RRS)
In order to screen for potential interactors with misfolded PrP, I took advantage of the 
Ras Recruitment System (RRS) developed by Aronheim and colleagues (Figure 3.2) 
(Broder et al., 1998). The RRS is based on the absolute requirement of both Ras
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localisation and activity at the plasma membrane in order to provide a growth signal. 
This is usually achieved by a famesyl moiety present at the C-terminus of the protein 
(Rine and Kim, 1990). The yeast strain Cdc25-2 is viable at the permissive temperature 
of 25°C but cannot grow when shifted to the restrictive temperature of 36°C because of 
a temperature sensitive mutation in the Cdc25 guanyl nucleotide exchange factor. The 
expression of a constitutively active form of mammalian Ras (RasV12) lacking the 
consensus sequence for famesylation and fused to the bait of interest is unable to rescue 
the Cdc25-2 mutation on its own. However, after successful protein-protein interaction 
between the bait and a member of the library, anchored at the plasma membrane by a 
specific localisation signal like the vSrc myristoylation sequence, RasV12 would be 
able to complement the Cdc25-2 mutation and finally confer cell growth even at the 
restrictive temperature. The system has been demonstrated to possess extreme 
versatility and capability to avoid false positives: the bait is under the control of the 
Met25 promoter that can be repressed by presence of methionine in the growth media, 
whereas the target library is under the control of a Galactose inducible promoter. 
Because PrP is highly expressed in the brain which is also the preferential site of prion 
accumulation and pathogenesis, I decided to screen a cDNA library obtained from adult 
mouse brain.
In a first experimental approach, the sequence encoding the mature form of mouse PrP 
aa23-aa230, missing both N- and C-terminal signal peptides, was originally fused in 
frame to the C-terminus of a constitutive active form of Ras. The resulting chimeric 
protein was expressed in a tightly regulated manner and as expected, no fusion protein 
was expressed in the presence of methionine. Quite surprisingly, the chimeric Ras-PrP 
protein was not insoluble, as predicted, since it was found in the detergent soluble 
fraction (data not shown). Moreover, it was totally sensitive to PK digestion, suggesting 
that the presence of Ras might confer higher solubility and protease sensitivity 
compared to the prion protein alone.
Unfortunately, RasV12-PrP was sufficient to rescue the Cdc25 mutation even in the 
absence of cDNA library expression, compromising the correct interpretation of the 
screen. One possible cause could be attributed to the presence of a highly conserved 
hydrophobic domain mapped between aal06-aal26 of PrP (Hay et al., 1987). This 
stretch of hydrophobic residues, responsible of the transmembrane isoforms of the prion
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Figure 3.2 The Ras Recruitment System (RRS).
Schematic representation of the Ras Recruitment system (RRS) for screening for proteins 
interacting preferentially with misfolded PrP. A myristoylated cDNA library is localised on the 
inner layer of the plasma membrane of a Cdc25-2 yeast strain. The yeast Ras (yRas) is present 
in the inactive GDP-bound form due to the absence of a functional exchange factor Cdc25 at 
the restrictive temperature. The bait, PrP23-230, is fused to a cytoplasmic version of a constitutive 
active form of Ras. Only upon successful interaction between the bait and a member of the 
library, RasV12 is translocated to the plasma membrane and confers cell growth at the restrictive 
temperature. Unfortunately, expression of the fusion protein RasV12-PrPp was sufficient to 
confer growth at the restrictive temperature even without library expression. This was explained 
to be the result of a possible weak interaction between the hydrophobic region present in PrP 
and the plasma membrane (red dotted arrow).
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protein, may weakly interact with the lipid bilayer: this domain alone could potentially 
target PrP, and therefore RasV12, to the plasma membrane, providing growth at the 
restrictive temperature even in the absence of any bait-pray interaction. Indeed, recent 
studies have demonstrated that the palindromic protein sequence 112-AGAAAAGA- 
119 is responsible for conferring PK resistance in yeast (Norstrom and Mastrianni, 
2005). In theory, this problem could be overcome by deleting this specific portion of the 
bait, however deletions may also eliminate regions of the protein required for 
interaction with one or more target proteins, limiting in principle the number of 
candidate proteins that could be obtained from the screen.
Therefore, the originally proposed screen was not performed since the RasV12-PrP 
fusion protein did not exhibit the expected biochemical properties required, namely 
insolubility and Protease K resistance. Furthermore, RasV12-PrP appears to be 
constitutively membrane associated, which made the original screening strategy 
impossible.
3.2.2 The reverse Ras Recruitment System (rRRS)
Although very powerful, the RRS is not suitable for studying interactions with integral 
plasma membrane proteins or proteins that may weakly associate with the plasma 
membrane, such as PrP. In order to overcome this specific problem, a novel approach 
has been developed: the reverse RRS (rRRS, Figure 3.3). The new technique was 
specifically designed to screen for candidates using membrane proteins like receptors or 
ion channels as bait thereby localising them to the plasma membrane and preserving 
their functional environment, conformation and binding specificity (Hubsman et al., 
2001). The rRRS was therefore a more suitable system to screen for potential PrP 
interactors. To allow the screen to be performed in this way, the reagents previously 
described needed to be modified. The original full mouse brain cDNA library was 
subcloned at the C-terminus of a cassette encoding oncogenic RasV12 lacking both a 
membrane localisation sequence and stop codon.
It is well established that the rRRS is associated with a higher background level of false 
positives that the original RRS. This is due to the fact that any member of the cDNA 
library, either directly encoding a membrane protein or proteins that associate with any
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Figure 3.3 The reverse Ras Recruitment System (rRRS).
The conventional Ras Recruitment System was found to be unsuitable for transmembrane or 
membrane associated proteins. To overcome this limitation, the reverse RRS has been established. 
The protein of interest, PrP23-230, is now anchored to the inner layer of the cell membrane via 
the vSrc myristoylation signal and is not sufficient to confer cell growth at the restrictive 
temperature. The cDNA library is fused to a cytoplasmic and constitutively active form of Ras. 
After protein-protein interaction, RasV12 is translocated to the plasma membrane, complements 
the Cdc25-2 mutation and allows growth at the restrictive temperature. Any cDNA directly 
encoding for membrane proteins or for proteins associating with membrane components would 
bypass the requirement of bait-pray interaction. These candidates could be identified for their 
ability to grow in a bait independent fashion and would be excluded from further analysis. Clones 
presenting the ability to rescue the Ccd25-2 mutation were expanded and the identity of the 
cDNAs established by sequencing.
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membrane component, could confer growth at the restrictive temperature independently 
of the expression of the bait. This problem can be solved in my experimental setting: 
only colonies that showed ability to grow in the absence of methionine, therefore in a 
bait-dependent manner, were selected for additional investigation.
The PrP sequence encoding amino acids 23-230 was reamplified by PCR in order to 
include at the N-terminus the v-Src myristoylation signal and was subcloned into a 
Met3 driven plasmid (MyrPrP). An alternative version lacking the membrane targeting 
sequence was generated at the same time as a control. Both constructs were sequenced 
to exclude point mutations generated by PCR amplification. The constructs were 
transformed into a Cdc25-2 yeast strain and the inducibility of the promoter I have 
chosen as well as the biochemical properties of the PrP protein were subject to analysis 
(Figure 3.4).
3.2.2.1 Promoter Inducibility
First of all, I had to ensure the stringent inducibility of the Met3 promoter; colonies 
previously grown in the presence of methionine were inoculated in duplicate in liquid 
media, with or without methionine, and allowed to grow for an additional 12 hours, 
before protein extraction and analysis by SDS PAGE (Figure 3.4A). No bait protein was 
detected when cells were grown in media containing methionine. Conversely, 
repression by methionine was promptly released after 12 hours. Promoter stringency 
and inducibility were therefore confirmed in my experimental set-up. This offered the 
ideal requisite to successfully perform the screen, since colonies would be chosen for 
their ability to grow in a bait dependent fashion.
3.2.2.2 Insolubility
Figure 3.4A shows that, after release of repression, MyrPrP preferentially partitioned 
into the detergent insoluble fraction, although some was still detected in the supernatant. 
This could in theory be explained by the presence of the myristoylation moiety but PrP 
was able to localise to the pellet fraction even in the absence of the specific 
myristoylation signal. This supports the hypothesis of PrP intrinsically association with
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Figure 3.4 Biochemical properties of the Prion protein expressed in the yeast cytoplasm.
A) Inducibility/Insolubility. The myristoylated PrP construct was transformed in the CDC25-2 
strain and subject to analysis by Western blot using the a-PrP antibody ICSM18. The protein 
was expressed only after release from methionine inhibition and preferentially partitioned in the 
detergent insoluble fraction (p:pellet; s:supernatant). B) Partial Protease K resistance. Yeast 
extracts were subjected to limited proteolysis with PK (5 pg/ml) for the indicated times. Both 
versions of the prion protein, with and without the myristoylation modification, showed partial 
resistance to digestion whereas the fusion protein RasV12-PrP, originally designed for the RRS, 
was totally sensitive to proteolysis.
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the plasma membrane, however, an unspecific interaction with one or more yeast 
membrane proteins cannot be excluded.
3.2.2.3 Protease K resistance
Limited proteolysis was performed and revealed that the prion protein was partially PK 
resistant, confirming the data obtained by the Lindquist laboratory. The resistance was 
not an artefact due to the presence of the myristoylation moiety because PrP alone also 
had the same biochemical property. As a positive control, the RasV12-PrP fusion 
protein that I initially intended to use confirmed to be totally PK sensitive; this could 
suggest that PrP lost its insolubility and protease K resistance when fused to another 
protein (Figure 3.4B).
3.2.3 The Screen
Once all the prerequisites of the screen were satisfied, I transformed the Cdc25- 
2/MyrPrP strain with the brain cDNA library. Transformants were plated on Glucose 
plates and allowed to recover for 5-7 days at the permissive temperature of 24°C. Once 
colonies were fully visible, cells were replica plated onto Galactose-containing plates, 
either containing or lacking methionine, and incubated at the restrictive temperature of 
36°C. Transformants exhibiting efficient growth only in the absence of methionine, 
therefore only when PrP was expressed, were picked and recovered on glucose plates 
for a few days at 24°C. Selected colonies were replica plated for a second time and 
retested for their methionine-dependent growth. Only colonies able to undergo the two 
consecutives rounds of selection were considered “bona fide” candidates. The detailed 
screening procedure is described in the Materials and Methods section. Colonies able to 
rescue the Ccd25 phenotype were picked from plates and expanded in liquid culture. 
Plasmid cDNAs, encoding the target candidates, were extracted from yeast clones and 
sequenced. The nucleotides sequences were then compared with all the known 
sequences present in the database (http://www.ncbi.nlm.nih.gov/BLAST/) in order to 
identify the potential candidates.
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3.2.4 Candidates evaluation
As a result from the screen, proteins were cloned and the working name “PIP” was 
chosen (Prion Interacting Proteins) (Table 3.1). Some information concerning the 
identity of some of the candidates, their sub cellular localisation and possible links with 
the prion protein are detailed below.
Table 3.1 Identification of the cDNAs retrieved from the rRRS screen.
Plasmids were extracted from yeast colonies and subject to DNA sequencing; sequences 
were submitted to the BLAST server and, when possible, matched to already known
proteins.
PIP1 * Not cloned, possibly due to plasmid integration in the yeast genome.
PIP2 Mus Musculus DnaJ (Hsp40) homolog, subfamily B, member 6, (in frame) 
Score = 577 bits (291), Expect = 3e-161 
Identities = 446/482 (92%), Gaps = 10/482 (2%)
UniProtKB/Swiss-Prot entry 054946
PIP3 Mus Musculus Poly(rC)-binding protein 2 (in frame), putative hnRNP X 
Score = 555 bits (280), Expect = le-154 
Identities = 442/480 (92%), Gaps = 11/480 (2%)
UniProtKB/Swiss-Prot entrv 061990
PIP4 Mus Musculus Enolase 2 (gamma Enolase) ( out of frame ) 
Score = 371 bits (187), Expect = 2e-99 
Identities = 249/263 (94%), Gaps = 6/263 (2%) 
UniProtKB/Swiss-Prot entrv P 17183
PIP5 Mus Musculus HCM7087 gene ( out of frame ), virtual transcript 
Score = 321 bits (162), Expect = 3e-84 
Identities = 297/340 (87%), Gaps = 7/340 (2%)
PIP6 Mus Musculus Ran (in frame)
Score = 345 bits (174), Expect = 3e-91 
Identities = 279/307 (90%), Gaps = 8/307 (2%) 
UniProtKB/Swiss-Prot entrv P62827
PIP7 Mus Musculus hnRNP M4 (in frame)
Score = 507 bits (256), Expect = 3e-140 
Identities = 386/414 (93%), Gaps = 15/414 (3%) 
UniProtKB/Swiss-Prot entry O9D0E1
Despite many attempts to rescue the plasmid encoding the first candidate, PIP 1, I did 
not manage to rescue it. I believe the library plasmid had integrated irreversibly into the 
yeast genome, preventing any possible identification.
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PIP2 was known as DnajB6, the mouse homologue of the bacterial chaperone groP. 
Hsp40 family members are known to function in concert with other molecular 
chaperones of the Hsp60 and Hsp70 families (Michels et al., 1997; Ohtsuka, 1993).
PIP4 encoded the neuronal specific isoform of the enzyme Enolase 2 which has 
neurotrophic and neuroprotective properties on central nervous system (CNS) neurons. 
It has enzymatic activity and produces phosphoenolpyruvate in glycolysis (Kaghad et 
al., 1990).
PIP5 was a novel gene; the sequence was annotated in the database by genomic survey 
and the existence of a genuine transcript has not yet been confirmed.
However, both PIP4 and PIP5 were out of frame. This had been previously reported in 
other screens and the explanation lies in the way the cDNA library was generated: a 
standard oligo dT primer, modified with an Xhol site at the 3 ’ end was annealed to the 
polyA tail of a total mRNA preparation. After the generation of a double strand cDNA a 
blunt-end linker containing an EcoRI site was randomly inserted at the 5’ end. The 
insertion of the linker was a random, therefore only approximately 1 out of 3 cDNAs is 
actually in frame.
PIP6 was positively identified as Ran, a well known member of small GTPases proteins, 
involved in the nucleocytoplasmic transport (Wennerberg et al., 2005).
Quite interestingly PIP3 and PIP7 were part of the RNA binding protein super family: 
hnRNPs (Krecic and Swanson, 1999; Weighardt et al., 1996).
At this point, on the preliminary analysis of the identified cDNAs, it was quite difficult 
to distinguish between potential candidates and false positive, known to occur quite 
often in this kind of screen. Many of the isolated proteins are known to be cytoplasmic 
or nuclear, making it difficult to suggest how they could interact in a physiological 
context with PrP. There was however one interesting exception: reading the literature 
related to the PIP7 candidate, I found different reports confirming its localisation both 
in the nucleus and on the cell surface (Bajenova et al., 2001; Blanck et al., 1994).
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Being in a subcellular compartment that would allow physical interaction, I established 
a GST pull down assay to quickly evaluate if the yeast interaction between PIP7 and 
PrP was real. The PIP7 cDNA was subcloned into a pGEX vector and recombinant 
fusion protein was produced in E. coli. GST alone and GST-PIP7 were coupled to 
glutathione sepharose beads and mixed with total mouse brain homogenate. Three 
bands, corresponding to di-, mono- and un-glycosylated PrP respectively, were enriched 
specifically by the GST-PIP7 fusion protein and not by GST (Figure 3.5A).
3.2.5 PIP7
PIP7 encodes the mouse ortholog of the human heterogeneous RNA binding protein 
M4. It was originally characterised as part of a cluster of four nuclear proteins (M1-M4) 
o f 64.000-68.000 Da by Two Dimensional Electrophoresis. Transcripts newly 
synthesized by RNA polymerase II are directly bound by the heterogeneous nuclear 
ribonucleoproteins (hnRNPs) which package them in a transcript specific manner and 
are involved in important RNA processes such as splicing, polyadenylation and nuclear- 
cytoplasm transport as a direct consequence of their binding. The exact molecular 
function of most members of the hnRNP family proteins has not been extensively 
studied. As a potential indication of their role in RNA editing, M family proteins are 
known to bind with high affinity to poly G and poly U homopolimers in vitro (Datar et 
al., 1993).
The primary sequence of PIP7 is composed of 728 amino acids and on Western blot the 
protein appeared to migrate as a doublet of 64 and 68 KDa. The shorter isoform, lacking 
29 amino acids in the region between the RNA binding domain 1 and 2, is believed to 
arise by alternative splicing of exon 6. Structural analysis revealed the presence of three 
RNA binding domains, also called RRM (amino acids 69-147, 202-279, 651-727) and 
four putative transmembrane helices (amino acids 158-178, 293-313, 322-342, 627-647) 
(Figure 3.5B).
The novel function of hnRNP M4 as a receptor was originally reported more than ten 
years ago (Blanck et al., 1994). A cDNA encoding a novel gene, called NAGR1, was 
cloned in the attempt to identify the receptor for human thyroglobulin hormone. Due to
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Figure 3.5 hnRNP M4 (PIP7), a novel PrP interacting protein.
A) The PIP7-PrP interaction was confirmed by in vitro GST pull down. Total brain homogenate 
obtained from adult mouse was incubated with glutathione beads coated with GST or GST-PIP7 
proteins. After extensive washing, beads were boiled and processed by standard SDS PAGE, a- 
PrP antibody ICSM18 was used for the detection. All three PrP isoforms, corresponding to di-, 
mono-, and unglycosylated PrP (red marks) were specifically enriched by GST-PIP7 and not by 
GST alone. In the first lane, total lysate was loaded (15%) to facilitate comparison.
B) Structural features of hnRNP M4. The protein presents three putative RNA binding domains 
(green boxes) and a region encompassing 27 repeats of a methionine-arginine-glycine rich 
sequence (blue squares). At least two different isoforms are present, arising from the alternative 
splicing of 29 amino acids between RRM1 and RRM2. Four transmembrane helices (red boxes) 
were predicted on the basis of a hydropathy plot, suggesting a putative topology with both the 
N- and C-terminus in the intracellular space. A black bar indicates the partial cDNA retrieved 
from the yeast library. The fragment was sufficient to confirm PrP interaction and was injected 
into mice in order to produce a panel of monoclonal antibodies.
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few errors in the DNA sequence analysis, the authors did not realise that the newly 
identified gene was almost identical to the one encoding human hnRNP M4. Because 
hnRNP M4 was known to be a nuclear protein with a function in RNA processing, the 
authors later considered its identification in their screen to be a false positive and 
subsequently retracted their conclusions (Blanck et al., 1995).
A second report confirming the cell surface localisation of hnRNP M4 came only very 
recently. The Carcinoembryonic Antigen (CEA) is a glycoprotein belonging to the 
immunoglobulin family. The overexpression of CEA has been correlated with tumour 
development and metastasis. Bajenova and colleagues came to the conclusion that 
hnRNP M4 was the receptor for CEA using two complementary approaches; antibody 
probing and a yeast two-hybrid screen (Bajenova et al., 2001). Antibodies raised against 
hnRNP M4 were generated and were able to specifically bind the cell surface of rat 
Kupffer cells (Bajenova et al., 2003).
CEA, thyroglobulin and, finally, PrP are highly glycosylated proteins of different 
molecular weight and with no apparent sequence or functional homology. Other 
members of the hnRNP super family, namely hnRNP A2/B1 and hnRNP C 1, although 
predominantly nuclear have been recently studied for their ability to bind albumin and 
their presence on the cell surface of tumour cells (Fritzsche et al., 2004). Although the 
roles of these proteins in the nucleus are poorly understood, even less is known 
regarding their apparent surface function. This dual localisation could hence reflect a 
hallmark of different members of this family.
3.2.5.1 Generation and characterisation of PIP7 monoclonal antibodies.
In order to better characterise the molecular basis of the PrP-PIP7 interaction, I decided 
to generate a panel of monoclonal antibodies (mAb), to use as a tool for my future 
experiments. Mice were immunised using specifically the PIP7 fragment present in the 
original yeast clone. The complete procedure is described in details in the materials 
section. As a result, a panel consisting of 5 mAbs was produced by the CRUK internal 
Monoclonal Service. First of all, the subclass of each antibody was determined by 
ELISA: with the only exception of clone 4G4 which is an IgG3, all the remaining
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monoclonal antibodies belong to IgGl subclass. Subsequently, the monoclonals were 
fully characterised using the different approaches detailed below:
3.2.5.2 Western Blot analysis
Because antibodies were raised against the last 300 amino acids at the C-terminus of 
PIP7, encompassing both the Tandem Repeats region (TR) and the RRM3 domain, I 
overexpressed the single regions, fused to a green fluorescence protein (GFP), in human 
293T cells: the aim of the experiment was to map the binding region of each mAb. The 
GFP-TR and GFP-RRM3 constructs did not have any overlapping sequence, allowing a 
clear interpretation of the result. GFP alone was included in the experiment to provide a 
suitable negative control. Protein extracts were loaded in parallel and each sample was 
probed with the specific a-PIP7 mAb or a GFP-specific antibody. Western blot analysis 
using a GFP antibody revealed correct expression of GFP fusion proteins of the 
expected molecular weight (Figure 3.6). All antibodies detected endogenous levels of 
the PIP7 proteins at the expected molecular weight of 64 and 68 KDa. Four of the 
clones, specifically recognised the Tandem Repeats region. This region presents 
repetitions of the same amino acids sequence and this could eventually explain its 
higher immunogenicity. No data were obtained for the 9H1 clone which failed to 
recognise both the endogenous and the over expressed PIP7 fragments.
3.2.5.3 FACS
Since one of the possible place of interaction with PrP is the cell surface, I wanted to 
check if was possible to monitor the PIP7 surface levels as have been previously 
reported (Bajenova et al., 2003). I investigated whether my panel of mAb were able to 
detect and confirm the presence of PIP7 on the surface of mouse neuroblastoma N2a 
cells, the most used cell line for studying the cell biology of PrP and prion replication. 
Untransfected N2a cells were fixed, following an optional step of permeabilisation in 
order to discriminate between the specific surface pool and the total population, known 
to be mainly nuclear. The FLOWJO analysis is shown in Figure 3.7: all antibodies, 
including the 9H1 clone, were able to detect PIP7 on the cell surface. The signal was 
specific compared to the background obtained when the primary antibody was omitted. 
Although similar levels of staining were observed on the cell surface, the antibodies
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Figure 3.6 PIP7 m onoclonal antibodies recognize the Tandem Repeats region.
In order to provide a further characterization of the PIP7 monoclonal antibodies, 
the original yeast clone used as an immunogen was divided into two non overlapping fragments, 
the Tandem Repeats region and the RRM3 domain, and expressed as fusion proteins with the 
Green Fluorescence Protein (GFP) in human 293T cells. All PIP7 antibodies were able to detect 
endogenous levels of protein (asterisk) and preferentially recognised the Tandem Repeat region 
but not the RRM3 domain. No data were produced by the 9H1 clone which failed to detect both 
endogenous and ectopically overexpressed PIP7 protein. As a positive control, extracts were 
probed with a GFP specific antibody (left side), which detected fusion proteins of the expected 
molecular weight.
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Figure 3.7 Specificity of PIP7 monoclonal antibodies shown by FACS analysis.
Human 293T cells were fixed and stained with the generated PIP7 antibodies. An optional step 
of permeabilisation was included in order to discriminate between the surface pool (top panel) 
and the total PIP7 population (bottom panel). All PIP7 antibodies gave comparable signal for 
the surface pool. A different situation emerged when the total population was examined. The 
4C2 clone gave the highest staining whereas the 9H1 the lowest. All antibodies have been used 
at the same final concentration (20 pg/ml).
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recognised the internal pool to varying degrees. The 4C2 clone gave the highest staining 
whereas the HI gave the lowest. Since all antibodies were used at the same final 
concentration, the relative intensity of the different staining must reflect the difference 
in affinity of the clones. Finally, the fact that the HI clone was able to recognise native 
PIP7 on the cell surface but failed in the Western blot suggests that the epitope may not 
be linear but conformational.
3.2.5.4 Immunofluorescence
Although extremely powerful and quantitative, analysis by flow cytometry would not 
provide any information about co-localisation between the candidate proteins. 
Moreover, PIP7 protein has been reported to be present both in the nucleus and in the 
cytoplasm of many cell lines (Bajenova et al., 2003).
Endogenous levels of PIP7 were subject to analysis using the human HCT116 cell line. 
In analogy with the previous experiment, cell were fixed and stained with the different 
a-PIP7 monoclonal antibodies. The experiment was carried out in duplicate, in the 
presence or absence of a permebilising agent. For simplicity only two representative 
examples have been presented (Figure 3.8).
Two different patterns have been observed regarding the plasma membrane distribution 
of PIP7. A speckled staining was observed with the 1B8 and the 4C2 clones whereas a 
more homogeneous signal was detected with the 9HI and 4H5 clones (compare panels 
A and B). Since all staining were performed in parallel, with the same antibody 
concentration, the observed difference may reflect differential affinity or specificity of 
each mAb. All antibodies recognised the nuclear PIP7 pool with the exception of the 
9H1 clone, which in the previous FACS analysis showed preferential specificity for the 
membrane pool only. No cytoplasmic stained was observed in any of the samples and 
the signal obtained in each staining was specific, because the signal was not present 
when the primary antibody was omitted (panel C)
3.2.5.5 Immunohistochemistry
Since PIP7 was cloned from a full brain cDNA library, I attempted to test the spatial 
distribution of the protein in adult brain by immunohistochemistry. Section were
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Figure 3.8 Surface and nuclear localisation of PIP7 in human HCT116 cells.
Immunofluorescent staining of endogenous PIP7 on the surface and inside the nucleus of the 
cell line HCT116. The figure illustrates the two different staining patterns observed on the surface 
of the cells. Clones 1B8 and 4C2 gave a speckled surface pattern whereas 9H1 and 4H5 exhibited 
a more continous and intense staining. All four antibodies appeared to detect the nuclear pool 
to comparable extents.
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Figure 3.9 PIP7 pattern of expression in the CNS.
Consecutive sections were obtained from a wild type mouse brain. Sections were stained with 
the PIP7 specific antibody 4C2 (left panel) or with secondary antibody only (right panel). 
A specific signal was observed in most areas of the brain including cerebellum and 
hippocampus. All sections were lightly counterstained with a Hematoxilin solution.
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prepared from paraffin embedded adult mouse brain and stained in the presence or in 
the absence o f the 4C2 primary antibody. PIP7 immunohistochemistry revealed an 
intense staining in all brain regions including the cortex, hippocampus and cerebellum 
(Figure 3.9). No signal was detected when the primary antibody was omitted. All 
sections were lightly stained with a Hematoxilin solution to discriminate the different 
regions.
3.3 SUMMARY
On the basis of the preliminary in vitro pull down result, I decided to further study the 
putative role of hnRNP M4, (which, for simplicity will from now be referred to as 
PIP7), in Prion biology. I based my decision on the following reasons. Firstly, I was 
able to reproduce the yeast interaction in vitro. Furthermore, the two proteins could 
possibly share the same cellular compartment, making PIP7 a putative novel cellular 
receptor for PrP. Taken together, I believe that PIP7 is a genuine new PrP interacting 
molecule and not a false positive. Further experiments will clarify the nature of the 
interaction and could greatly contribute to the characterisation of the still unknown role 
of PrP in cell physiology. Most importantly, since PIP7 had been identified for its 
ability to bind misfolded PrP, I believe it should also be evaluated for a role also in 
prion pathology and as a potential therapeutic target in the treatment of the diseases. 
The panel of monoclonal antibodies I have generated and preliminarily characterised 
will provide a very valuable tool for my future analysis.
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Chapter 4: Characterisation o f the PrP-PIP7 
interaction
4.1 INTRODUCTION
The original proposition of one or more prion protein receptors was initially suggested 
more than 10 years ago (Shyng et al., 1994). The nature of the prion protein, which is 
devoid of any cytoplasmic tail, suggested it might associate with one or more 
transmembrane proteins, able to recruit the endocytic machinery. The most studied PrP 
receptor is the 37/67 KDa laminin receptor (LRP/LR). It was originally discovered in a 
screen performed in S. cerevisiae (Rieger et al., 1997). PrP and LRP interacted both in 
vitro and in vivo (Gauczynski et al., 2001). Recombinant PrP is able to bind mammalian 
cells in a LRP dependent manner, as shown by antibody competition experiments. 
Moreover the LRP complex is responsible for the internalisation of up to 50% of the 
PrP molecules bound to the cell surface, indicating the need for other components to 
mediate PrP cell entry. Alternatively, other pathway besides clathrin coated pits could 
also be involved (Marella et al., 2002).Two different regions within the prion molecule 
are responsible for the interaction, amino acids 53-93 and 144-179, whereas the region 
proximal to the LRP transmembrane domain (161-179) binds PrP directly.
In Chapter 3 I described a novel screening procedure I have used with the intent to find 
novel PrP interacting proteins (PIPs). I have successfully identified a potential 
candidate, PIP7, and confirmed its ability to interact in vitro with the prion protein. The 
experiments described in this chapter attempt to understand the biology of the PrP-PIP7 
interaction, using a series of complementary approaches. Particular attention has been 
focused on the protein pool of PIP7 present on the cell surface, which is the most likely 
place of interaction.
In order to dissect the molecular mechanism of interaction, different PrP mutants have 
been used. Every construct used has been extensively characterised and its behavior in 
the cell context is well understood. Since the suggested role for PIP7 was a novel PrP 
receptor, different chemical treatments were applied to stimulate PrP endocytosis and 
the fate of the PIP7 protein was monitored.
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4.2 RESULTS
4.2.1 Biochemistry of the PIP7-PrP interaction.
4.2.1.1 PrP-PIP7 co-immunoprecipitation studies
A GST pull down is a powerful and flexible system to confirm novel protein-protein 
interaction but has the disadvantage of using a fusion between the sequence of interest 
and the Glutathione-S-Transferase tag. Such recombinant proteins might not reflect the 
original biochemical properties of the native protein and the exposure of hydrophobic 
patches due to incorrect folding could be responsible for aspecific protein associations. 
From this point of view, the use of GST alone is not a sufficient negative control to 
exclude partial misfolding in the PIP7 sequence resulting possibly in a non 
physiological interaction.
Despite the association inferred from the screen and the positive interaction in the pull 
down assay, I wanted to investigate whether PrP-PIP7 interaction could take place in a 
more physiological environm ent. To do so, I performed a standard co- 
immunoprecipitation assay (Figure 4.1 A). Total lysate was obtained from uninfected 
N2a cells and incubated with the a-PrP specific antibody 6H4 or, as a negative control, 
with an isotype control. The a-PrP antibody was able to enrich for the prion protein as 
shown in the lower panel of the figure and to selectively co-immunoprecipitate PIP7 
(upper panel). Conversely, the isotype control antibody neither enriched PrP nor was 
able to co-immunoprecipitate PIP7, confirming the specificity of the observed 
interaction.
In a parallel experiment, I tested different a-PIP7 mAbs for their ability to enrich PIP7 
from total brain homogenate. The antibodies were able to immunoprecipitate PIP7 
albeit to different extents and, since they were used at the same final concentration (10 
pg/ml), the difference should reflect their different relative affinities: PIP7 enrichment 
by the 4H5 clone was undetectable when compared to the 4C2 and 4G4 clones, with the 
latter providing the highest enrichment in PIP7 levels. When the same membrane was 
probed with a a-PrP antibody, only the 4G4 clone was able to co-immunoprecipitate
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Figure 4.1 PrP-PIP7 interaction by co-immunoprecipitation.
A) PrP was immunoprecipitated from N2a cell lysates using the 6H4 antibody. Western blot 
analysis reveals enrichment in PrP levels and concomitantly, co-immunoprecipitation of PIP7 
protein. The control antibody neither immunoprecipitated PrP nor enriched PIP7.
B) Total brain homogenate from adult mouse was used for PIP7 immunoprecipitation. The 4G4 
clone was not only able to immunoprecipitate PIP7 but also allowed co-immunoprecipitation 
of the prion protein. As a positive control, the 6H4 antibody was included in parallel and enriched 
both PrP and PIP7 levels. The position of the light chain of the antibodies is annotated by the 
asterisk.
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PrP. The experiment was internally controlled: the 4C2 clone enriched in PIP7 but did 
not co-immunoprecipitate the prion protein, possibly due to epitope masking. As a 
positive control, the a-PrP 6H4 antibody was included and the result was consistent 
with the one described in Figure 4.1 A. Interestingly, there is a difference in the gel 
mobility between the PIP7 isoforms present in the input lane compared to the slightly 
higher migration in the co-immunoprecipitated sample. This difference was also 
observed when PIP7 was directly immunoprecipitated irrespective of whether total 
brain homogenate or cell lysate were used as starting material. The reason of such a 
difference is still matter of investigation since it could reflect some post-traslational 
modifications like glycosylation or phosphorylation.
In summary, the PIP7-PrP interaction, originally described in a heterologous system and 
confirmed by standard GST pull down experiment, was reproduced in vivo by co- 
immunoprecipitation, using both cell lysates and brain homogenate. The fact that the 
interaction was detectable using endogenous PrP and PIP7 levels further strengthens the 
potential relevance of the reported interaction.
4.2.1.2 PrP-PIP7 co-localisation by confocal microscopy
PrP is localised to the plasm a membrane of different cell types by its 
glycosylphosphatidylinositol moiety. Correct localisation on the cell surface and 
possibly intracellular trafficking has been implicated in the generation of PrPSc. Despite 
the fact that the biological function of the prion protein is still not fully understood, the 
trafficking o f the molecule has been well characterised. Newly synthesised PrP 
molecules reach the plasma membrane and are rapidly endocytosed: as a consequence 
the steady state of surface PrP levels is the result of a fine balance between transport, 
internalisation and degradation or recycling to the plasma membrane. In order to further 
characterise the physiological relevance of the novel interaction described, a 
microscopy approach was undertaken.
Mouse neuroblastoma cells were transfected with a GFP-PrP fusion construct that had 
been shown to be functional in respect of its correct localisation and prompt 
internalisation in response to copper stimulation (Lee et al., 2001b). Forty-eight hours 
after transfection, cells were fixed and stained with a fluorescence conjugated a-PIP7-
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F igure 4.2 C o-loca lisa tion  of PIP7 and PrP  on the surface of N2a cells.
Mouse N2a cells were transiently transfected with GFP-PrP, fixed and stained with a directly 
labeled a-PIP7 antibody (4G4-Cy3). Samples were analysed by confocal microscopy. PIP7 (left 
panel) and PrP (middle panel) were both present on the cell surface. In the right side panel the 
overlay of both signals indicated co-localisation.
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Figure 4.3 PrP-PIP7 co-localisation in the endocytic compartment.
A) Live N2a cells were incubated with PIP7 labelled antibodies at 4°C and shifted at 37°C before 
confocal analysis; the experiment showed the fast kinetic of endocytosis of the PIP7 protein 
when analysed. B) The experiment described in A) was repeated with GFP-PrP transfected cells. 
PrP-PIP7 co-localisation was observed on the cell surface and in vesicular compartment underneath 
the plasma membrane.
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F igure 4.4 D irect in te ra c tio n  of P rP  and PIP7 m onitored by FR E T/FL IM .
A) Diagram schematising fluorescence lifetime imaging microscopy: FRET involves the transfer 
of energy from an excited donor molecule to a nearby spectrally overlapping acceptor. One 
method to quantify FRET is by measuring fluorescence lifetime of the donor, which is reduced 
as energy is transferred to the acceptor molecule. B) Epifluorescence Frequency Domain FLIM 
images of N2a cells transfected with GFP-PrP (donor) alone or in the presence of the acceptor 
PIP7 antibody (Cy3-aPIP7) as indicated. The left panels represent the intensity image of the 
donor fusion construct GFP-PrP whereas the right panels represent the calculated average lifetime 
maps of GFP-PrP alone or in presence of the acceptor PIP7 antibody. The lifetimes are shown 
on a pseudo-coloured scale from 1.6 ns (red) to 2.0 ns (blue).
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4G4 antibody. A scanning confocal microscope was used to achieve greater emission of 
the fluorescence dye and better resolution than a conventional microscope. Cells were 
not permeabilised in order to evaluate the PIP7 signal present only from the cell surface. 
PrP was found, as previously reported, at the plasma membrane and in perinuclear 
structures, possible the Trans Golgi network. PIP7 was, instead, localised exclusively on 
the cell surface and showed partial co-localisation with the prion protein, as shown in 
the merged image. The PIP7 signal was likely to be specific since an isotype control 
antibody did not give any signal. The absence of PIP7 nuclear staining demonstrates 
that the cell integrity was preserved during the experimental procedure (Figure 4.2).
In a second series of experiments, neuroblastoma cells were preincubated at 4°C in 
order to minimize endocytic processes. Following addition of the a-PIP7 labelled with 
Cy3, cells were shifted to 37°C for 5 minutes, to allow internalisation. Images were 
collected in a Z series and assembled into a 3D reconstruction of a group of cells 
(Figure 4.3A). The experiment shows that the a-PIP7 antibodies can be rapidly 
internalised, possibly after triggering endocytosis upon protein clustering or following 
the normal trafficking o f the molecule. Considering the above results, I wanted to 
investigate whether PIP7 and PrP not only co-localise on the cell surface but also in 
internal compartments. GFP-PrP transfected N2a cells were labelled, as previously 
described with the Cy3-conjugated a-PIP7 mAb prior to live imaging. Both PrP and 
PIP7 seem to be present in a vesicular compartment, underneath the plasma membrane 
(Figure 4.3B). At the present moment, it is difficult to conclude whether the observed 
vesicles are endosomes in the process of being internalised or recycling to the plasma 
membrane. Because of the short time frame of the experiment, they are more likely to 
reflect internalising vesicles. Further studies using specific vesicle markers should allow 
the complete dissection o f the nature of the PrP-PIP7 association in the internal 
compartment.
4.2.1.3 In vivo interaction measured by FRET
Interactions between proteins in living cells are extremely dynamic, and techniques that 
simply co-localise putative partners offer only limited information about these 
interactions. Fluorescence Resonance Energy Transfer (FRET) measures distance- 
dependent interactions between the electronic excited states of two fluorescent
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molecules. If  the two molecules of interest are interacting in an in vivo context, 
excitation energy would be transferred from the donor molecule to the acceptor. The 
efficiency of FRET is inversely proportional to the intermolecular distance, therefore 
the phenomenon would only be observed if the donor and the acceptor are in close 
enough spatial proximity to allow physical interaction.
Since PrP and PIP7 have the ability to interact, as shown by co-immunoprecipitation, 
and they co-localise in the same cellular compartment, as observed by confocal 
microscopy, they were suitable candidates for an energy transfer approach, keeping in 
mind that protein-protein interaction is a requisite necessary but not sufficient to 
produce FRET. N2a cells were transfected with GFP-PrP, which would provide the 
donor molecule. Forty-eight hours post transfection, cells were fixed and, after 
permeabilisation, were incubated with the Cy3-conjugated a-PIP7 mAb, as an acceptor. 
The obvious choice for this experiment was the 4G4 clone, which in the co- 
immunoprecipitation experiment proved to be the only antibody compatible with the 
PrP-PIP7 interaction. A scheme of the experiment is represented on the left side and the 
result is presented on the right (Figure 4.4A and 4.4B respectively). There was a 
significant decrease in the donor lifetime, following the phenomenon of energy transfer, 
in the presence of the acceptor molecule. The experimental setting used did not permit 
determination of the exact location of the interaction; the FRET was measured as a 
mean intensity of the whole cell image. Further studies using a microscope with higher 
resolution would allow the discrimination of the specific sub cellular compartments 
involved in the energy transfer (e.g. endosomes); the FRET is so far the first piece of 
evidence for the in vivo protein-protein interaction between the prion protein and PIP7, 
in the presence of an intact cellular environment.
4.2.1.4 Determination of the PrP minimal binding region in PIP7.
The cDNA clone retrieved from the brain library consisted of the C-terminus of the 
PIP7 protein where two distinct structural domains are present: an unusual motif rich in 
glycines and methionines (approximately 200 amino acids long) and a RNA binding 
domain (90 amino acids). I wanted to narrow down the PrP interaction domain to one of
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Figure 4.5 D e te rm in a tio n  of th e  P rP  b ind ing  dom ain in the PIP7 p ro te in .
The PIP7 fragment present in the yeast clone contained two distinct domains: a region presenting 
27 repetitions of a sequence rich in methionine-arginine-glycine (TR) and a RNA binding domain 
(RRM3). The single domains were expressed as GST fusion proteins and subject to pull down 
assay. The result shows that the Tandem Repeats region is sufficient to interact with PrP.
Chapter 4
the above mentioned regions. In Silico analysis predicted a possible transmembrane 
helix between the Tandem Repeats region (TR) and the RRM3 domain in PIP7; if the 
prediction was correct, there could be no direct cooperation between the two different 
regions in the binding of PrP as they would lie on opposite sides of the plasma 
membrane. To test this hypothesis, the original PIP7 cDNA from the yeast clone was 
divided into two portions corresponding to the TR region and the RRM domain alone. 
The constructs were expressed as recombinant proteins fused to GST and subject to a 
pull down assay to determine the minimal PIP7 sequence still able to bind PrP. The 
region containing the 27 repeats was found to be sufficient for the specific binding to 
the prion protein. Conversely, the RRM3 shows no ability to interact with PrP (Figure 
4.5). The results also offered a possible explanation for the specificity of the interaction; 
searching for RRM containing proteins against the Swiss Prot database retrieved 4522 
entries meanwhile the methionine-glycine rich region is a motif present exclusively in 
PIP7. Since the TR region contains 27 repetitions of the [GEVSTPAN]-[ILMV]-[DE]- 
[RH]-[MLVI]-[GAV] no further attempt to minimise the interacting region has been 
made but future experiments based on peptide competion will confirm the present 
observation.
4.2.1.5 PrP-PIP7 requirements for binding
The PIP7 protein had been reported in the literature as a receptor for thyroglobulin and 
CEA. I tried to use this previous knowledge towards the elucidation of the mechanism 
of its novel interaction with PrP.
The synthesis of the thyroid hormone involves several steps, including secretion by 
thyrocytes and maturation in the follicular lumen of the thyroid (Malthiery and 
Lissitzky, 1987). Since studies had revealed a period of 48 hrs in order to achieve 
complete maturation, it had been proposed that thyroglobulin is internalised by 
thyrocytes. However, the hormone has to escape degradation by lysosomes and this had 
been proposed to occur through a mechanism called “receptor mediated exocytosis”. A 
protein located on human chromosome 19 had been cloned as a monomer of the N- 
acetylglucosamine-specific receptor for the thyroid hormone and further analysis had 
demonstrated that the sequence was identical to the one of human hnRNP M4 (Blanck 
et al., 1994; Blanck et al., 1995). Interestingly, the interaction between thyroglobulin 
and its N-acetylglucosamine-specific receptor was reported to be both calcium and pH
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dependent. In light of this information, the influence of these criteria on the PIP7-PrP 
interaction was investigated using the previously established GST pull down assay.
Calcium dependency
PIP7, as mentioned before, acts as receptor for the Carcino Embryonic Antigen (CEA) 
and for thyroglobulin. In both cases, investigators had reported a strict requirement for 
calcium ions in the ligand-receptor interaction.
PIP7 did not present any apparent sequence homology with C-type lectins, cation 
dependent receptors containing carbohydrate recognition domains (CRD), consisting of 
two anti-parallel beta strands and two alpha helices but the TR region contains negative 
charged amino acids that have been suggested as a potential coordination site for 
calcium ions. Moreover, the interaction between PrP and PIP7 was originally described 
in the yeast cytoplasm, where neither of them could have been glycosylated, suggesting 
that the presence of sugar chains was in principle not an absolute requirement for the 
interaction. However, I wanted to test whether the presence of calcium could contribute 
in establishing the binding.
The standard protocol for purification of fusion proteins included ImM EDTA in the 
buffer used, a concentration sufficient to chelate endogenous concentrations of calcium 
and magnesium. Nevertheless, it could not be excluded an inhibitory effect when the 
putative coordination site of the repeat regions were loaded with exogenous calcium. 
The GST pull down was performed in the presence of an end-point concentration of 10 
mM CaCb which resulted in a detectable decrease in the amount of PrP bound, 
compared to the untreated situation or when the experiment was performed in presence 
of 10 mM EDTA. When calcium and EDTA were added together, the chelating agent 
was able to block the inhibitory effect of calcium and the PrP-PIP interaction had the 
same efficiency as the untreated sample (Figure 4.6). Taken together, the presence of 
calcium ions was not only necessary to establish but partially prevented the PIP7-PrP 
interaction.
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Figure 4.6 The role of calcium ions in PrP-PIP7 interaction.
The standard pull down assay was performed in the presence of exogenous calcium ions and/or 
EDTA. A significant reduction in the amount of PrP bound to PIP7 was observed when calcium 
was added to the buffer. EDTA alone had no apparent effects and was able to restore initial 
binding intensity, when added in combination with calcium.
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Figure 4.7 pH dependency of the PrP-PIP7 interaction.
Mouse total brain homogenate was equilibrated at the specified pH and subject to GST pull down 
with GST alone or with GST-PIP7; two independent experiments are here presented: A) PrP- 
PIP7 interaction was more easily detectable at pH values lower than the physiological 7.4, at 
which value the interaction is only barely detectable. B) The experiment described above was 
repeated testing an extended range of pH values. Interaction was stronger at the mild acidic value 
of 6.0 and at the most extreme value of 3.0. Despite of the pH used in the experiment, the 
interaction was exclusively specific to PIP7, since no binding was detected with GST alone.
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The PrP-PIP7 interaction is pH  dependent
Many mammalian receptors have been studied for their ability to internalise 
glycoprotein and to regulate their intracellular transport. The ligands, once endocytosed, 
could dissociate from the receptor and are usually targeted to the lysosome for 
degradation or, as in the case of Tranferrin molecules, recycled to the cell surface 
together with their receptors (Alberts et al., 1994). Cells have developed a simple 
mechanism to recycle the receptors: many ligands interact with their receptor in a pH 
dependent manner. Optimal binding occurs at the neutral values present on the cell 
surface whereas the complex dissociates in the endocytic pathway in the presence of a 
more acidic pH. The result is the recycling of the receptor and the delivery of the 
ligands to lysosomes. This is the case of the LDL receptor which dissociates from its 
ligand LDL in the endosome and is recycled to the plasma membrane whereas the 
discharged LDL undergoes degradation (Beglova et al., 2004). In striking contrast to 
this general mechanism, the PIP7 molecule shows the unique property of binding to its 
ligand thyroglobulin with high affinity at the optimal pH of 5.0 (Miquelis et al., 1987). 
First of all, I wanted to establish whether there was any pH dependency in the ability of 
PIP7 to bind PrP in vitro. In the first experiment, I compared three different pH values, 
which might reflect the physiological environments encountered by PrP on its journey 
from the plasma membrane (pH 7.4) to the lysosomal compartment (pH 5.0). There is a 
clear preference for interaction at an acidic pH: the binding at pH 7.4, which should 
mainly recapitulate the situation on the cell surface, was in this particular setting barely 
detectable when compared to the binding at pH 6 and 5 (Figure 4.7A).
In a second experiment, the pH range tested was extended in order to establish the 
optimal value for the interaction. The range spanned from the physiological value of pH
7.4 to the extreme acidic value of pH 3.0 (Figure 4.7B). The binding was stronger at a 
mild acidic value (6.0) and decreased proportionally to a minimum value (4.0). The 
interaction between GST and Glutathione beads was stable and comparable in the range 
from pH 7.4 to 4.0, as revealed by Ponceau staining of the membrane, and allowing a 
direct correlation between the binding strength and the pH value. Most surprisingly, the 
PrP enrichment was even more pronounced at the lowest value tested (3.0), originally 
included in the test as an end point value at which no interaction was expected to be 
detected. The result obtained at pH 3 is even more striking because the Ponceau analysis
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revealed that only approximately 20% of fusion proteins were present on the sepharose 
beads at the end of the washing procedure, possibly due to the instability of the GST- 
glutathione interaction in such extreme condition. Nevertheless, even if the beads 
presented on their surface a smaller amount of fusion proteins compared to all the other 
samples, the maximal interaction between PrP and PIP7 was observed at this pH. 
However, it is difficult to find a rational explanation since no cellular compartment 
shows such acidic conditions.
In both experiments GST alone was not sufficient to bind PrP at any pH tested. In light 
of this evidence, it is possible to conclude that, in the in vitro GST pull down assay, the 
interaction preferentially occurs at an acidic pH. However in vivo data are required to 
confirm the significance of these findings in a more physiological setting.
4.2.2 Reciprocal co-regulation of PrP-PIP7 surface levels.
4.2.2.1 PrP overexpression leads to PIP7 surface accumulation.
During the microscopy assay described above (Figure 4.2), I noticed that the strongest 
PIP7 immunostaining was observed preferentially in the cells showing the highest PrP- 
GFP expression, I therefore further investigated a possible direct correlation between 
PrP and PIP7 surface levels.
Human 293T cells were transfected, as described, with the GFP-PrP construct used in 
the co-localisation study and analysed by surface flow cytometry; a GFP plasmid was 
used as a negative control to exclude any artefact due to the transfection protocol used 
and to judge the specific effect of PrP overexpression. The transfection efficiency was 
estimated at around 50% by microscopic observation. Figure 4.8 panel A) shows the 
appearance of a discrete population of cells expressing high levels of PrP whereas in 
panel D) an increase in PIP7 surface levels (marked by a red arrows) is observed 
specifically in the GFP-PrP transfected cells. Subsequential analysis, with FLOWJO 
software, allowed the distinction between transfected (GFP positive) and untransfected 
(GFP negative) cells to be made. PrP and PIP7 levels were unaltered in the GFP 
negative subset (panels B and E) despite of which plasmid was used for the transfection.
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Figure 4.8 PrP overexpression leads to P1P7 surface accumulation.
Human 293T cells were transiently transfected with a GFP-PrP fusion construct (blue line) or GFP alone (red line), as negative control. Forty- 
eight hours after transfection, cells were fixed and stained with PrP and PIP7 antibodies and surface protein levels were monitored using a 
FACScalibur device. Total subset cells are represented (1) or specifically transfected (2) or untransfected (3) populations by gating according 
to the presence or absence of the GFP signal. PIP7 levels were specifically increased in cells transfected with the PrP encoding 
plasmid and not the empty vector (compare C and F).
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Figure 4.9 PIP7 surface accumulation is not cell specific.
Human 293T cells (panel A) and mouse N2a cells (panel B) were transfected, as previously 
described, with GFP-PrP (blue) or GFP (red) plasmid. After 48 hours, cells were fixed and PrP- 
PIP7 levels were monitored by FACS assay. The previously reported surface accumulation was 
observed in both cell lines, despite the difference in the basal levels of the studied proteins. Only 
the GFP positive subsets are represented in the Dot Plot.
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In contrast, during the analysis of the tranfected population (GFP positive cells only), 
the levels of PIP7 on the cell surface increased in response to GFP-PrP overexpression 
but not with GFP alone. The data illustrated in Figure 4.8 were reproducible in several 
independent experiments. Since the PrP-PIP7 immunostaining for the FACS analysis 
was performed within the same sample using isotype specific secondary antibodies, it 
was possible to visualise the PrP-PIP7 levels in a Dot Plot (Figure 4.9). The 
consequence of PrP overexpression is a direct proportional accumulation of PIP7 on the 
cell membrane: the higher the number of PrP molecules present on the surface of a 
given cell, the more pronounced was the accumulation of endogenous PIP7. Moreover 
PIP7 accumulation, in response to increased PrP levels, was not cell type specific or 
species specific since it was observed both in mouse neuroblastoma cells and in human 
293T cells. Different basal levels of PIP7 and PrP was also observed in the above cell 
lines: PrP and PIP7 appeared to be more highly expressed in N2a compared to 293T, 
although this observation could in principle reflect as well differences in the antibody 
affinities between mouse and human proteins.
4.2.2.2 PrP structural requirements for PIP7 accumulation
In order to better characterise the direct proportionality observed, different PrP mutants 
were tested in the FACS assay with the aim to understand which features of the prion 
protein are required for PIP7 accumulation.
Different PrP N-terminal deletion mutants have been generated in the past with the 
purpose of defining the minimal region able to support scrapie pathogenesis. Transgenic 
mice harbouring two of the constructs, named AE and AF (respectively missing residues 
32-123 and 32-134 respectively), surprisingly developed ataxia and neurodegeneration 
of cerebellar cells. When expressed in N2a cells, they were shown to be correctly 
processed and reach the cell surface (Shmerling et al., 1998).
When used in the above FACS assay, both AE and AF were able to accumulate PIP7, as 
had been observed for the full length PrP (Figure 4.10 and data not shown). In the same 
experiment, cells transfected with the wild type construct presented an approximately 3 
fold increase in surface levels of PrP meanwhile cells transfected with the AE mutant 
resulted in a 4.5 fold increase, possibly due to less efficient internalisation of the mutant 
molecule (Lee et al., 2001b).
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Figure 4.10 Specific effect of P rP  overexpression  on PIP7 su rface  levels.
Human 293T cells were transfected with an empty GFP vector or with constructs encoding GFP- 
PrP wild type or the N-terminal deletion AE. Forty-eight hours post transfection, samples were 
fixed and stained with the above-indicated antibodies. PrP levels were greatly increased by 
ectopic overexpression; this resulted in a concomitant accumulation on the cell surface of 
endogenous PIP7. The levels of Transferrin Receptor (TfR) did not change, arguing that PIP7 
surface accumulation was a specific result of PrP overexpression. The mutant construct AE has 
been reported to show abnormal endocytic behavior as reflected here by the higher surface levels 
achieved post-transfection ; as a consequence, also PIP7 levels were higher.
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Figure 4.11 P rP  s tru c tu ra l  re q u ire m e n ts  for PIP7 surface  accum ulation .
Transiently transfected 293T cells expressing wild type GFP-PrP, mutants GFP-PrP-AE, PrP- 
ASP or GFP-GPI were fixed and analysed by FACS. In order to provide an internal control, 
transfected cells, (blue) and untransfected cells (red) were compared for each construct. Full 
length GFP-PrP and the N-terminal deletion construct AE generated a proportional increase in 
PIP7 surface levels. Conversely, the increase was not observed either when a PrP mutant lacking 
the signal peptide was expressed or when a minimal GFP construct was targeted to the plasma 
membrane via a GPI moiety.
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Alteration in PrP levels resulted in a proportional increase in PIP7 levels (2.8 and 4.3 
fold respectively).
PrP has the ability to cycle rapidly between the plasma membrane and the endocytic 
compartment via a clathrin mediated mechanism. Such behaviour is not unique to PrP 
since other membrane proteins such as the Transferrin Receptor (TfR) and the LDL 
receptor share the same characteristic. In order to assess whether PrP overexpression 
was specifically affecting PIP7 accumulation or simply saturating the endocytic 
pathway, I monitored the levels of TfR as a suitable control: the observed accumulation 
revealed to be specific since the TfR levels were unaltered in response to 
overexpression o f wild type and mutant PrP (Figure 4.10).
A PrP mutant, lacking the N-terminal signal peptide (GFP-PrP-ASP) required for the 
correct translocation to the endoplasmatic reticulum has been shown to fail to reach the 
plasma membrane and has been found to localise exclusively in the cytoplasm (Lee et 
al., 2001b). When cells were transfected with this mutant no increase in PEP7 levels was 
observed as no difference was observed in cells transfected with the minimal construct 
composed by GFP targeted to the plasma membrane by a GPI anchor (Figure 4.11). 
Taken together, these data suggested that: a) the increase in the PIP7 surface pool is a 
direct consequence of PrP accumulation on the cell surface b) targeting GFP to the cell 
surface via a GPI anchor moiety was not sufficient to accumulate surface PIP7.
To further confirm that PrP alone, and not the GFP moiety of the fusion protein was 
responsible of the observed PIP7 behaviour, I transfected a vector encoding untagged 
PrP or a empty control vector into human 293T cells. The result obtained with the GFP- 
PrP construct was successfully reproduced, as overexpression of untagged PrP caused 
PDP7 surface accumulation, suggesting there was no contribution of the GFP tag which 
theoretically could alter PrP structure by steric hindrance and be in part responsible for 
the stabilisation o f the PrP-PIP7 interaction (Figure 4.12).
4.2.2.3 Reduction of PIP7 surface levels by treatments aimed to reduce PrP levels
To further dissect the biology of the novel interaction I applied different drug 
treatments.
127
■I
PrP
10 '
10
10 '
A)
• • •
lEMPTY VECTOR
104 T
t?V 
?Vv^ .T- •'•: •
A *v . r  •'-
10 '
B)
10 ' 10 10 10 10 *  10 ' 10 10 10 10 '
PIP7
F ig u re  4.12 P rP  o v e re x p re s s io n , lik e  G F P -P rP , in c re a se s  PIP7 levels.
Human 293T cells were transfected with an empty vector (A) or with vector encoding untagged 
PrP (B). After fixation, samples were stained with PrP and PIP7 antibodies and processed by 
flow cytometry. PIP7 accumulation was observed only as direct consequence of PrP overexpression. 
The result argued against any possible contribution of the GFP tag in stabilising PIP7 surface 
levels.
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The choice of treatments was based on prion literature and more emphasis has been 
given to compounds which have been shown to affect PrPSc biogenesis in vitro or in 
vivo.
PENTOSAN SULPHA TE
Polyanionic glycans, such as Pentosan Sulphate, have been studied in the past twenty 
years as a potential therapeutic agent against prion disease progression. Originally used 
against conventional viruses, they proved effective in inhibiting PrPSc accumulation in 
vitro and demonstrated potential prophylactic activity in vivo (Caughey and Raymond, 
1993; Farquhar et al., 1999; Ladogana et al., 1992). Their mechanism of action remains 
unclear but they have been suggested to decrease the amount of PrP on the cell surface 
by interfering with PrP-glycosaminoglycans interaction and altering its physiological 
distribution by stimulating endocytosis (Shyng et al., 1995a).
In the next set of experiments, the aim was to alter the newly established surface steady- 
state, characterised by high levels of exogenous PrP and endogenous PIP7, by 
stimulating PrP endocytosis and follow the fate of PIP7 molecules. I decided to use 
GFP-PrP since, as previously shown, the fusion protein appeared to be functional and 
allowed easy discrimination between transfected and untransfected cells. GFP-PrP-AE 
was included in the panel as the minimal mutant that was still able to produce PIP7 
surface accumulation. Finally, the GFP-PrP-ASP mutant, unable to produce PIP7 
surface accumulation, was used as a negative control (Figure 4.13).
The experimental protocol included transfection of the above constructs and subsequent 
treatment with Pentosan Sulphate (100 pg/ml) for 24 hrs. Samples were fixed and 
double stained with a-PrP  and a-PIP7 monoclonal antibodies. In line with previous 
experiments, PIP7 accumulation was observed in the samples transfected with wild type 
PrP and the AE mutant but not with the ASP. Pentosan Sulphate treatment has been 
shown to lower PrP levels by triggering endocytosis and was able to decrease PrP levels 
by approximately 50% (Figure 4.14). This led to a parallel decrease in PIP7 levels to a 
comparable extent (70%). PrP-AE still retained the ability to get internalised in response 
to PS stimulation and a proportional PIP7 decrease was also observed.
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Figure 4.13 Decrease in PIP7 surface levels after treatments intended to reduce PrP levels.
Human 293T cells were transfect with GFP fusion constructs encoding wild type PrP or mutant versions of the protein. After 24 hours, 
Pentosan Sulfate (100 pg/ml) or Suramin (200 pg/ml) were added to the media and cells were examined the following day for the amount 
of PrP and PIP7 present on their surface. Both treatments produced a decrease in PrP surface levels; which was mirrored by PIP7 reduction. 
Cells transfected withPrP ASP did not accumulate either exogenous PrP or PIP7 on their surface but the endogenous levels were responsive 
to the applied treatments. Only GFP positive populations are shown in the analysis.
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Figure 4.14 Quantification of the effect of Pentosan Sulphate and Suramin on PrP transfected 
cells.
The mean fluorescence intensity of the samples analysed in Figure 4.13 was plotted for more 
precise quantification. The experiment was standardised fixing the values of PrP and PIP7 
on the GFP-PrP untreated samples to 100%.
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Figure 4.15 Effect of Pentosan Sulphate and Suramin on endogenous PrP-PIP7 levels.
Human 293T cells were left untreated (black bars) or were treated for 24 hours with Pentosan 
Sulphate (white bars) or Suramin (grey bars). After fixation, samples were analysed for the 
surface content of PrP, PIP7 or TfR. Both treatments produced a reproducible decrease in PrP 
surface levels and in parallel also the PIP7 surface pool was reduced. The treatments did not 
produce significant changes in the levels of TfR.
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SURAMIN
Suramin was originally developed to treat trypanosomiasis but proved to have a partial 
anti-prion effect when injected in a hamster scrapie model (Ladogana et al., 1992). 
More recently two different mechanisms of Suramin action have been proposed. In 
neuroblastoma cells treated with Suramin, PrP formed aggregates and partitioned in the 
insoluble fraction when a standard solubility assay was performed. PrP aggregation was 
observed in the Trans-Golgi Network, with subsequent targeting for lysosomal 
degradation. As a direct consequence, PrP surface levels were drastically reduced in 
Suramin treated cells, compared to the untreated sample (Gilch et al., 2001).
An independent study demonstrated that Suramin could not only stimulate PrP 
aggregation in the intracellular compartments but could also induce misfolding of PrP 
directly at the plasma membrane (Kiachopoulos et al., 2004). Misfolded PrP was 
subsequently rapidly internalised by a mechanism requiring its unstructured N-terminus. 
The same group had also proposed an analogous mechanism following copper 
treatment. Copper binding to the prion protein would partially misfold the protein and 
stimulate endocytosis with consequential uptake of the ions.
Therefore, I have tested the effect of Suramin in my FACS assay. Overnight treatment 
of 293T cells with Suramin (200 p,g/ml) produced a marked decreased in PrP surface 
levels with an analogous decrease in the PIP7 pool (Figure 4.13 and 4.14). Suramin 
proved even more effective than PS. PrP levels showed a reduction of more than 70% in 
cells transfected with wild type PrP and 40% in cells receiving the AE construct. 
Conversely, a PIP7 decrease in the order of 75 and 80% was observed for both 
constructs.
In summary, a direct proportionality was again observed, regardless of which treatment 
was used: PIP7 surface levels were reduced in response to decrease of surface PrP. 
Treatments produced the same effect not only in transfected cells but also on 
endogenous protein levels, arguing against any transfection artifact and most 
importantly the drugs effect was specific for PrP and PIP7 since the TfR levels were 
unaltered (Figure 4.15).
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PIPLC
Treatments with the phosphatidyilinositol specific phospholipase C (PIPLC) have been 
shown to release the prion protein from the cell surface (Borchelt et al., 1990). 
Neuroblastoma N2a cells were chosen for this particular experiment because of their 
higher amount of surface PrP compared to 293T. Untransfected cells were treated with 
PIPLC (250 mU/ml) for 2 hrs at 37°C and PrP-PIP7 surface levels were analysed by 
FACS. Upon treatment, almost all the PrP (>80%) present at the plasma membrane had 
been removed. When cells were stained with the 4G4 specific CX-PIP7 antibody, a 
concomitant decrease in surface PIP7 levels was observed (30%). Once again the TfR 
was used as a control to assess specificity and its levels remained unchanged following 
the enzymatic treatment (Figure 4.16).
4.2.2.4 PIP7 accumulation is independent on PrP endocytosis.
Previous experiments have shown that PIP7 accumulation is dependent on correct 
localisation of PrP on the cell surface. Once PrP reaches the plasma membrane, 
molecules get rapidly internalised and, via a recycling compartment, mainly redirected 
back to the cell surface, with a small percentage targeted to lysosomes. PIP7 
accumulation seemed to be the direct consequence of protein-protein interaction 
occurring primarily on the cell surface. An alternative scenario would be the increased 
recycling from the acidic compartment back to the cell surface, as originally proposed 
for the thyroglobulin receptor and suggested by the data I presented showing the higher 
interaction affinity at acidic pH (Blanck et al., 1994). Cells ectopically expressing the 
prion protein would not only have increased surface levels but possibly also an 
increased amount in the endocytic/recycling pathway. The N-terminus of the prion 
protein contains a characteristic m otif rich in positively charged amino acids 
(KKRPKP) suggested to mediate interaction with sulphated proteoglycans, molecules 
known to stimulate PrPc endocytosis (Pan et al., 2002). Substitution of three basic 
residues generating KQHPHP (a mutant which for simplicity is referred to as NGAG) 
had the dramatic result of completely abolishing PrP endocytosis (Sunyach et al., 2003).
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Figure 4.16 PIPLC treatment of N2a cells.
Mouse neuroblastoma N2a cells were treated with 250 mU/ml of PIPLC for 2 hours at 37°C 
(grey bars) or left untreated (black bars). Following fixation, cells were stained for PrP, PIP7 
and TfR. The figure shows only relative amounts present on the cell surface after treatment.
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Figure 4.17 PIP7 surface accumulation does not require PrP endocytosis.
Human 293T cells were transfected with a PrP wild type construct or with a mutant which cannot be efficiently endocytosed (NGAG). 
Double staining analysis by FACS reveals higher PrP levels detected in cells transfected with the mutant compared to the wild type; 
however the proportional accumulation of PIP7 is still observed suggesting a direct stabilisation of PIP7on the plasma membrane, without 
the necessity to transit through the endocytic compartment. Percentages indicate the proportion of cells present in the selected area.
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Figure 4.18 D ecreased PIP7 surface levels in the b ra in  of Prnp~!~ mice.
Brain homogenate was obtained from wild type or PrP deficient mice and subjected to a membrane 
enrichment procedure. Western blot analysis revealed a marked decrease in the PIP7 levels, 
approximately 50%, in the PrP null sample. The same amount of total proteins was loaded in 
each lane (100 pg) as confirmed by the actin immunoblot. The levels of Syntaxinl, an integral 
membrane protein involved in vesicular trafficking and membrane fusions, were unaltered, 
suggesting that the decrease in PIP7 surface pool was a specific consequence.
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A comparison between wild type PrP and the NGAG mutant, which cannot be 
efficiently internalised and therefore recycled to the plasma membrane, would allow the 
discrimination between the two alternative possibilities. Human 293T cells were 
transfected with each of the two constructs or left untransfected (Figure 4.17). PIP7 
accumulation occurred both in the presence of wild type PrP and the NGAG mutant: the 
latter was more efficient as estimated by the percentage of cells present in the marked 
area (23% and 30.8% respectively). Untransfected cells did not show any variations. 
The results confirmed the hypothesis that PIP7 accumulation occurs independently of 
the mechanism of PrP endocytosis and recycling.
4.2.2.5 Reduced PIP7 surface levels in PrP knockout brain.
Since PIP7 levels seemed to be influenced by PrP overexpression, I decided to 
investigate whether in vivo PIP7 levels were altered in the complete absence of the prion 
protein. Prnp+/+ and Prnp A brains were obtained from adult mice, sex and age matched. 
A first attempt using total brain homogenate, without any subsequent cellular sub­
fractionation, did not reveal any significant difference in the level of PIP7 between wild 
type and mutant samples (data not shown). In the second attempt, samples were 
processed, as described in the materials section, in order to enrich a crude membrane 
preparation. In this case, Western blot analysis revealed a consistent decrease in PIP7 
membrane levels, estimated at around 50% when compared to wild type (Figure 4.18). 
The decreased was specific because the levels for syntaxinl, an integral membrane 
associated protein, were unchanged. Equal amount of protein was loaded in each lane as 
judged by Ponceau staining of the membrane and later confirmed by the a-|3actin  
immunoblot. A reasonable explanation for the apparent discrepancy observed between 
the two performed experiments might be the presence in the total brain homogenate of 
the intracellular PIP7 pool which makes up the majority of the total population and 
might obscure any difference present at the plasma membrane where PIP7 levels are 
comparatively low. Such a difference at the plasma membrane could only be 
appreciated after separation of soluble and membrane-bound fractions.
138
Chapter 4
4.2.2.6 PrP response to PIP7 surface levels alteration
So far, manipulations aimed at increasing or reducing the levels of surface PrP have 
resulted in an accumulation or reduction of endogenous PIP7 levels, respectively. Since 
the PIP7 knockout was not available to perform an in vivo analysis such as the one 
performed using the PrP knockout, I took an alternative approach to better understand 
the possible role of PIP7 in the biology of the prion protein. In the experiments 
presented below, PIP7 levels were altered either by overexpression or siRNA-mediated 
knock-down and the PrP surface population was monitored.
PIP7 overexpression
Considering the accumulation of endogenous PIP7 following PrP overexpression, I 
decided to investigate if the increase of PIP7 levels had any effect on the steady state of 
endogenous PrP. Human 293T cells were transfected with an empty vector or with a 
plasmid encoding the PIP7 short isoform. Forty-eight hours post transfection, cells were 
fixed and subjected to surface FACS analysis (Figure 4.19). Specifically in the PIP7 
transfected sample but not in the control one, a PIP7 increase of 28.6% correlated with a 
PrP decrease of 20.9%. The result was considered specific in the light of the TfR, which 
remained unaltered (+1.0%). The experiment was repeated twice and the result was 
reproducible.
PIP 7 siRNA
Following the result obtained by increasing PIP7 levels on the plasma membrane, I 
decided to try a complementary approach using gene silencing by RNA interference. A 
pool of four different siRNA oligos directed against human PIP7 (locus ID 4670) and a 
non targeting control pool were transfected in 293T cells. Samples were collected at two 
different time points (36 and 60 hours post transfection) and subjected to analysis by 
Western blot (for total levels) and by FACS (surface levels only, Figure 4.20). The cell 
lysates analysed for total PIP7 levels revealed a reduction in response to the PIP7- 
specific pool at both time points, with higher knock-down efficiency after 36 hours 
compared to 60 hours post transfection. The reduction was specific since the levels of (3- 
actin, considered here both as a control for equal loading and specificity of the siRNA
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Figure 4.19 P1P7 overexpression in human 293T cells leads to a proportional decrease in 
PrP surface levels.
Human 293T cells were transfected with plasmids encoding the PIP7 Short isoform or an empty 
vector. Cells were collected 48 hours post transfection and surface FACS staining was performed. 
Analysis revealed an increase in PIP7 levels (+28.6%) whereas PrP levels exhibited a corresponding 
descrease (-20.9%). The TfR surface pool, included as a control for specificity, remained relatively 
unaltered (+1.0%).
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Figure 4.20 Effect of PIP7 siRNA on PrP.
Human 293T cells were transfected with a PIP7 specific siRNA pool or with a 
control pool. Samples were collected 36 and 60 hours post transfection respectively, and 
subject to analysis by Western blot or FACS. A) The effect on total PIP7 levels was more 
pronounced at the first time point compared to the later time point; the same amount of 
protein (100 pg) was loaded for each sample as confirm by the actin immunoblot.
B) Surface protein levels monitored by FACS assay. The surface PIP7 pool was reduced by 
43.5% after 36 hours and 28.3% after 60 hours. PrP levels were slightly reduced as well 
(-6.6% and -4.6%) whereas TfR levels showed a small increase (+2% and +4.6%).
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pool, remained unaltered. The knock-down observed in total levels was also reflected on 
the cell surface upon antibody labeling and FACS analysis. A 43.5% reduction was 
observed at the first time point whereas a 28.3% decrease was registered after 60 hrs. 
However, in the PIP7 knock-down cells, there was only a slightly decrease in the 
surface levels of PrP (6.6% and 4.6% at the 36 and 60 hrs time point respectively). This 
reduction appeared nevertheless specific since TfR levels did not decrease but 
underwent a slight increase (+2% and +4.6% correspondingly). The variations measured 
for the TfR are indicative of some variability in the system and the experiment has to be 
repeated to confirm its significance before making any conclusion. One alternative 
possibility could be the transfection of a vector driving inducible expression of a 
specific PIP7 siRNA. Moreover, the presence of a suitable selectable marker will allow 
to perform long-term gene knock-down studies, as well as transient assays where low 
transfection efficiency could otherwise preclude detection of a reduction in target gene 
expression.
4.3 SUMMARY
The focus of the experiments described in this chapter was to provide a preliminary 
characterisation for the novel described interaction. Different aspects have emerged and 
the results obtained provide the starting point to develop further analysis.
First of all, I was able to map the interaction domain of each interaction partner, using 
GST pull down and FACS analysis respectively: PrP binds the so called Tandem 
Repeats region which is characterised by a very atypical amino acid composition 
whereas PIP7 is assumed to bind PrP at the C-terminal as judged by PIP7s ability to 
accumulate in response to the PrP-AE and PrP-AF mutant, lacking the flexible N- 
terminal domain.
In vitro studies have allowed me to identify the optimal binding conditions. PIP7 was 
known to interact with CEA and Thyroglobulin in a calcium-dependent manner. The 
PrP-PIP7 interaction, quite strikingly, was partially inhibited by the presence of 
exogenous calcium. Moreover the two partners seem to associate strongly at acidic pH 
values, in analogy with the optimal binding condition reported for the PIP7- 
Thyroglobulin interaction.
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Co-localisation between PrP and PIP7 was observed on the cell surface and in a not yet 
defined vesicular compartment, possibly endosotrnCS, as observed by co focal 
microscopy. The interaction was confirmed by standard immunoprecipitation and by 
Fluorescence Resonance Energy Transfer, a very sensitive technique which allowed me 
to monitor the protein-protein interaction in a cellular context without alteration or 
disruption of the physiological environment.
Finally, the increased PIP7 surface levels in response to PrP overexpression was 
correlated with the observation of reduced PIP7 membrane levels in the brain of Prnp'A 
mice.
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Chapter 5: Investieation o f  the possible 
involvement o f PIP7 in prion disease
5.1 INTRODUCTION
Although many proteins have been shown to interact with the physiological isoform of 
the prion protein PrP , to date only plasminogen has been suggested as specific ligand 
for PrPSc (Fischer et al., 2000; Maissen et al., 2001). Possibly the best studied prion 
interacting protein is the laminin receptor (LRP/LR). Preliminary studies have 
suggested its involvement not only in PrPc metabolism but also in prion propagation. 
Treatments with specific LRP/LR antibodies or antisense RNA were able to clear PrPSc 
from infected neuronal cells (Leucht et al., 2003). Since the conversion between the 
physiological and the pathological conformation of PrP is believed to take place either 
directly at the plasma membrane or in the endocytic pathway, it is highly likely that
n  ✓-»
PrP formation was impaired due to fewer PrP molecules being internalised. Recently, 
a transgenic mouse line, ectopically expressing antisense LRP RNA in the brain under 
control of a neuronal promoter, was generated (Leucht et al., 2004). A significant 
reduction of LRP/LR protein levels was observed in different brain regions. These mice 
might act as powerful tools to investigate the role of the laminin receptor in scrapie 
pathogenesis in vivo.
In the present chapter, I will extend my analysis of PrP-PIP7 interaction specifically to 
different aspects of prion disease. I will divide this chapter into two parts: the 
biochemical characterisation of PrPSc-PIP7 binding and the attempt to interfere with 
prion disease progression by modulating PIP7. The former approach was based on the 
previously described GST pull down whereas the latter used two different but 
complementary approaches. In a cell based assay, a-PIP7 mAbs were tested for their 
ability to clear PrPSc. Alternatively, the in vivo requirements of PIP7 for prion infection 
and replication was assessed by a neurografting approach, where PIP7’A cells were 
grafted in a P r n p 'A recipient mouse and challenged with RML prion-infected 
homogenate.
144
Chapter 5
5.2 RESULTS
5.2.1 Scrapie binding assays
5.2.1.1 PIP7 does not bind p rpRes
The flexibility of the GST binding assay allowed the relative affinity of PIP7 for the 
physiological conformation o f PrP or for the pathological form to be tested. In the 
previous chapter, I observed an interaction between PIP7 and PrPc; the term PrPc is 
commonly used to refer to the normal structure of the prion protein, as found in 
uninfected mice. In the literature, PrPSen is an alternative designation for PrPc and is 
exclusively based on the ability to be digested by PK treatment, irrespective of the 
actual conformation of the protein. Conversely, the definition of PrPSc as the scrapie 
specific isoform has to be clarified due to the existence of protease resistant PrP 
conformations that may or may not be infectious. The more general definition PrPRes 
encompasses all forms of PrP that resist digestion by PK.
Using uninfected and infected brain homogenate as a source of PrPc and PrPSc and 
following limited PK treatment, I attempted to characterise the biochemical properties 
of the PrP pool bound to PIP7. Total homogenate was prepared from the brain of 
terminally sick mice, previously intracranially inoculated with RML, or from healthy 
littermate controls. The experiment was performed as previously described, at pH 6, 
with the optional step of PK digestion after the last wash, at the standard concentration 
of 50 p,g/ml. As shown in the previous chapter preferential binding between PrP and 
PIP7 was observed at low pH values; since pH 6 was not the standard value used for PK 
digestion in the literature, a preliminary experiment was performed in order to test 
whether PK activity would be preserved. After one hour incubation at 37°C, the N- 
terminus of PrP was removed giving rise to a subset of bands characterised by lower 
molecular weight and indicative of PrP27'30, the PK resistant core of PrPSc, suggesting 
that PK is fully functional at pH 6.0.(Figure 5.1).
In the absence of protease treatment, GST-PIP7, but not GST alone, was able to enrich 
for PrP both from uninfected healthy brain and terminally sick brain homogenate.
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Figure 5.1 Test of Protease K activity at pH 6.0.
Total brain homogenate from terminally sick mice, previously inoculated intracerebrally with 
RML prions, was equilibrated at pH6.0 and digested with Protease K (50 pg/ml) for 1 hour 
at 37°C. Increasing amount of proteins, corresponding to 50-100-200 pg, were loaded on a 
SDS polyacrilamide gel and probed for PrP using ICSM18. The shift observed in the PrP molecular 
weight in the PK treated samples compared to the untreated ones confirmed the ability of 
Protease K to cleave the N-terminus of PrPSc and give rise to a resistant core, known 
as PrP27 30, even at pH 6.0.
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Following the treatment with PK, PrP27'30 was detected in the input lane but not in any 
of the samples subjected to pull down. Quite remarkably, there seemed to be a selective 
specificity in the binding of different glycosylated isoforms: in wild type brain, as 
shown in the input lane, the predominant isoforms are the di- and un-glycosylated, with 
very little of the mono-glycosylated version present; meanwhile in the infected 
preparation all three isoforms were equally represented. If no binding specificity was 
present, the same isoforms ratio observed in the input should have been reflected in the 
pull down. This was the case for the wild type brain but PIP7 proved to have higher 
affinity for di-glycosylated PrP and lower affinity for the remaining isoforms in the 
infected sample (Figure 5.2).
5.2.1.2 PIP7 does not bind PrP27 30
The result obtained from the previous experiment might suggest PIP7 specificity for a 
PK sensitive conformation of the prion protein PrPSen, that might overlap or not with 
PrPc. Nevertheless, it was not possible at this stage to exclude whether PrPc and PrPSc 
have different binding affinity for the PIP7 receptor. In this possible scenario, PrPSen 
might have a higher affinity and could engage PIP7 in the binding and prevent the 
interaction with PrPRes, characterised by having a lower affinity for the receptor. In 
order to test this hypothesis, infected brain homogenate was digested with Protease K, 
before performing the pull down assay, in order to eliminate any PK-sensitive 
conformations (PrPSen) and to have a pure preparation of PrP27'30: this would provide a 
homogeneous population that could be unequivocally tested for its binding ability 
towards PIP7. This hypothesis is supported by previous data suggesting that the N- 
terminal region, cleaved upon protease treatment, was not required for the interaction 
with PIP7 as the PrP-AE mutant despite lacking the N-terminus was still able to 
accumulate PIP7 on the cell surface.
On the left side of Figure 5.3, PrP was specifically pulled down by PIP7 in absence of 
protease treatment. However, when the sample was pre-treated with PK, as shown in the 
right panel, no PrP27'30 was detected either bound to GST or to GST-PIP7. Therefore I 
conclude that PrPRes was not able to bind PIP7 under these experimental conditions.
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Figure 5.2 PIP7 does not bind PrPSc.
Brain homogenate (10% w/v) was obtained from healthy or scrapie infected mice. GST pull 
downs were performed in duplicate: after the final wash, one aliquot was treated with Protease 
K (50 pg/ml, 1 hour at 37°C) and one left on ice. The reaction was blocked by addition of PMSF 
to a final concentration of 1 mM for 30 minutes on ice. Loading buffer was added to the samples 
which were analyzed by SDS-PAGE. Following Western blot analysis with the specific a-PrP 
antibody ICSM18, PrP-PIP7 interaction was detected in both infected and uninfected samples 
prior to proteolysis treatment. After treatment PrP27'30 was detected only in the infected cell lysate 
but was not detected in the sample subjected to pull down. The position of Protease K is marked 
in red (*). Total cell lysate corresponding to 10% of the amount used for the pull down was 
loaded as input.
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5.2.2 Testing the role of PIP7 in prion disease in vivo
It is widely accepted that one or more cellular proteins might play a role in the 
transconformation process leading to the formation of PrPSc (Kaneko et al., 1997b). One 
of the most ambitious experiments in the prion field is the generation of animals lacking 
a specific protein, which has been demonstrated to interact with PrP, and the 
subsequential delay, or ultimately failure, to develop the disease after inoculation. This 
has only been shown for mice devoid of the prion protein itself which remains 
completely free of scrapie symptoms (Biieler et al., 1993). The postulated auxiliary 
factor Protein X is without doubt the most suitable candidate for this kind of approach 
but its existence remains speculative (Telling et al., 1995). One molecule that has been 
investigated for its involvement in prion replication is the neural cell adhesion molecule 
(NCAM) purified in a high molecular complex containing PrP. However the 
observation that NCAM'7' mice succumbed to prion disease suggested its dispensability 
in PrPSc formation (Schmitt-Ulms et al., 2001).
On the basis of this I attempted to address whether PrPSc formation and scrapie 
pathogenesis could be affected in response to disruption of the PIP7 gene.
5.2.2.1 Overview of Gene trap
Gene trap technology was originally designed to provide functional information for 
novel genes (Gossler et al., 1989). The approach is based on the availability of murine 
embryonic stem cells (ES) and a specific class of reporter plasmids, containing a splice 
acceptor site upstream of a chimeric p-geo cassette, encoding both p-galactosidase and 
neomycin resistance activity but lacking a promoter. When the vector is integrated 
downstream of a functional promoter, the construct allows the expression of the reporter 
gene as a fusion transcript with the endogenous exon located upstream of the integration 
site (Figure 5.4). The integration occurs randomly but can be easily determined by 
5’RACE (Townley et al., 1997). The expression of the trapped gene should faithfully 
recapitulate the endogenous pattern and can be monitored by X-gal staining. This for 
example is quite helpful in the examination of the pattern of expression during 
development. More importantly, the function of the trapped gene is often disrupted after 
the insertion, providing a loss of function phenotype.
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Figure 5.4 Schematic description of the Gene Trap technique.
A gene-trap vector, contains a splice-acceptor sequence upstream of a reporter gene (fi-geo 
is a fusion between |3-galactosidase and neomycin phosphotransferase II) but no endogenous 
promoter. The vector inserts randomly into genes, resulting in a fusion transcript containing 
sequences from exons upstream of the insertion joined to the p-geo marker but missing the 
sequences from exons downstream of the integration site. The identity of the trapped gene can 
easily be determined by 5’ rapid amplification of cDNA ends (5’RACE) followed by automated 
DNA sequencing.
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The mutated ES cell clones can be indefinitely maintained in vitro in a multipotent state 
and with a stable karyotype. They can be differentiated into various cell lineages or 
reintroduced into blastocysts where they contribute to all cell types, including the germ 
line (Baker et al., 1997). The chimeric mouse can subsequently be used to produce FI 
offspring of heterozygous animals carrying the trapped allele. Intercross of 
heterozygous mice produces F2 offspring homozygous for the loss of function allele.
5.2.2.2 Generation of PIP7 targeted mouse lines
Two ES cell clones harbouring insertions in the PIP7 open reading frame were obtained 
from a Gene Trap library (http://baygenomics.ucsf.edu/). Both clones presented 
insertion of the pgeo cassette upstream of the Tandem Repeats domain responsible for 
the interaction with PrP. The XE413 and NPX275 ES cell clones were expanded and 
introduced by microinjection into recipient blastocysts. Chimeras were obtained and, by 
germ line transmission, FI heterozygous mice were produced (PIP7+/ ).
I performed an X-gal staining on heterozygous mice for each of the two lines, with the 
aim to compare the staining pattern with the PIP7 immunohistochemistry (see Figure 
3.9). A wild type sample was included in the panel as a control for staining specificity. 
Neither the wild type brain nor the NPX275 clone showed clear staining whereas the 
XE413 clone presented a pattern compatible with the previously observed PIP7 
distribution in the cerebellum (Figure 5.5).
There could be a number of explanations for the observed phenotype: chimeric proteins 
could either exhibit a folding which might inhibit the p-galactosidase enzymatic activity 
or be unstable and promptly degradated. It is known that insertions capturing the N- 
terminal signals sequence of a secreted or membrane protein are inactive (Skames et al., 
1995). Nevertheless, PIP7 is not exclusively localised on the cell surface since most of 
it is found in the nucleus. It is more likely that the two clones are encoding fusion 
proteins with different stability. To test the hypothesis, total brain homogenate was 
prepared from each of the lines and blotted with a specific a-P-galactosidase antibody.
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Figure 5.5 Monitoring LacZ activity in wild type and PIP7 trapped alleles by X-gal staining.
X-gal staining was performed on wild type (negative control) and PTP7 mutant mice. 
For simplicity, only the cerebellum is shown. The XE413 clone produced strong straining whereas 
the NPX275 clone remained unstained. As expected, no staining was found in the wild type 
sample.
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A band at 175 KDa was observed in the XE413 lysate but no specific band was detected 
in the NPX275 lysate (data not shown). It was possible to conclude that the lack of (3- 
galactosidase activity in the NPX275 was due to protein instability.
FI mice positive for the insertion were intercrossed and the F2 offspring analyzed for 
the presence o f knockout animals. None of the two lines, NPX275 and XE413, were 
able to produce null offspring, even in sub-mendelian ratio. After a preliminary 
analysis, it seemed that PIP7 disruption resulted in embryonic lethality.
5.2.2.3 Neurograft of PIP7 mutant neuroectoderm
An alternative strategy to investigate the dependence of prion disease on the presence of 
PIP7 was provided by a neurografting approach. Embryonic lethality of knockout mice 
can be quite common but neuronal tissue can nevertheless be obtained by grafting 
immature neuroectodermal cells from genetically modified embryos into an adult 
recipient host (Isenmann et al., 1996). The host mouse is healthy and permits the study 
of the properties of the neuronal tissue derived from the donor. However, in this case, it 
relies on a double assumption: a) knockout embryos must reach E l3.5 since 
neuroectoderm cannot be grafted before that stage; b) PIP7 function must not be 
required for growth and differentiation in adult neural tissue, after transplantation. In 
order to test the first assumption, I established time mating by intercrossing the two 
previously described lines (NPX275 x XE413) and embryos were extracted at E l3.5.
Neuroectoderm was surgically removed from 41 embryos and grafted in the 
caudoputamen of Prnp A recipient mice. The use of a P r n p y' background for the 
recipient mice was decided for two reasons: a) animals can remain healthy for 
prolonged times because prions cannot successfully replicate in the host; b) the absence 
of endogenous PrP provides a “clear” background where PrPRes accumulation can be 
easily detected in the tissue originated from the graft. At the same time, total protein 
lysate was prepared from the same set of embryos and analysed by immunoblot. Figure 
5.6 presents the comparison between a mutant and a control. The double mutant 
presented PIP7 levels which were almost undetectable when compared to the wild-type 
control, suggesting that the compound mutants were still viable at the stage required for 
neuroectoderm transplant. The same amount of total proteins was loaded, as checked by 
both Ponceau staining and a-|3actin immunoblot.
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Figure 5.6 Decreased PIP7 levels in embryos obtained from NPX/XE intercross.
After surgical removal of the neuroectoderm, embryos were analysed by immunoblot in 
order to confirm the absence o f PIP7. In the NPX/XE mutant total PIP7 levels were 
largely decreased. Equal protein loading was confirmed by actin immunoblot. The p-galactosidase 
positive band at 175 KDa reflected the presence of the XE fusion protein whereas no band was 
detected for the NPX allele.
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The reduction of PIP7 protein levels observed in Western blot analysis was estimated to 
be at least 80%. A LacZ positive band, corresponding to the XE413 trapped allele was 
detected at approximately 175 KDa. No band, as previously reported, was detected for 
the NPX275 allele.
Twenty-two days after implantation was performed, 27 out of 41 recipient mice were 
intracranially challenged with infected brain homogenate (RML strain) whereas the 
remaining 14 were mock treated. Animals were sacrificed after 150 days and the brains 
were subjected to immunostaining. All grafts exhibited normal neuronal development as 
shown by strong synaptophysin immunoreactivity, suggesting that PIP7 is not required 
for neuronal development and maintenance. Following Protease K digestion and 
immunostaining with the a-PrP antibody ICSM35, which has affinity for both PrP and 
PrPSc, specific immunoreactivity due to PrPRes was observed in all the grafts but in none 
of the surrounding recipient tissue.
As outlined in Figure 5.7, PrPRes deposits were found both in PIP7+/+ and pipy™5*7^  
grafts. A slight reduction in the ICSM35-specific signal intensity was not reproducible
■v ^ t 'd 'y  rv  T-
in other PIP7 grafts and may be due to the prolonged PK treatment which 
compromised the tissue architecture (compare panels C and D). Mock infected grafts 
did not show immunoreactivity after Protease K digestion. Moreover, other hallmarks of 
prion disease including spongiosis and gliosis were readily detectable in RML- 
inoculated p ip 7npx/xe grafts. Immunostaining with the 4G4 antibody revealed that, 
although decreased, PIP7 specific signal was still detectable in the mutant mice, as 
better seen with higher magnification of the selected area (panels G and H, dotted lines 
have been placed on the boundaries between the host and the grafted tissue). Thus, a 
significant reduction of PIP7 protein levels did not have any appreciable effect on PrPSc 
generation and neuronal degeneration, at least in the neuroectodermal graft paradigm.
5.2.3 Attempt to cure chronically infected cells with PIP7 antibodies
Several cell lines can be infected by prions and they retain the ability to accumulate 
PrPSc after multiple passages (Markovits et al., 1981; Race et al., 1988). These lines are 
mainly derived from neuronal tissue such as mouse neuroblastoma N2a (Butler et al., 
1988), mouse hypothalamic GT1 (Schatzl et al., 1997) rat pheochromocytoma PC 12 
(Rubenstein et al., 1984) and also a rabbit epithelial line has been reported (Vilette et 
al., 2001).
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Figure 5.7 Scrapie accumulation in neuronal grafts with reduced amounts of PIP7.
Time mating was set up between the XE413 and NPX275 line previously described. 
Neuroectoderm was extracted from embryos (E l3.5) and grafted in Prnp; recipient mice. 
Twenty-two days after transplantation, mice were stereotactically injected with RML and 
histological analysis o f the graft was carried out 150 days after inoculation. 
Hematoxylin & Eosin staining allowed the boundaries between the host and the graft tissue to 
be distinguished (A and B); PrPRes was detected after Protease K treatment (50 pg/ml for 4 hours 
at 37°C) in both wild type and mutant samples (C and D); immunostaining with the 4C2 revealed 
reduced expression of PIP7 protein in mutant grafts (E and F, higher magnification G and H). 
Abbreviations: C:Cortex, G:Graft, H:Hippocampus.
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Figure 5.8 Curing activity of PIP7 monoclonal antibodies on chronically infected N2A cells
Five thousand chronically infected IPK1 cells were plated into each well of a 96 well plate in 
the presence of the specified antibodies. After four days of incubation, cells were split 1:8 and 
grown for an additional three days, in the continous presence of the antibodies. To determine 
the exact number of PrPSc positive cells, a sample of 1000 IPK1 cells were supplemented with 
24000 non infected cells and immobilized onto 7 wells of a standard ELISPOT plate. Cells were 
digested with 1 mg/ml PK (90 minutes at 37°C) before reading the plate with a Zeiss KS Elispot 
system. All antibodies were used at the final concentration of 50 pg/ml, apart from ICSM18 (10 
pg/ml).
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Only a small percentage of murine neuroblastoma N2a cells can be infected with the 
mouse-adapted Rocky Mountains Laboratory (RML) scrapie strain but subclones with 
higher susceptibility to infection have been established (Bosque and Prusiner, 
2000).Different reports have shown that infected cultures rapidly lose PrPSc upon 
treatment with specific monoclonal antibodies directed against PrP (Enari et al., 2001; 
Peretz et al., 2001; White et al., 2003). It has been suggested that antibodies might act 
by occluding PrPc, PrPSc or eventually both conformations. Originally, PrPSc decrease 
following such treatments has been tested by standard techniques such as Western blots 
or the cell blot assay, which are semi-quantitative and not particularly accurate. 
Recently a highly sensitive assay based on cell infectivity has been developed. The 
Scrapie cell (SC) assay allows the rapid quantification of infectivity with the same 
sensitivity of a standard mouse bioassay and more importantly has an enhanced signal- 
to-noise ratio (Klohn et al., 2003).
In order to test a possible role of PIP7 in scrapie propagation the full panel of a-PIP7 
mAbs was tested for the ability to cure chronically infected N2a cells. For this particular 
experiment the highly susceptible clone iPKl has been used and standard concentration 
of 50 pg/ml of antibody was used (Klohn et al., 2003). The specific PrP antibody 
ICSM18 (10 pg/ml) was used in the experiment, as a positive control, having been 
demonstrated to eradicate prion infectivity both in vitro and in vivo (White et al., 2003). 
After one week of treatment, cells were analysed for the presence of PrPSc by standard 
SC assay. Treatment with ICSM18 (10 pg/ml) successfully abolished more than 95% of 
the positive cells when compared to the sample treated with an irrelevant isotype control 
antibody (Figure 5.8). The treatment with the a-PIP7 monoclonals did not produce a 
decrease comparable with the one obtained by the a-PrP antibody. Thus a-PIP7 mAbs 
do not alter PrPSc levels in chronically-infected N2a cells.
5.3 SUMMARY
In the previous chapter, I attempted a general characterisation of PrP/PIP7 biology using 
uninfected cell lines hence looking only at the presence of PrP . The aim of the studies 
presented in the current chapter was to clarify whether PIP7 has the ability to interact 
with the disease-associated isoform PrPSc and participate in scrapie pathogenesis.
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From the first set of experiments, it emerged that PIP7 specifically interacts with a PK 
sensitive PrP subset. PIP7 seems to have no affinity for PrPSc or PrP27'30 as shown in 
GST pull down assays.
In the second part of the chapter, I have used an in vivo and in vitro approach 
respectively to address the potential role of PIP7 in prion disease. I have generated 
transgenic mice harbouring gene trapped alleles of the PIP7 open reading frame. It has 
to be mentioned that frequently the trapped allele is not a null allele, but rather a 
hypomorphic allele. This scenario could occur if the targeted genomic locus undergoes 
splice-around events, such as when the spliceosome machinery ignores the splice 
acceptor site present in the vector. Splice-around events can occur in a time- and space 
restricted manner, resulting in a hypomorphic allele. I believe this is the most probable 
explanation for the different levels of PIP7 expression observed in the mutant embryos 
and in the corresponding grafted tissue (compare Figure 5.6 and 5.7). As a consequence, 
using the neurograft paradigm, I was only able to show that a 50% reduction in PIP7 
levels did not have significant effect on prion replication.
Finally, I tested the a-PIP7 mAbs in a cell-based assay for their ability to clear PrPSc. 
None of the specific monoclonals produced a significant reduction in total PrPSc levels, 
compared to the mock treated cells. I am planning to test the a-PIP7 antibodies for their 
prophylactic activity: de novo infection will be performed in the presence of the 
monoclonals and infection efficiency will be monitored by SC assay.
The generation of a conditional mouse for PIP7 would be the most suitable approach to 
clarify its function. This will allow a definitive answer to the role of PIP7 role in prion 
disease and the study of not only its requirement in replication within the CNS but also 
via peripheral inoculation, its possible role in neuroinvasion.
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Chapter 6: Discussion
6.1 Overview
Prion diseases are a related group of transmissible neurodegenerative conditions 
affecting humans and a variety of animals. One of the typical features of TSEs is the 
deposition, mainly in the brain but also in other tissues, of PrPSc which is the abnormal 
isoform of the host protein PrPc (Budka et al., 1995). PrPSc not only has the ability to 
co-purify with infectivity but is the most prominent component of infectious 
preparations, providing a reliable marker (Prusiner and Scott, 1997). Although much 
knowledge has been acquired in past years, basic questions such as the physiological 
role of PrP and the mechanism by which prions cause brain damage remain 
unanswered.
6.2 A novel screen for PrP interacting proteins
Many attempts have been taken in the past to identify PrP-interacting proteins in order 
to elucidate the cellular pathways in which PrP is involved. The aim of the present study 
was to isolate new interacting partners for the prion protein.
The yeast two-hybrid system is a simple and reliable tool to isolate novel protein- 
protein interactions (Fields and Song, 1989) and has allowed the identification of 
interesting PrP partners, as reviewed in the introduction chapter. However, with very 
few exceptions, the majority of candidates show cellular localisations which are not in 
line with the trafficking of the prion protein, questioning their relevance. A possible 
explanation for such results was provided by a recent study showing that proteins of 
membrane origin were generally under-represented using this kind of approach, 
possibly because of their incorrect folding in the yeast nucleus, where the yeast two- 
hybrid takes place (Uetz et al., 2000). The Ras Recruitment System attempts to 
circumvent this limitation by studying protein-protein interactions in the yeast 
cytoplasm but still does not allow the use of membrane proteins as bait due to their 
intrinsic ability to translocate to the plasma membrane independently of protein-protein
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interactions (Broder et al., 1998). This was the case for PrP, which was probably able to 
associate with the plasma membrane even in the absence of its GPI anchor thereby 
invalidating the screen.
Subsequently, I opted for the reverse Ras Recruitment System in which PrP was located 
in its natural membrane environment which was supposed to conserve its functional 
conformation (Hubsman et al., 2001). A second important reason why I performed the 
rRRS as opposed to the conventional yeast two-hybrid was the observation that, when 
expressed in the yeast cytoplasm, PrP adopts a misfolded conformation characterised by 
increased detergent insolubility and partial resistance to proteolysis, two hallmarks of 
PrPSc (Ma and Lindquist, 1999). There is no definitive explanation as to why PrP 
presents such PrPSc-like properties in this environment. It is conceivable that the acidic 
and reducing environment found in the yeast cytosol stimulates partial PrP misfolding, 
as suggested by in vitro conversion experiments using recombinant PrP (Jackson et al., 
1999). Alternatively, a contribution of some yeast enzymatic factors cannot be 
excluded.
My approach differs from the classic yeast two-hybrid by exploiting two novel aspects 
offered by the rRRS. Firstly, PrP was expressed in a more physiological membrane- 
bound environment and I believe this may play a key role in the identification of 
candidates which might have failed to be isolated in the past. Secondly, the rRRS takes 
place in the yeast cytoplasm where PrP seems to acquire biochemical properties typical 
of PrPp, as I was able to reproduce, whereas there is no information available in the 
literature about the conformation adopted by PrP in the yeast two-hybrid system. My 
experimental conditions could in theory allow the isolation of proteins not only able to 
interact with PrPc but also with PrPp. The outcome of such a screen could not only 
increase the knowledge about the still unknown functions of PrP but also identify 
possible candidates which may be involved in the transconformation process. Such 
proteins, once isolated and characterised, could provide novel therapeutic targets for a 
pathology that up to now has no effective cure.
6.3 PIP7 isolation and evaluation
As a result of the screen, I cloned a number of potential PrP interacting proteins and I 
have initially chosen to focus on the hnRNP M4 clone, which I referred to as PIP7,
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firstly because of its reported localisation at the plasma membrane where most PrP 
molecules are present at any given time (Stahl et al., 1987). Moreover, PIP7 has been 
reported to act as a surface receptor for the Carcinoembryonic antigen in rats and 
thyroglobulin in humans (Bajenova et al., 2001; Blanck et al., 1994). These lines of 
evidence raised my interest regarding the possible interaction between PrP and PIP7 and 
I successfully confirmed the interaction in vitro by GST pull down assay and in vivo by 
co-immunoprecipitation studies. With the aid of a panel of monoclonal antibodies I was 
able to confirm the presence of the PIP7 protein on the cell surface of different cell lines 
including mouse neuroblastoma N2a cells which are widely used to study the biology of 
Prion disease.
The PrP interacting domain within PIP7 encompasses a region with a very atypical 
amino acid composition. The identified Tandem Repeats region includes 27 repetitions 
of the consensus sequence [GEVSTPAN]-[ILMV]-[DE]-[RH]-[MLVI]-[GAV]. This 
feature is unique to PIP7 since it is not found in any other protein described in the 
databases. This region had been suggested as a potential coordination site for calcium 
ions but in the present case the PrP-PIP7 interaction was partially inhibited by the 
addition of exogenous calcium.
An indication of which region in PrP was responsible for the interaction with PIP7 was 
provided by the structure/function analysis by FACS. The accumulation of endogenous 
PIP7 following PrP overexpression allowed the determination of which portion of PrP 
was responsible for the interaction. Although I did not identify any PrP mutant, with the 
exception of the ASP which remains in the cytoplasm, unable to produce PIP7 
accumulation, I was able to show that the PrP-AF mutant, lacking amino acids 32 to 
134, was still able to increase endogenous PIP7 surface levels. Assuming that 
accumulation was a direct consequence of protein-protein interaction, the PIP7 binding 
site is likely to be in the C-terminal globular domain of the prion protein with no 
apparent contribution from the N-terminal flexible region.
6.4 Biology of the PIP7-PrP surface interaction
The increase in the levels of the PIP7 surface population following PrP overexpression 
offered a new perspective to the present study. Overexpression of membrane proteins
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could in theory saturate either the lipid environment or the endocytic machinery, 
resulting in non-specific accumulation of membrane proteins simply by impairing their 
normal trafficking. To assess the specificity of my observations, I followed the fate of 
the Transferrin Receptor which is known to be excluded from the raft environment and 
to become endocytosed by a mechanism based on clathrin coated pits (Shogomori and 
Futerman, 2001). Recent studies have shown that endogenous PrP expressed on primary 
neurons has to exit lipid rafts before undergoing coated pit-mediated endocytosis 
(Sunyach et al., 2003). Furhtermore, TfR and PrP have been characterised for their 
analogous kinetics of endocytosis and recycling and for their co-localisation during the 
internalisation process. On the basis of these data, I believe TfR provided a suitable and 
stringent control for my experiments.
Cells expressing a cytoplasmic version of the prion protein did not accumulate either 
PrP or PIP7 on their surface, suggesting that PIP7 stabilisation required the presence of 
PrP specifically on the cell surface. More interestingly, the stabilisation of PIP7 levels 
required PrP overexpression on the surface of the same cell (an in cis event); when cells 
were transfected with the GFP-PrP construct, only the GFP positive subpopulation 
displayed an increase in both PrP and consequently PIP7 surface levels; this argued 
against an in trans event because no PIP7 increase was observed in the GFP negative 
subset despite the intimate contact with PrP overexpressing cells. The finding suggests 
but does not prove that the PrP-PIP7 interaction cannot be established in trans between 
molecules present on neighbouring cells. This hypothesis can ultimately be confirmed 
by expressing a PrP mutant devoid of its C-terminal signal peptide. Such a mutant 
would lack the GPI anchor, resulting in its secretion in the extracellular space, and 
should not stabilise PIP7 levels exclusively in transfected cells.
An in trans effect would be suggestive of a cell surface mechanism whereas the 
observed in cis mechanism of stabilisation could involve either the plasma membrane or 
the internal endocytic pathway or a contribution from both compartments at the same 
time. I specifically tested the requirement for effective PrP endocytosis/recycling on 
PIP7 stabilisation using the NGAG mutant, which suggested that PIP7 surface 
accumulation does not require PrP endocytosis.
Another interesting question I would like to address is whether PIP7 surface 
accumulation depends on correct PrP raft localisation: either transfection with the 
previously described chimeric PrP-CD4 construct, which localises exclusively to
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clathrin coated pits, or treatment with drugs such as filipin or methyl-p-cyclodextrin, 
which compromise raft integrity, will be able to clarify this issue.
Evidence supporting PrP-PIP7 co-endocytosis
Microscopic analysis in living cells suggested a possible association between the 
studied proteins not only on the cell surface but also in the endocytic pathway. I 
proceeded to address whether PIP7 internalisation correlated with PrP endocytosis. To 
do so, I used chemical or enzymatic treatments able to alter PrP surface levels either by 
stimulating its endocytosis or by releasing it to the extracellular space by cleavage of the 
GPI anchor. A summary of the results obtained from my in vitro studies is outlined in 
Figure 6.1. Pentosan Sulphate has been reported to act exclusively by stimulating 
endocytosis whereas the mechanism of action of Suramin is subject to alternative 
interpretations since it has been reported to affect PrP trafficking both in the secretory 
and the endocytic pathways (Gilch et al., 2001; Kiachopoulos et al., 2004; Shyng et al., 
1995a). The PIP7 decrease in the Suramin treated sample could therefore reflect the 
result of a reduction in PrP exocytosis or an increase in PrP endocytosis. Although a 
direct effect of Suramin on PIP7 cannot be excluded, regardless of the mechanism by 
which PrP surface levels are lowered, a decrease in the PIP7 surface population was 
always observed whereas the levels of the TfR remained unaltered. The above data is 
suggestive of a possible PrP-PIP7 association during the endocytic process since a PrP 
reduction was always followed by PIP7.
Although the membrane topology of PIP7 remains unclear, in silico analysis has failed 
to predict any GPI modification. Therefore, in light of the result o f the PIPLC 
experiment, where PIP7 levels were reduced after PrP release from the plasma 
membrane, it is possible to argue that PIP7 not only could undergo endocytosis 
independently of the presence of PrP but also that its internalisation is stimulated by 
releasing PrP from the membrane environment. From this point of view, it is 
foreseeable that the presence of PrP could affect the kinetics of PIP7 internalisation as 
further supported by the trapping of endogenous PIP7 on the cell surface following PrP 
overexpression.
The PrP surface pool was specifically reduced in response to PIP7 overexpression. This 
result can be explained by the heterogeneous nature of the surface lipid environment. 
PrP is known to localise in lipid rafts and its internalisation implies its exit from such
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Figure 6.1 R eciprocal effect of P rP -P IP 7  eq u ilib riu m  on the cell su rface
Data obtained from previously described in vitro experiments are here summarised. In the 
untransfected/untreated situation, there is a steady state between the exocitosys and endocytosis 
of PrP and PIP7. Such equilibrium could be altered by overexpression of each component (A 
and D) or with chemical and enzymatic treatments (B and C). PrP increase correlates with PIP7 
accumulation whereas PrP decrease produces the same effect on PIP7. On the contrary, PIP7 
overexpression is able to reduce endogenous PrP levels. Arrows refer to PIP7 kinetics only.
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compartments before entering clathrin-coated pits (Gorodinsky and Harris, 1995; 
Sunyach et al., 2003). Assuming that PrP can exist in equilibrium between detergent- 
insoluble rafts and detergent-soluble compartments, PrP overexpression could cause 
PIP7 sequestration to lipid rafts and, conversely, PIP7 overexpression could extract PrP 
from its raft environment and relocate it into clathrin-coated pits where it can undergo 
endocytosis. In support of this hypothesis, I performed a sucrose gradient and confirmed 
the presence of PIP7 in lipids rafts (data not shown). Moreover, PIP7 presents a putative 
clathrin internalisation motif (YXXd>) whose function I am planning to confirm by site- 
directed mutagenesis. The impairment of recognition by the adaptor complexes (APs) 
could result in a dominant negative PIP7, still able to bind PrP but unable to undergo 
endocytosis. The effect of such a mutant on PrP will be monitored by FACS and 
confocal microscopy.
In my experimental conditions, PIP7 siRNA did not alter PrP levels. Although in theory 
this could be attributed to the incomplete knock-down obtained, the ablation of PIP7 
surface pool could in eventually be compensated for by alternative PrP partners such as 
the laminin receptor.
6.5 Study of i n  v iv o  correlation between PrP and PIP7 levels
The results obtained in vitro, either by PrP overexpression or PIPLC treatment, revealed 
that the PIP7 surface pool has the ability to respond to PrP variations. I wanted to 
further extend my analysis in vivo by looking at the PIP7 levels in the total absence of 
PrP and addressing whether PrP had any role in determining the residency of PIP7 on 
the cell surface. The marked reduction in the PIP7 membrane subpopulation in PrP 
knockout mice further strengthens the hypothesis of a role for PrP in establishing the 
amount of PIP7 present at the plasma membrane (Figure 6.2A and B). To my 
knowledge there is one other reported case of an identified PrP interactor whose levels 
appear to be altered in response to the ablation of the Prnp gene. NCAM, originally 
identified by chemical cross-linking experiments, has been recently shown to directly 
interact with PrP and the targeting of NCAM to lipids rafts was reduced specifically in 
Prnp'A brain. The authors suggested that PrP would facilitate NCAM recruitment to 
lipid rafts with subsequent Fyn kinase activation and stimulation of neurite outgrowth 
(Santuccione et al., 2005; Schmitt-Ulms et al., 2001).
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6.5.1 PIP7-PrP as a potential signal transduction complex
NCAM and PIP7 present quite remarkable analogies since both appear to be regulated 
by PrP levels. PrP has been previously implicated in signal transduction but, due to the 
absence of a cytoplasmic domain, it is difficult to conceive any mechanism not relying 
on as-yet unidentified transmembrane molecules (Mouillet-Richard et al., 2000; 
Solforosi et al., 2004). NCAM has been suggested to provide such a link between PrP in 
the extracellular space and the signal transduction machinery present in the cytoplasm 
(Santuccione et al., 2005). Hypothetically, PIP7 could also play an analogous role, as 
suggested by published data. In fact, CEA stimulation of in vitro cultures of rat Kupffer 
cells results in the production o f IL - la , IL-6, IL10 and TNF-acytokines as a 
consequence of a signalling cascade depending on tyrosine phosphorylation 
(Gangopadhyay et al., 1997). A later study revealed that PIP7 itself, known to be the 
CEA receptor, is phosphorylated on tyrosine residues following CEA binding (Laguinge 
et al., 2005). I performed a preliminary experiment where N2a cells were treated with 
the a-PIP7 specific mAbs or with control antibodies. An increase in total tyrosine 
phosphorylation was observed exclusively in the samples treated with the 4H5 and 1B8 
mAbs (data not shown). PIP7 contains five tyrosine residues and the NetPhos server 
predicts two possible tyrosine phosphorylation sites (amino acids 63 and 99). These 
residues are located before the first transmembrane helix and are predicted to be located 
in the cytoplasm. Further work is required to study the effect o f tyrosine 
phosphorylation on PIP7 endocytosis and signal transduction ability, to further 
clarificaty its function.
6.5.2 Possible involvement of PIP7 in the Shmerling Syndrome
Shmerling and colleagues originally proposed the idea of an interaction between PrP 
and a putative ligand (Lprp), which elicits an essential signal, and also hypothesised the 
existence of a PrP-like molecule (jt) with lower binding affinity able to fulfil the same 
function as PrP. According to this hypothesis, PrP-AF could interact with Lprp, 
displacing n without eliciting the survival signal. PrP could compete with its truncated 
counterpart and restore the signal, providing an explanation why PrP-AF is toxic only in 
the PrP knockout background. PrP would be able to engage Lprp with the C-terminal 
domain whereas the N-terminal flexible region would somehow be involved in eliciting
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Figure 6.2 In vivo PrP-PIP7 correlation and putative involvement in the Shmerling Syndrome
PrP-PIP7 correlation was observed in vivo where decreased PIP7 levels were found in the 
membrane fraction of PrP knockout brain compared to wild type control (A and B). 
According to the model proposed by Shmerling and colleagues, the interaction between full 
length PrP and a putative ligand is required to transduce a survival signal. 
In the absence of PrP, the signal can be elicited by 71, a molecule with structural similarities to 
PrP. However, PrP-AF is able to engage the ligand, after displacing tc, without 
producing the required signal cascade. Since PIP7 role in signal transduction has been previously 
suggested, ongoing experiments will be able to address the PIP7 role in the Shmerling Syndrome 
(C and D). Black arrows represent ability to transduce the hypothesised survival signal whereas 
red crosses indicate the impairment of the signal cascade.
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the signal. PIP7 possess two of the required properties that allow speculation about its 
potential role as Lprp. Firstly, it has the ability to bind PrP-AF and secondly it could be 
part of the suggested signalling pathway required for cell viability. Figure 6.2 (C and D) 
illustrates the hypothetical effect of PIP7 interaction with PrP and the AF mutant in 
eliciting the putative survival signal. To test the possible role of PIP7 in the Shmerling 
Syndrome, the transgenic line harbouring the AF mutation are being crossed with the
N P X /X EPIP7 and mice will be analysed for any difference regarding the onset of the 
ataxic phenotype.
6.6 PIP7 binds PrPSe"but not PrPRes
The screen was originally performed with the intention of gaining insight not only into 
PrP physiology but eventually also prion pathology. I have shown the ability of PIP7 to 
bind PrP and I addressed whether PIP7 was also able to interact with the aberrant 
isoform PrPSc. Experiments with Protease K digestion, performed either before or after 
the in vitro GST pull down, have shown that PIP7 interacts exclusively with PrPSen 
molecules whereas PrPRes from terminally sick animals did not have the ability to bind 
PIP7. The result is not in contradiction with the original aim of the screen and it can be 
subject to alternative interpretations.
The first explanation concerns the original characterisation of the bait I used to isolate 
PIP7. When expressed in the yeast cytoplasm PrP was mainly found in the detergent 
insoluble fraction but a small percentage was also detected in the soluble fraction. I 
observed that insoluble PrP was partially PK resistant although I did not test the soluble 
pool. Taken together, it cannot be excluded that during my screen alternative PrP 
isoforms with different biochemical properties, namely detergent insoluble-PK resistant 
species as well as detergent soluble-PK sensitive isoforms were present at the same 
time. Taking this into consideration, it is at present not possible to determine which PrP 
isoform interacted with PIP7 to rescue the Cdc25-2 mutation.
The second possible explanation is based on my original working hypothesis: to screen 
for interactors that preferentially recognize misfolded PrP which not necessarily has to 
be PK resistant or overlap with PrPSc. The screen took place in an environment that was 
only mildly acidic compared to the more extreme conditions used to generate PK 
resistant PrP in vitro; such conditions involved complete denaturation and secondary
170
Chapter 6
structure rearrangement by using chaotropic and reducing agents, such as GdnHCl and 
DTT and the far more extreme pH value of 4.0.
I believe both explanations must be taken into consideration to determine the validity of 
the screen, which successfully identified a new PrP interacting partner.
Possible explanations for the pH dependency
pi
PIP7 has the ability to interact in vivo with PrP but in the GST pull down assay the 
interaction showed a strict preference for acidic conditions whereas at the physiological 
pH of 7.4 the interaction was much weaker. The interaction was stable and reproducible 
in the pH range 6 to 5 and minimal binding was observed at pH 4.0. The explanation of 
such behaviour is still under investigation but a reasonable hypothesis could be the 
preference for a specific PrP misfolded intermediate, reported to be present exclusively 
at pH values between 6.0 and 4.0 (Swietnicki et al., 1997). Acidic conditions and the 
presence of strong denaturants have the ability to trigger a conformational change in 
human PrP (90-231) and mouse PrP (121-231) towards a (3-sheet rich intermediate, 
unveiling the intrinsic pH dependency of the C-terminal globular domain (Homemann 
and Glockshuber, 1998). Acidic conditions influence protein conformation primarily by 
altering the protonation state of residues such as glutamic/aspartic acid, lysine, arginine 
and histidine. Previously established salt bridges could be disrupted and new ones could 
be formed, resulting in a different folding. However, since PrP rearrangement occurs 
even at mildly acidic values, histidines are believed to become protonated most readily. 
This hypothesis finds experimental evidence in molecular dynamics studies, showing 
that protonation of His 187 alone could result in protein transition with a rapid decrease 
in a  helical content and parallel increase in |3 structures (Langella et al., 2004). In the 
Hisl87Arg substitution, associated with GSS, the presence of a constitutive positive 
charge is believed to destabilise PrP resulting in a (3-rich conformation. (Cervenakova et 
al., 1999).
However, the effect of pH cannot be restricted to PrP only. The pH has also the ability 
to change the binding properties of PIP7, since it has been reported to bind human 
thyroglobulin specifically in acidic conditions. However, no other information is 
available at present regarding the influence of pH on the PIP7 protein.
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In summary, two different components might be responsible for the pH dependency of 
the studied interaction since the acidic conditions could alter either the conformation of 
PrP, PIP7 or both. This could affect their relative affinity for each other and at this point 
neither possibility can be excluded.
6.7 Potential role of PIP7 in prion disease
The possible involvement o f PIP7 in prion replication has been tested using two 
complementary approaches. The in vivo assay using mutated PIP7 grafted tissue 
excluded its absolute requirement for PrPSc replication. However, the tested tissue still 
contained a small amount of PIP7, making it difficult to unambiguously rule out a 
function of PIP7 in scrapie pathogenesis. However, the lack of effect obtained in the 
Scrapie Cell assay after one week of treatment with a panel of the a-PIP7 mAbs further 
argues against a role of PIP7 in prion diseases.
6.8 Concluding remarks and future directions
The aim of this work was to identify novel prion interacting molecules and, based on 
the preliminary characterisation, PIP7 fulfils the original idea. The link between PrP and 
PIP7 had been demonstrated both in vitro and in vivo.
Many possible functions have been attributed to the prion protein in the past (Lasmezas, 
2003). PrP does not seem to possess a biological activity that can be easily identified 
although it may be able to modulate the function of other proteins. A possible scenario, 
compatible both with the data I have acquired on PIP7 and the NCAM studies, proposes 
that PrP is able to play the role of a docking molecule able to anchor other molecules to 
specific lipid microenvironments. The reasons behind this could be multiple: PrP could 
favour the interaction of the target protein with alternative partners by localisation in 
specific lipid microdomains, such as lipids rafts which have been shown to be involved 
in signal transduction (Lucero and Robbins, 2004). Otherwise, PrP could prevent its 
partner’s interaction with other molecules simply by sequestration. In both cases, the 
surface concentration of such molecules would be strictly regulated by PrP levels and 
turnover as suggested by my in vitro and in vivo analysis. However, this hypothesis 
requires more experiments in order to be confirmed and the isolation of other membrane
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molecules showing an analogous mechanism of regulation to PIP7 and NCAM would 
certainly strengthen the case.
PIP7 is an interesting molecule which is able to play very diverse functions in light of 
its dual localisation both inside the nucleus and on the cell surface (Bajenova et al., 
2001; Datar et al., 1993). Many attempts have been previously taken to find proteins 
interacting with PrP, mainly with the aim to clarify its enigmatic physiological role. I 
originally performed a screen in order to identify PrP partners with a well understood 
biology. However, the biology of PIP7 seems as unclear as that of PrP, allowing only 
speculative conclusions to be drawn.
PIP7 seems to fulfil the original idea of a PrP receptor as stated by David Harris of a 
cell surface molecule with the ability to bind and regulate PrP levels (Shyng et al., 
1995b). It is possible that more than one PrP receptor exists and this would not be in 
contradiction with the proposed function of the laminin receptor (Gauczynski et al., 
2001). My data suggests an intimate relationship between PrP and PIP7 since 
modulating the amount of either one reflects the levels of the other. Further experiments 
have to be done to confirm the effective role of PIP7 as a PrP receptor. The results of 
the present study and of future efforts would be extremely beneficial to clarify both PrP 
and PIP7 biology.
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